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I-1 Preface 
Cancer is one the deadliest maladies afflicting mankind amounting to 1 in 6 of all global 
death totalling to about 8.8 million deaths in 2015, as estimated by WHO. Cancer is the 
second leading cause of death globally, and the number of new cases is expected to rise by 
about 70% over the next 2 decades. Approximately 70% of deaths from cancer occur in low 
and middle-income countries. The financial burden of cancer management has been 
tremendous, with the estimated total annual economic cost of cancer in 2010 to be around 
US$ 1.16 trillion (www.who.int). A significant quantum of resources has been invested to 
address this medical need at the academic as well as industry level that has led to 
improvements in our understanding of the disease.   
However, this comprehension of the cancer biology has not been proportionately translated 
into corresponding improvements in cancer care. One of the important reasons that precluded 
this is the lack of selective delivery of anti-cancer compounds to cancerous tissue. Owing to 
lack of selectivity, a high systemic exposure to anti-cancer agents more often leads to a dose-
limiting toxicity. As a result, many efforts are being directed towards selectively delivering 
the toxic payloads to cancer, making targeted delivery an important approach in overcoming 
the current limitations of cancer therapy. Recent developments in immunology, gene/cell 
therapy and nanotechnology are expected to significantly improve the therapy and diagnosis 
of cancer, thereby increasing efficacy with which the disease is being treated currently. 
Nanotechnology has been one of the major breakthroughs in research that has found its value 
in life sciences amongst several other applications and cancer is no exception to this. Several 
nanotechnology driven approaches have borne fruits as evident from the growing list of the 
nanomedicines approved by health authorities across the globe. In 2011, the European 
Commission published a recommendation on the definition of nanomaterial predisposing size 
as the critical factor (1-100 nm) with the acknowledgment that the upper limit of 100nm not 
justified across whole range of nanomaterials. Several research programs have been funded 
by European Union (EU) focussing on leveraging the science at nanoscale and ARGENT has 
been one of them. The FP7 European Multi-ITN (Marie Curie Actions Initial Training 
Network) project “Advanced Radiotherapy, Generated by Exploiting Nanoprocesses and 
Technologies (ITN ARGENT)” started in March 2014. The prime objective of this inter-
sectorial and multidisciplinary ITN is to create a new generation of researchers and experts 
able to develop and propose to the society new tools and concepts for the improvement of 
cancer therapy and diagnosis.  
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I-1.1 Overview of ARGENT project: 
50% of the patients receive radiotherapy as part of their cancer treatment. The main limitation 
of this treatment is the lack of tumor selectivity, which causes severe side effects, and 
radioresistance. The most promising developments to improve the performances of radiation-
based therapies is the use of fast ion beam radiation (carbon therapy and proton therapy) and 
nanoparticles-enhanced therapies. ARGENT brings together world-leading researchers of 
different disciplines, physicists and medical physicists, chemists, biologists, medical doctors 
and SMEs with the aim of understanding and exploiting the nanoscale processes that drive 
these phenomena (http://itn-argent.eu/). This European effort should lead to the development 
and optimization of new nanodrugs together with advanced radiation protocols. This will 
open a new era for radiotherapy with subsequent economic and ‘quality of life’ benefits for 
the EU population. In order for Europe to fully exploit its world-lead, a new generation of 
supra-disciplinary researchers familiar with following domains must work in an orchestrated 
manner: i) Physics and medical physics: explaining the physical interactions of radiation; ii) 
Chemistry: describing the chemical processes and methodologies for tailoring nano-agents; 
iii) Biology: elucidating the effects in vitro and in vivo.  
 
Figure I-1: The partners within the ARGENT consortium spearheading the collaborative 
interdisciplinary research on cancer. 
This project is strongly supported by the medical community. As an end point, this inter-
sectoral and multi-disciplinary programme will form young researchers and experts able to 
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create a platform on which next generation cancer therapy will be built. The consortium aims 
to train a cohort of 13 PhDs (Early Stage Researchers – ESRs) to subsequently act as leaders 
and ambassadors in the field. The ITN ARGENT strategy relies on i) improving our 
understanding of the processes and mechanisms underlying radiation damage on a nanoscopic 
level, ii) applying the improved know-how in the production and development of 
functionalised nanodrugs to amplify the effects of medical beams and iii) developing of 
concepts and codes for clinical applications, taking into account the new information.  
The ITN-ARGENT consortium is represented by 6 academic, 3 industrial and 6 associated 
partners that complement and leverage the competencies and expertise developed since their 
establishment (Figure I-1). The ARGENT research program is based on three work packages; 
nanodosimetry, theranostic nanoagents and preclinical evaluation. Each work package is with 
group of ESRs based on their respective projects and scientific/technical competencies.  
The Preclinical Evaluation team combines their efforts to understand better how nanoscale 
processes initiated by the interaction of radiation with living matter affects biological 
responses, establishing a link between nanoscale interaction and clinical effects. Combining 
advanced experimental, theoretical, and modelling tools, the team investigates nanoscale 
interactions for preclinical testing in cell-based models and exploring their clinical 
applicability. The major goal of this team in ARGENT is to evaluate the use of the new 
methods and tools developed in the project for better patient outcome. The scientific work 
package on theranostic nanoagents is comprised of experimentalists from chemistry, biology, 
and medical physics. The goal of this work package is to design, synthesize, and characterize 
the next generation of technologies as radiosensitizers and diagnostic tools. The group also 
studies their fate inside the cellular environment and the cell damage caused by the 
combination of nanoparticles and different radiation beams. The Nanodosimetry team 
combines experiments and simulations to answer the most fundamental questions regarding 
the mechanisms present in radiation induced damage in cells. They study the interactions 
between biomolecules, nanoagents, and ion and photon radiation with both experiment and 
simulation. Being a part of the ARGENT team as one of the ESRs gave me an opportunity to 
perform my doctoral research at Chematech, one of the industrial partners in the consortium 
along with its affiliate Institute of Molecular Chemistry (UMR CNRS 6302), Université de 
Bourgogne-Franche Comté, Dijon. 
Chematech is one the leading European research based enterprise developing chemical tools 
based on chelation chemistry. These chemistries find applications in antibody conjugation, 
nanoparticle development and other technologies useful in therapy and diagnosis of diseases. 
Chematech is led by its CEO, Dr. Frédéric Boschetti and represents one of the pillars of the 
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ARGENT team owing to its unique capability in the development of the macrocyclic 
compounds used in imaging and nuclear medicine. This is further strengthened by the 
scientific and advisory support received from Institute of Molecular Chemistry, Université de 
Bourgogne-Franche Comté, Dijon which is spearheaded by Prof. Franck Denat. Apparently, 
this thesis has received the unique mentorship of both Dr. Boschetti and Prof. Denat who are 
experts in the field of macrocyclic and conjugation chemistry from industry and academia. In 
the context of the aforementioned objectives, the work package designated towards 
‘Nanoagents for cancer theranosis’ forms the important aspect of the current thesis and steers 
in the direction that aims to develop novel tools for cancer theranosis. 
I-2 Cancer theranosis: Approaches and avenues 
 
Figure I-2: Key drivers of cancer therapy, diagnosis and theranosis. 
The term “theranostics” signifies any material that permits the combined diagnosis and 
treatment along with the potential to follow up of a disease and has been coined by the US 
consultant John Funkhouser, in August 1998 [1]. Theranostics implies the development of the 
two modalities in an integrated manner that serves the function of a diagnostic test and a 
therapeutic agent in an interdependent and concerted manner so as to cater towards 
comprehensive care of a specific disease. The ultimate aim of developing a theranostic is to 
simultaneously image and monitor the diseased tissue, drug pharmacokinetics, and 
pharmacodynamics with the long-term objective of fine tuning the therapy and dose with a 
control unattainable hitherto. 
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I-2.1 Cancer therapy: 
As implied in the Figure I-2, the cancer therapy relies on four major treatment modalities 
namely; surgery, radiotherapy, chemotherapy and immunotherapy. These approaches could be 
used as standalone or in combination with each other depending on the tumor type and its 
stage. Majority of the benign cancers can be treated by surgical resection, whereas the 
malignant ones need a concomitant approach. Radiotherapy involves exposing the tumor 
lesions to high energy ionising radiations (e.g: X-rays) as an external beam radiotherapy. On 
the other hand, ‘brachytherapy’ or internal radiation therapy involves locally exposing the 
cancerous tissue to radiation by implanting the seeds of radioactive substance at the affected 
site. Alternatively, the radiotherapy can also be provided by delivering the sequestered 
radioisotope (e.g: 177Lu, 90Y) at the cancerous lesions in conjunction with a targeting ligand. 
This typically involves conjugating the chelator molecule to the targeting ligand that targets 
specific receptors on the cancer cells. The chelator molecule serves the purpose of 
sequestering the radioisotope which otherwise would be difficult to target. The ligand can be 
a peptide as in the case of recently (January 2018) FDA approved Lutathera(Lutetium 
dotatate) which is referred to as Peptide Receptor Radionuclide Therapy (PRRT) or it can be a 
monoclonal antibody where it is referred to as ‘Radioimmunotherapy’. Zevalin(90Y 
ibritumomab tiuxetan) and Bexxar (131I- tositumomab) are the approved products in this 
category (www.fda.gov). Chemotherapy represents one of the most traditional approaches in 
the cancer therapy that involves administration of a chemotherapeutic (synthetic or semi-
synthetic drugs) to the cancer patients. These drugs are cytotoxic as they usually interfere 
with the key metabolic processes that are important for the cell survival or cell growth. Since 
the action of the cytotoxic drugs is not selective to cancer cells they also affect the normal 
healthy cells resulting in serious side effects. Many research efforts are being directed to 
address this issue by modifying the existing drugs or developing the new drugs that are more 
selective to cancerous cells. Much of the nanoparticle based research focussing on drug 
delivery encompasses the delivery of such anti-cancer drugs so as to target them only to the 
tumor site minimising the deleterious effects on the healthy tissue [2].  Immunotherapy 
represents the most recent and advanced therapeutic modalities for cancer therapy based on 
sound understanding of the molecular immune mechanisms underlying the pathophysiology. 
Monoclonal antibodies (mAbs) form the mainstay of the immunotherapy and were first 
produced by Milstein and Köhler (Cambridge University), who were awarded the Nobel Prize 
in Physiology or Medicine in 1984. mAbs possesses exquisite specificity owing to their 
greater surface area binding, which results in decreased ‘off-target’ effects/toxic effects as 
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compared with most small molecule drugs. With the advancement and the synergy of 
immunology, molecular biology and protein engineering, it has been possible to developed 
engineered proteins including monoclonal antibodies that are highly efficacious, stable and 
cater to different type of diseases/cancers. Various mechanisms have been thought to play 
roles in mediating the tumoricidal effects of mAb. These include signalling promoted by 
cross-linking of surface antigen that leads to cell death, blockade of an activation signal that is 
essential for continued cell growth, antibody-dependent cellular cytotoxicity (ADCC), 
complement mediated cytotoxicity (CMC) and the ability of mAb to alter the cytokine milieu 
or augment development of an active anti-tumor immune response. Of the various 
monoclonal antibodies approved for diverse disease categories 27 have been only approved 
for cancer highlighting the importance these magic bullets in cancer therapy [3, 4]. Bolstering 
the concept of the magic bullets, monoclonal antibodies have also been utilized as a cancer 
targeting cargo to deliver the highly potent cytotoxic molecules giving rise to new class of 
drugs; antibody drug conjugates referred to as ADCs. With only four approved ADCs 
currently in market, this is a very recent addition to the armamentarium against cancer, yet 
with lot of promise as witnessed by the prolific pipeline (> 50) that is at moment under 
clinical investigation (www.adcreview.com). 
I-2.1.1 Nanoparticles in cancer therapy: 
One of the hallmarks of the cancerous lesion is its altered physiological and anatomical state 
that makes it more vulnerable to the action of nanoparticles by virtue of an effect termed as 
‘Enhanced Permeability and Retention effect’. The EPR effect is a combined result of 
complex biological processes viz; angiogenesis, vascular permeability, lymph-angiogenesis, 
heterogeneous tumor genetic profile and microenvironment and poor lymphatic clearance. 
Any macromolecular system including nanoparticle that is injected into the biological subject, 
has propensity to get lodged in the milieu of the cancerous tissue owing to its leaky 
vasculature and poor lymphatic drainage. This enables the dislodged cargo to exert its action 
locally at the site endogenously (drug release from nanoparticle) or under the influence of an 
external stimuli (radiosensitization by nanoparticles upon radiation). Many approaches based 
on the macromolecular/nanoparticulate delivery have been developed for the cancer therapy 
and diagnosis as exemplified in the Figure I-3. Categorically, they have been classified as 
lipid based carriers, polymeric carriers, inorganic nanoparticles, conjugates and viral 
nanoparticles. 
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Figure I-3: Schematic illustration of different nanotherapeutic platforms. Adapted from [5]. 
Lipid nanocarriers include liposomes, solid lipid nanoparticles, SMEDDS etc. that are made 
from fatty acid derivatives. Several liposomal formulations like Doxil, Myocet, Mepact, 
Marqibo, DaunoXome etc. have been appoved in US/EU/Asia for cancer therapy. Polymeric 
nanoparticles are composed of the matrix based nanoparticles fabricated using chemically 
synthesized polymers (e.g: PLGA), polymeric micelles which are made up of amphiphilic 
copolymers (e.g: Polycaprolactone-polyglutamic acid) and polymer encapsulated/coated 
systems (e.g: Abraxane – Albumin bound paclitaxel nanoparticles). Conjugates include more 
often covalently conjugated polymer drug systems or antibody drug conjugates which have 
been one of the hot topics in the targeted drug delivery with the clinical pipeline abuzz with 
several lead candidates. Virus like particles (VLP) are viruses devoid of genetic materials 
making them non-infectious. VLP are made up of the viral surface proteins/capsids that can 
house drug/tracer/gene/protein which acts as a cargo and can be useful in therapeutic, imaging 
and vaccine applications. Inorganic nanoparticles typically encompass silica nanoparticles, 
gold nanoparticles, iron oxide nanoparticles and other metallic nanoparticles (e.g: quantum 
dots etc). Inorganic nanoparticles are usually non-biodegradable and can pose toxicity issues 
and hence need a due consideration with respect to their physico-chemical characteristics so 
as to address any potential biocompatibility/bio persistence issues. Nonetheless, despite these 
challenges several inorganic nanoparticles have made it to clinic (ferumoxtran, ferucarbotran 
etc.) and many are on their way to do so (e.g: AGuIX – Phase I and Hafnium oxide NPs – 
Phase I/II) as can be seen from the clinical trial database (www.clinicaltrials.gov). 
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I-2.1.1.1 What is the difference between passive and active targeting of nanoparticles? 
By virtue of the anatomic and physiological peculiarities of the cancerous lesions, the 
nanotechnology based research has been able to drive the results in its strides and is one of the 
main reasons that justify the application of nanomedicines in oncology compared to other 
disease areas. Passive targeting of the nanoparticles harnesses the EPR effect and involves use 
of the nanoparticles without any specific surface chemistry manipulations but within a certain 
size range. Active targeting involves modification of the nanoparticle surface with the ligands 
that have higher affinity to the receptors expressed mainly on the surface of the cancerous 
cells.  
Although the approved nanomedicines justify the promise offered by the nanoparticles, there 
are multitude of factors that pathophysiologically differentiate patients from each other 
depending on the tumor type and its extent. Moreover, the distribution and accumulation of 
NPs in tumors could be highly variable and is likely influenced by the biological and 
physicochemical properties of each material. As a result of this, an EPR effect alone might 
not be effective in eliciting the adequate response giving rise to molecularly specific 
approaches in the context of personalized medicine. Active targeting of the nanoparticles with 
small molecule ligands/peptides/antibody or its fragments that target the specific receptors on 
the cancer cells presents one such avenue to bolster the performance of nanoparticles [6]. 
I-2.1.2 Nanoparticles in radiotherapy: 
The line of treatment for the cancer has improved in recent years owing to development of the 
drugs with targeted mechanism of actions. However, the elements associated with diet, 
environment, lifestyle and the ageing population still increase the likelihood of cancer 
incidence. Amongst the population benefitted by the increase in the survival post treatment, it 
has been observed that 49% are cured by surgery, 40% by radiotherapy alone or combined 
with other modalities, and 11% by chemotherapy alone or combined with other modalities. 
Radiotherapy represents a very cost-effective component (5% of total) of cancer care 
particularly for palliation and symptom control in patients with advanced-stage or recurrent 
cancer [7]. 
Radiotherapy has witnessed significant advances resulting in sophisticated modalities such as 
image-guided radiotherapy, stereotactic radiotherapy, intensity-modulated radio- therapy, and 
proton therapy. These techniques have enabled the application of the higher doses to 
cancerous tissue with higher accuracy and precision whilst sparing or minimising the 
radiation exposure to the surrounding healthy tissue making radiation therapy more effective. 
Recently, the nanoparticles based on heavy atoms (Z >50) have shown the promise in 
improving the radiotherapeutic outcomes by acting as radiosensitizers. Continued research in 
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this field; understanding the biological matter and radiation interactions, developing new 
chemistries for nanoparticles and preclinical and clinical studies of the promising 
nanoparticulate candidates is helping understand their potential to address and explore this 
avenue. 
I-2.1.2.1 How do nanoparticles enhance the radiotherapy? 
Upon exposure to the ionising radiations, elements with high atomic number like; gadolinium 
(Gd, Z = 64), gold (Au, Z = 79), iodine (I, Z = 53) and platinum (Pt, Z = 78), exhibit elevated 
photoelectric absorption of IR energy in comparison to surrounding soft tissue eliciting a 
radiosensitizing effect. The effect of ionizing radiations on biological systems can be broadly 
classified into physical, chemical, and biological phases. The phase in which high energy 
particles (photons, electrons, protons, or heavy ions) travel through their biological medium 
and bring about ionization and/or excitation of the molecules is referred to as physical phase, 
which leads to breakage of chemical bonds and generation of free radicals [8].  
The physical phase is followed by the chemical phase that entails; scavenging and fixation 
reactions involving highly reactive free radicals that interact rapidly with molecules. 
Scavenging indicates the inactivation of free radicals by reducing agents such as thiol 
containing molecules (e.g: glutathione), whereas fixation causes an irreparable damage to 
biological components by molecules with high electron affinity, such as oxygen. Damage to 
the key components of the cellular machinery causes impairment of the cell function [9]. 
In the context of radiobiology, the biological (molecular, cellular and tissue) phase/effect is 
exhibited as the 5 Rs: repair, reoxygenation, redistribution, repopulation, and intrinsic 
radiosensitivity. Radiosensitizers enhance the effects of radiotherapy via multiple mechanisms 
through a cascade of events entailing three phases that ultimately results in the amplification 
of damage caused to the targeted tissue [10].  
The inorganic nanoparticles have a key role in augmenting the radiation therapy as most of 
these nanoparticles are composed of the elements with high atomic mass number making 
them ideal for radiosensitizing aplications. Within the purview of the ARGENT program, 
gadolinium based silica nanoparticles and gold nanoparticles have been identified as key 
theranostics considering several years of research experience of consortium members 
dedicated to the development of these systems.  
Gold nanoparticles represent one of the widely researched inorganic nanoparticles for their 
radiosensitizing potential. The chelate functionalized gold nanoparticles is one of the main 
areas of research within the frame of collaboration between Chematech andICMUB, 
Université de Bourgogne-Franche Comté (from Dijon)and UTINAM, Université de 
Bourgogne-Franche Comté (Besançon). The group in Besançon is led by Prof. Stephane Roux 
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who has been spearheading the activities relevant to development of these nanoparticles since 
last few years. The nanoparticles developed by the team of Prof. Roux have also been 
extensively studied by researchers within the consortium of ARGENT.    
AGuIX nanoparticles are a novel class of Gadolinium based nanoparticles that have shown 
promise as radiotherapeutic sensititizers and MR contrast agents. With the proof of concept 
demonstrated at the pre-clinical stages, these nanoparticles are under clinical development 
(Phase I) for indications relevant to brain metastases. These nanoparticles are being developed 
under the concerted efforts of Nano-H and Theraguix (co-founded by Prof. Olivier Tillement) 
along with other academic partners. 
These nanoparticles will be exploited in this thesis by developing advanced synthetic ligands 
that will be used as building blocks for the fabrication of the next generation of 
multifunctional nanoparticles.  
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I-2.2 Cancer Diagnosis: 
Cancer diagnosis forms one of the integral part of the cancer management even before the 
commencement of the therapy. It entails understanding the spatial and temporal distribution 
of the cancer lesions and also involves identifying the molecular signatures associated with 
cancer form. Imaging plays a crucial role in cancer diagnosis with different modalities 
offering different levels of information and can be broadly categorized as nuclear and non-
nuclear; nuclear imaging typically involves use of a radioisotope/ionising radiation whereas a 
non-nuclear imaging involves use of electromagnetic radiation or energy forms least likely to 
cause any radiation induced damage (Figure I-4 and  
Table I-1). Although, diagnosis based on imaging is crucial in terms of the body level 
assessment of the malignancy, this has to be supported by the histopathological and 
immunochemical examination of the cancerous tissue to identify and get molecular insights 
into nature of the cancerous lesions. This can also help and subsequently refine the selection 
of the tracer and imaging tools to keep track on the disease prognosis. 
I-2.2.1 Imaging in cancer diagnosis: 
 
Figure I-4: Key nuclear and non-nuclear molecular imaging tools used in pre-clinical and 
clinical set ups. Adapted from [11]. 
I-2.2.1.1 PET and SPECT imaging: 
PET and SPECT are nuclear/radioactivity based molecular imaging tools that can ascertain 
the biochemical changes and extent of molecular targets with a seamless depth of penetration 
and high sensitivity. Imaging of the molecular target using PET/SPECT entails identification 
and synthesis of a radiolabelled imaging agent that is specific and selective for the target of 
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interest.  
Table I-1: Molecular imaging tools and their features. Adapted from [12]. 
Imaging 
Technique 
Source of 
energy 
Spatial 
Resolution (mm) 
Acquisition 
Time 
Amount 
of tracer 
Detection 
Sensitivity 
Depth of 
penetration Safety Profile 
Animal Clinical (time units) (ng) (mol/L) (mm) 
SPECT Gamma rays 5-12 1-4 min-h 1-1000 10-10-10-11 limitless Ionising Radiation 
PET 
Photon 
annihilation 
3-8 1-3 min-h 1-100 10-11-10-12 limitless Ionising Radiation 
MRI Radiofrequency 
0.01-
0.1 
0.5-1.5 min-h 103- 106 10-5-10-6 limitless 
Non-Ionising 
Radiation 
CT X-rays 50m 1-2mm min - 10-3 limitless Ionising Radiation 
Optical 
Visible to 
infrared waves 
1-5 <5 s-min 103- 106 10-9-10-12 1-20 
Non-Ionising 
Radiation, safety 
linked probe dose 
 
The small quantity of this radiolabelled agent in the magnitude of nanomolar quantities is 
administered intravenously to the subject following which, the radioactivity is then traced 
through the body and its distribution determined from scans obtained with a PET/SPECT 
camera or detector. 
 
Figure I-5: Scheme illustrating the principles imaging based on PET and SPECT[13]. 
In SPECT imaging, the radioisotope emits γ-rays that is detected by a 360° rotating gamma 
camera consisting of photon detector array. The detection of gamma rays enables 
reconstruction of an image that identifies the location of the radioisotopes which in turns 
helps in diagnosis. On the other hand, PET is based on positron emission decay, where the 
injected radioisotope emits a positron that traverses through the tissue (∼ <2 mm) and gets 
decelerated by loss of its kinetic energy till it ensues collision with an electron. The emission 
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of a positron and its annihilation with electron results in an emission of two 511 keV photons 
at 180° to each other; these photons are detected as a coincident event, making it possible to 
localize more precisely their source and reconstruct an image (Figure I-5). 
I-2.2.1.2 Radioisotopes used in nuclear medicine: 
Radioactive isotopes have been widely used in diagnosis as well as for therapy in oncology in 
addition to their use in drug development research. These isotopes can be used after 
integration into a pertinent chemical structure (e.g: 18F, 11C) or they can be 
sequestered/chelated using chelators (ligands) to have them in a form that is stable under 
physiological conditions. A vast number of radiometals are being routinely produced, with a 
broad variety of half-lives and emission profiles. A wide range of radioisotopes at disposal 
makes it feasible to select specific nuclear properties that are necessary for requisite 
applications. Table I-2 summarizes the list of the radioisotopes with their properties and 
applications that are currently in use in nuclear medicine and research. 
Table I-2:Different radioisotopes used in imaging and therapy [14, 15]. 
*EC- Electron Capture; IT-Isomeric Transition. 
I-2.2.1.3 Magnetic Resonance Imaging: 
MRI is a widely used imaging modality that is analogous to nuclear magnetic resonance 
(NMR) in principle and allows imaging of atomic nuclei within the body. MRI involves using 
Radioisotopes Atomic Number Half-Life Decay Mode (%) Production Application 
11C 6 20.4 min + (100) Cyclotron PET Imaging 
13N 7 9.96 min + (100) Cyclotron PET Imaging 
15O 8 2.03 min + (100) Cyclotron PET Imaging 
18F 9 109.8 min + (97) Cyclotron PET Imaging 
62Cu 29 9.76min + (100), EC (3) Cyclotron PET Imaging 
64Cu 29 12.8 h + or -, EC Cyclotron PET Imaging 
67Ga 31 3.3 days EC (100) Cyclotron SPECT Imaging 
68Ga 31 68 min + (89), EC (11) Generator PET Imaging 
82Rb 37 1.25 min + (95), EC (5) Generator PET Imaging 
94mTc 43 52 min + (72), EC (28) Cyclotron PET Imaging 
99mTc 43 6 hr IT (100) Generator SPECT Imaging 
111In 49 2.8 days EC (100) Cyclotron SPECT Imaging 
123I 53 13.2 hr EC (100) Cyclotron PET Imaging 
124I 53 4.2 days + (23), EC (77) Cyclotron PET Imaging 
125I 53 60 days EC (100) Reactor 
SPECT Imaging, 
Brachytherapy 
44Sc 21 3.9 hr + (94), EC (6) Generator PET Imaging 
47Sc 21 80.2 hr - (100) Generator Radiotherapy 
90Y 39 64.1 hr - (100) 90Zr (n, p)90Y Radiotherapy 
89Zr 40 78.5 hr + (23), EC (77) Cyclotron PET Imaging 
177Lu 71 159.4 hr - (100) 176Lu(n,)177Lu Radiotherapy 
Chapter 1. Introduction 
Multifunctional platforms for cancer theranosis   25
high power magnet and radiofrequency (RF) energy so as to visualize the internal structure 
and soft tissue morphology of the body.  
MRI involves use of a strong magnetic field that aligns the magnetic moments of protons in a 
sample producing an equilibrium magnetization along the z-axis (Mz) with a magnitude of 
M0. When a radio frequency (RF) pulse is applied to the sample, at a resonance frequency 
capable of transferring energy to protons, magnetic moments of the protons rotate away from 
the z-axis by an angle called the flip angle. The flip angle depends on the imaging sequence 
applied, but it is generally the transverse plane (xy-plane), resulting in a net magnetization of 
Mxy. When the RF is removed, the magnetic moments of the protons relax to equilibrium. The 
time needed for the magnetic moments to relax to its equilibrium state is termed as the 
relaxation time and is dependent on the tissue under investigation [16, 17]. By varying the 
parameters of the pulse sequence, different contrasts may be generated between tissues based 
on the relaxation properties of the hydrogen atoms therein. In principle, MRI is based on the 
study of Nuclear Magnetic Resonance (NMR) of protons (water) present in the tissues and the 
contrast of an MRI image depends in particular on the density of the water and the relaxation 
times of the proton spins, which vary according to the physiological properties of tissue/site 
[18, 19]. 
The contrast in soft tissue with MRI arises due to differences in the proton density, spin-
lattice or longitudinal relaxation time (T1) and spin-spin or transverse relaxation time (T2) of 
the protons. T1 is the time constant of the exponential recovery process of M0 along the z-axis 
after an RF pulse. Protons that relax quickly (short T1) are able to recover full magnetization 
along the z-axis and can produce high signal intensities. For protons that relax more slowly 
(long T1), full magnetization is not recovered before subsequent RF pulses, as a result they 
produce less signal and result in saturation effect. T1 weighted images illustrate anatomical 
information and are envisaged when a clear image of the structure is necessary. On the other 
hand, T2 is the time constant of the exponential decay of the transverse magnetization (Mxy) 
after an RF pulse. T2 reflects the amount of time taken by the magnetic moments of protons 
to become randomly aligned in the xy-plane after an RF pulse, resulting in a net magnetic 
moment of zero in the xy-plane. T2 weighted images are generated by eliminating the 
dephasing effects caused by extrinsic magnetic field inhomogeneities and taking into account 
only the molecular interactions. Thus, T2 weighted images can generate good pathological 
information wherein accumulation of the abnormal fluid appears bright against the normal 
tissue background [16, 20]. 
Although, water in the biological milieu acts as an endogenous contrast for the MRI the 
intrinsic variations of T1 and T2 are small. As a result, it has become obvious that in many 
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clinical situations an exogenous contrast agent is administered which can greatly improve the 
diagnostic value of MR, just as the case for X-ray and CT [21]. Ideally, a MR contrast agent 
must induce a strong local effect on the T1 or T2 relaxation times of water, have suitable 
pharmacokinetic properties and be nontoxic at the administered doses. One of the common 
approaches to altering the relaxivity of water is to introduce a high spin paramagnetic metal 
such as Fe or Gd into its vicinity. Water molecules bound to the high-spin metals relax in 
orders of magnitude faster than free water, leading to a dramatic change in T1 that can be 
observed by MR. As the paramagnetic ions cannot be administered directly, owing to their 
inherent toxicity resulting from the interference of the physiological process, it is imperative 
to administer these ions in a form that is innocuous to cellular machinery. This can be 
typically achieved by sequestering the metal using an organic chelate or administering the 
metal in non-ionisable atomic form [22, 23]. 
At present, there are two main classes of MRI contrast agents: the first is gadolinium-
containing small molecule complexes (with chelate) and the second is superparamagnetic iron 
oxide nanoparticles (SPIONs). Whereas, gadolinium shortens the T1 relaxation time of 
protons inside tissues, the iron present in SPIONs possesses a large magnetic moment that 
reduces the MRI signal intensities resulting in a negative contrast enhancement in T2 
weighted images. In the context of the targeted MRI agents, the nanoparticles based on 
gadolinium and iron oxide have been widely studied and reported [23, 24]. 
MRI has a number of important advantages compared with other imaging modalities 
including 1) no need for ionizing radiation. 2) unlimited depth of penetration. 3) high spatial 
resolution ( 
Table I-1).4) concurrent collection of physiological or metabolic data with high-resolution 
anatomical images. 5) High soft tissue contrast superior to that attainable with CT.6) 
molecular information/imaging when used in conjunction with targeted MRI compatible 
imaging agents; and 7) Excellent clinical utility and value. Although MRI is an extremely 
useful imaging technique, it suffers from few drawbacks like; poor sensitivity compared to 
other imaging modalities, high cost and use of contrast agents (potential dose limiting toxicity 
concerns). Nonetheless, the high spatial resolution of MRI has hugely benefitted medical 
diagnostics and basic research [11]. 
I-2.2.1.4 Optical imaging: 
Optical imaging is advantageous compared to radiological imaging as it is rapid, inexpensive 
and sensitive. Optical imaging obviates the need for exposure to harmful radiation by 
employing non-ionizing radiation like visible, ultraviolet, and/or infrared light. This 
electromagnetic radiation spectrum generates images by exciting electrons which upon 
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relaxation to ground state release energy that is transduced into signals revealing the 
information associated with the tissue, cell or organelles in the form of an image. Unlike the 
whole-body imaging techniques such as MRI and PET, optical imaging can offer real-time 
images with high resolution. As, the subcellular processes can be captured by optical 
microscopy, optical imaging has been used to understand the behaviour of various 
nanomaterials at the cellular levels in living subjects [25]. Currently, numerous fluorescent 
dyes are being widely used as optical imaging probes (discussed in detail in following 
sections). However, in vivo optical imaging suffers from a major drawback of limited 
penetration depth in tissue and background signals caused by light scattering. As result, many 
efforts in advancing optical imaging techniques and probes are being made to maximize 
penetration depth and minimize background signals. Advanced techniques stemming from 
optical imaging include; Optical Coherence Tomography, Photoacoustic Imaging, and Raman 
Spectroscopy to list few. Employing NIR radiation and NIR based fluorophores have been 
proven to overcome the tissue auto-fluorescence. On the other hand, the photo-bleaching and 
the limited absorption coefficient of fluorescent dyes can be to certain extent overcome by 
developing nanoparticle-based optical probes [26]. 
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I-2.2.2 Multimodal Imaging: 
Despite development of various imaging techniques, no single imaging modality offers a 
comprehensive functional or anatomic information. Every technique has its own unique 
shortcomings on spatial or temporal resolution, depth of tissue penetration detection 
sensitivity and cost [27]. MRI and CT can provide high resolution images with detailed 
information of anatomy but lacks target sensitivity (mM to μM range). In contrast, PET is 
high sensitivity imaging modality, but is limited by the range of positron in tissue, resulting in 
low spatial resolution (4–6 mm for human whole-body PET scanners, 1 mm in small animal 
imaging and preclinical PET scanners).This causes partial volume effects and the anatomic 
information offered is inconclusive [28]. On the other hand, optical imaging techniques suffer 
from low tissue penetration, despite the high detection sensitivity; while ultrasound offers 
good spatial resolution, but is limited by its poor penetration and sensitivity. Thus, the above 
nuclear and non-nuclear imaging techniques represent the strengths of molecular imaging 
each with their own share of advantages and disadvantages. Synergistic combination of the 
above modalities offers hope to overcome clinical diagnostic challenges by offering 
complementary and comprehensive information. Multimodality aims to combine the 
techniques that provide structural/anatomical information (MRI, CT or US) and the one that 
offers high sensitivity with functional or molecular information (PET, SPECT or optical). 
This has resulted in different dual modal technologies like PET/CT, PET/MRI, SPECT/MRI, 
and MRI/optical [27, 29]. Combination of PET or SPECT with optical imaging also holds 
potential as a technology that helps combine whole body imaging with image guided surgery 
giving rise to PET/optical and SPECT/optical imaging [30]. 
Although multimodality offers potential to improve diagnostic capabilities at clinic, it has 
several challenges at different levels. Hybrid imaging necessitates development of the 
multimodal scanners that present design and engineering complexities. This has to be 
supported by the image processing advancements to combine the results obtained from the 
two measurements without any loss/masking of the information [31]. Multimodal imaging 
also poses the significant challenge to chemists to develop the multimodal probes or contrast 
agents that can help maximise and refine the hybrid imaging outcomes. Administering a 
single agent that combines two modalities is a desirable feature in terms of the patient 
convenience and compliance. Emergence of the targeted or personalized therapy based on 
molecular signatures of the cancer has further added a new dimension to this area of hybrid 
imaging. Small molecule/peptide, antibody and nanoparticles based multimodal contrast 
agents play a very crucial role in multimodal imaging. Research outlined in this thesis aims to 
address this concern and contribute to the new strides taken in this direction. 
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I-2.2.2.1 Nanoparticles in multimodal imaging:  
Although there are lot of preclinical studies reported in literature [32], very limited number of 
nanoparticles are used in the clinic [24]. Amongst the ones used in clinic, majority of them are 
for the cancer therapy as most of them cater to the drug delivery challenges of the anti-cancer 
drugs. Nanoparticles for imaging or theranosis is relatively a new concept and present 
challenges and opportunities different from the nanoparticles for drug delivery. As an unmet 
clinical need, the detection of early tumor development at primary and metastatic sites can be 
improved by use of nanoparticles owing to their potential of targeting accuracy to tumors. The 
design of imaging methodologies based on nanoprocesses and technologies that could detect 
tumors earlier would significantly improve patient outcomes. The properties of the 
nanoparticles that are desirable from the viewpoint of imaging are slightly different from 
those expected for drug delivery and this difference stems mainly from the pharmacokinetic 
requirements. A nanoparticle for imaging is expected to quickly reach the tumor environment 
and get cleared from the system as early as possible whereas the one for drug delivery needs 
to remain in the circulation for relatively longer time so as to deliver adequate dose at the site 
of cancerous lesion. As a result of this, nanoparticles in the size range of 5-10nm are generally 
favourable for imaging application. Size in this range also ensures that the nanoparticles are 
quickly cleared from the circulation mostly via renal clearance [33]. Other factors that can 
influence the biological behaviour of nanoparticles is the surface chemistry, surface 
potential/charge and particle shape. Nanoparticles present a versatile platform to combine 
different modalities in order to be used as bi/multimodal tracer in imaging and/or theranosis. 
Presence of the high specific surface area (surface area per unit weight or volume) enables 
appending of the high sensitivity probes to the nanoparticles surface whereas the bulk/core of 
the nanoparticles can possess the properties needed for other imaging tracers/therapy.  
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I-3 Monomolecular Multimodal Platform in cancer theranosis: 
 
Figure I-6: Multimodal platform for the development of diverse theranostics. 
Broadly, imaging contrast agents include small molecules, peptides, proteins, and 
nanoparticles. Majority of the scans use small molecules based tracers that are below 2,000 
kDa and measure approximately 1 nm (e.g:18F-FDG for PET, iodinated small molecules for 
CT, and chelated gadolinium for MRI). Peptide based imaging agents are gaining momentum 
owing to their specificity and ease of synthesis relative to larger proteins. This has led to the 
approval of such agents towards specific class of cancer (e.g: NETSPOTTM/68Ga-
DOTATATEfor neuroendocrine tumors)(www.adacap.com).Protein imaging agents, such as 
radiolabelled monoclonal antibodies, are less common but offer precise molecular 
information and are a growing area of research. Nanoparticles offer an exciting class of 
imaging agents that can be used for both anatomic and molecular imaging. Developing a 
platform that caters to multiple such avenues forms the basis of the current thesis. 
Monomolecular multimodal platforms have been one of the thrust areas of research at 
Chematech and ICMUB.  Monomolecular multimodal platform (MOMIP) aims to develop 
the systems (conjugates/nanoparticles) that are easy to develop and characterize and yet retain 
their multimodality. For instance, modification of an antibody for PET-Optical probe 
development using independent stepwise approach i.e conjugation first with PET probe and 
then optical probe appears very complex in terms of the developing optimal process of 
conjugation as well as the precise characterization of the probe conjugated in this manner. 
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Whereas, conjugation with MOMIP is one step process along with precise characterization of 
the resulting bioconjugate. This is furthermore important and valuable in 
development/functionalization of the nanoparticles where these systems are inherently 
complex to characterize. Thus, the purpose of this platform is to provide researchers and the 
clinicians, the tools that encompass diverse modalities in a single integrated system towards 
improved cancer/disease management. In this context, the current thesis aims to harness this 
approach in diverse possible manner and generate multimodal tools for cancer therapy. This 
platform can be applied for the development of the small molecule based multimodal imaging 
ligands or for the ligands that can be in turn used for nanoparticle synthesis or antibody 
bioconjugation that can have substantial theranostic value. Figure I-6 highlights this approach 
in a pictorial/infographic format representing the general and versatile nature of the 
multimodal platform that can be easily customized or adapted based on the product and the 
feasibility of the chemistry desired. 
I-3.1 Chelators used in multimodal platforms: 
The increasing number of radioisotopes in nuclear medicine has necessitated the 
corresponding increase in the development of the novel chelators to suit the requirement of 
the complex’s stability in terms of thermodynamic stability and kinetic inertness. Each 
radiometal ion has different physical and chemical properties like; ligand donor atom 
preferences (e.g. N, O, S), size, oxidation state, coordination number and coordination 
geometry. As result of this, a correct choice of the chelator suiting the attributes of the chosen 
radioisotope has to be made so that the resulting complex exhibits optimal characteristics 
suitable for the in vivo stability. Broadly, the chelators have been classified as linear or 
acyclic and macrocyclic. In the context of this doctoral thesis, the key radiometals/metals that 
are of interest for theranostic applications include Gadolinium/Gd (for MRI and 
radiosensitization), Copper 64/64Cu (for PET) and Indium-111/111In (for SPECT). As a result, 
only those chelators useful for the complexation of above radiometals will be discussed. A 
detailed account of the chelators used in radiochemistry has been outlined in an excellent 
review by Price and Orvig [14]. 
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Table I-3: Properties of the chelators used in this thesis for theranostic applications. 
Chelator 
Radiometal/ 
metal 
Labelling/ 
radiolabelling 
conditions 
logKML 
 
DOTA (1,4,7,10-tetraazacyclododecane- 
1,4,7,10-tetraacetic acid) 
Coordination Number: maximum 8 
Donor Site: N4O4 
Bifunctional Derivative used in this 
thesis: DOTAGA 
64Cu+2 
 
25–90°C, 30–60 
min, pH 5.5–6.5 
22.2, 22.7 
 
111In+3 37–100°C, 15–60 
min, pH 4.0–6.0 
23.9  (pM 
17.8–18.8) 
 
Gd+3 
 
37–100°C, 15min–
6 h, pH 5.0–6.0 
24.7 
 
NOTA (1,4,7-triazacyclononane-1,4,7- 
triacetic acid) 
Coordination Number = 6 
Donor Site: N3O3 
Bifunctional Derivative used in this 
thesis: NODAGA 
 
64Cu+2 
 
25 °C, 30–60 min, 
pH 5.5–6.5 
21.6 
111In+3 60–95 °C, 20–30 
min, pH 4.0–5.0 
26.2  (pM 
21.6) 
 
DTPA, diethylenetriaminepentaacetic 
acid 
Coordination Number = 8 
Donor Site: N3O5 
Bifunctional Derivative: DTDTPA 
 
64Cu+2 
 
40 °C, 60 min, pH 
6.5 
21.4 
111In+3 25 °C, 5–10 min, 
pH 4.5–5.5 
29.0  (pM 
24.9) 
The table has been adapted from [14, 34, 35]. Green-Best match; Orange-moderate match; Red-poor match. 
DTPA is one of the oldest and most widely used acyclic chelator in radiochemistry and can be 
radiolabelled with many radiometal ions at room temperature within few minutes. However, 
the complexes of DTPA suffer from potential stability issues in vivo and are not as stable as 
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the ones formed with macrocyclic chelators. As a result of this, there is a decrease in its use 
which is gradually being replaced by chelators like DOTA and NOTA derivatives [36]. 
Nonetheless, DTPA has been successfully used in the FDA approved SPECT agent 
OctreoScanTM(111In-DTPA-octreotide), a somatostatin-targeting peptide-conjugate used for 
imaging neuroendocrine tumors [37]. DTPA (Gd complexed) based contrast agents for MRI 
have been approved and marketed under different brand names (Table I-4). Also, the first-
generation gold nanoparticles from our group were based on the bifunctional chelator (BFC); 
DTDTPA (thiolated DTDTPA) and are currently being upgraded to the advanced form by use 
of the BFC based on DOTA and NOTA. 
Table I-4: Gadolinium based contrast agents marketed in US and Europe [34]. 
Chemical Name Generic Name Trade/Product Name 
Acyclic Chelators 
Gd-DTPA Gadopentetate Dimeglumine Magnevist® 
Gd-DTPA-BMA Gadodiamide Omniscan® 
Gd-DTPA-BMEA Gadoversetamide Optimark® 
Gd-BOPTA Gadobenate Disodium Multihance® 
Gd-EOB-DTPA Gadoxetate Disodium Primovist® 
MS-325 Gadofosveset Trisodium Vasovist® 
Macrocyclic Chelators 
Gd-DOTA Gadoterate Meglumine Dotarem® 
Gd-HP-DO3A Gadoteridol Prohance® 
Gd-DO3A-Butrol Gadobutrol Gadovist® 
 
DOTA is the most versatile and widely used chelator and is of significant value for MRI as 
several marketed products are based on the gadolinium complex of the DOTA in its different 
forms as can be seen from the Table I-4. Due to relatively lower stability, the DTPA based 
contrast agents are more likely to release the Gd+3 in vivo. This can have implications in 
potential kidney toxicity that can result in Nephrogenic Systemic Fibrosis (NSF) and hence 
are being widely replaced by DOTA based complexes [38]. DOTA has been gold standard for 
some of the radioisotopes and forms stable complexes with 111In, 177Lu, 86/90Y, 225Ac, and 
44/47Sc. Owing to the lack of geometric fit, DOTA does not form very stable complexes with 
PET isotopes like 64Cu and 68Ga, which can be addressed by deployment of NOTA. NOTA is 
a hexadentate N3O3chelator and has been successfully used as chelator of choice for67/68Ga 
and 64Cu. NOTA is now considered to be the ‘‘gold standard’’ for 64Cu+2 and Ga3+ chelation, 
with facile and favourable radiolabelling conditions (RT, 30–60 minutes) and excellent in 
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vivo stability [39, 40].  
Table I-1 summarizes the properties of the key chelators that are relevant to the research work 
described in this thesis. 
I-3.1.1 Influence of the chelator on the properties and stability of the theranostics: 
Selection of the correct combination of the chelator and metal is key to the successful 
development of theranostics. In vivo kinetic inertness of the metal–chelate complex is of 
utmost consideration in identifying the right match between the chelator and metal. Although, 
thermodynamic stability constants (KML= [ML]/[M][L]) can be a useful gauge for the initial 
level comparisons, but they do not necessarily predict the in vivo stability. Experiments like 
acid dissociation and competitive radiolabelling have been proposed but they are not 
representative and do not reflect the environment encountered at physiological conditions. 
Challenge studies can be performed by incubating the chelate-metal complex with ions like 
Na+, K+, Ca2+, Mg2+, Cu2+ or Fe3+ to identify the trans-chelation mediated instabilities. 
Alternatively, the complex can be subjected to EDTA challenge assays to mimic the potential 
endogenous chelators. Ultimately, the correct match can only be justified by performing the in 
vitro stability assessment in serum and performing in vivo studies focussing on 
biodistribution and pharmacokinetics.   
Despite the stability and inertness with a given radiometal (e.g. NOTA vs. DOTA for 68Ga), it 
may not be the optimal match for a certain application (e.g. a specific peptide vector). For 
instance, NOTA forms a more stable complex with 68Ga than does DOTA, but owing to 
differences in charge and physical properties (e.g. neutral vs. charged complex), DOTA may 
provide superior in vivo properties with certain vectors [41]. This exemplifies the complex set 
of variables that need due consideration when constructing radiometal-based 
radiopharmaceuticals. Another interesting feature related to the influence of chelator, is that 
they can modulate the binding affinity of the peptide based radiopharmaceuticals. Findings by 
Maecke et al., claim that ‘The chelate makes difference’ in the context of peptide based 
imaging agents. It has been demonstrated that the combination of the chelate and metal can 
have a substantial effect on the binding affinity as well as the tumor localization in animal 
models [42]. 
In the view of the multimodality, it is necessary to use the right form of the bifunctional 
chelators so as to conjugate it to the multimodal assembly. This necessitates the use of the 
bifunctional chelator so that properties of the base chelators are unaffected. One of the 
strategies in offering the bifunctionality to the chelator (e.g: DOTA and NOTA) is to append a 
side arm containing two carboxylate groups on the macrocyclic ring. This can be done for 
instance, by employing the glutaric arm during the macrocycle synthesis so that the original 
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coordination sphere of the chelator remains intact yet offering a site for conjugation (e.g: 
DOTAGA and NODAGA) [42-44]. Thus, chelator remains an integral and important 
component in development of a multimodal theranostics. 
I-3.2 Fluorescent probes for NIR based optical imaging: 
Optical imaging based on NIR light for fluorescence possesses several merits in comparison 
to visible light. NIR range light does not cause any potential damage to the biological tissue 
unlike the ionising radiations. Majority of the biomolecules are transparent to NIR due to very 
low absorption coefficients. As a result, the auto-fluorescence signals arising from the 
background tissue are very low resulting in increased signal-to-noise ratio and high sensitivity 
of detection. Moreover, the NIR light can penetrate deeper in the tissue owing to reduced light 
scattering and the low absorption from the background [12]. Although many biological 
windows have been proposed for defining the diagnostic range of wavelength for NIR 
imaging the one comprising between 650 and 1450 nm holds and appears reasonable for most 
of the studies (Figure I-7) [45].  
 
Figure I-7: Absorption spectrum of the oxygenated whole blood and the biological diagnostic 
window defined from 650–1450 nm. Adapted from [46]. 
An ideal fluorescent probe should cater to below requirements:  
- Good photo stability,  
- High quantum yields, 
- High molar extinction coefficients, 
- Large Stokes shifts (energy difference between maxima of absorption and emission spectra) 
to prevent the reabsorption effects, 
- Chemical stability and adequate solubility in physiological media, 
- Low toxicity and minimal tendency to aggregation.    
NIR imaging can be realised by the probes with different physico-chemical characteristics and 
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can be broadly classified into four families; 1. Organic fluorophores, 2. Fluorescent proteins, 
3. Quantum dots (QDs) 4. Lanthanide(III)-based complexes and nanomaterials [46]. The 
interest of the thesis lies in particularly using the organic fluorophores for the development of 
the multimodal platform.  Organic fluorophores offer significant advantage over the 
counterparts owing to their customizable nature and possibility to integrate them with other 
systems to offer multimodality. Based on their widespread use in the biology, organic NIR-
emitting probes, can be considered belonging to three general classes: BODIPYs, squaraines 
and cyanines.  
BODIPY fluorescent probes belong to a family of probes based on borondipyrromethane 
characterized by high quantum yields and distinctively sharp absorption and emission spectra 
Moreover, they possess very high photostability and chemical stability under physiological 
conditions. Some of the disadvantages that preclude their practical applications include low 
water solubility, small Stokes shifts and comparatively low molar extinction coefficients (104 
M-1.cm-1). Furthermore, most of the BODIPY-based probes emit in the visible/deep red 
ranges making it difficult for their use in NIR based imaging [47]. 
Table I-5: Photophysical properties of the representative fluorophores. Adapted from [46, 48]. 
Fluorescent Probe abs (nm) em (nm)  (105.M-1.cm-1)  (%) 
Cy5-NHS 646 662 2.5 20 
Cy5.5-NHS 673 707 2.09 20 
Cy7-NHS 750 773 1.99 30 
Cy7.5-NHS 788 803 2.23 - 
BODIPY NIR 557 723 - 3 
ICG 785 807 - 0.3 
IR820 818 867 - 4.2 
IR783 777 812 1.3 2 
IRDye®800CW 774 789 2.4 - 
KSQ-4 786 817 - 8 
 
Squaraines are zwitterionic fluorophores bearing a oxocyclobutenolate core that is substituted 
with heterocyclic/aromatic groups located on the opposite ends of the molecule. Due to its 
peculiar structure, the photophysical properties of the squaraine dyes are very sensitive to the 
surrounding medium and hence can be explored for development of the responsive 
fluorescent probes. Squaraines have high molar extinction coefficients (in order of 105 M-
1.cm-1) in NIR regions with moderate quantum yields and photostability. Squaraines suffer 
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from drawbacks related to smaller Stokes shift and solubility. The vulnerability to the 
nucleophilic attack and the aggregation induced fluorescence quenching are the other factors 
that can limit their use [49]. 
Cyanine fluorophores are composed of two heteroaromatic rings that are linked together by a 
polymethine bridge (Figure I-8). The excitation and emission wavelengths of the probes are 
strongly influenced by the length of the polymethine bridge: the longer the bridge, the higher 
the values of absorption and emission wavelengths. These properties can also be tuned by 
extending the aromaticity as be seen based on change from Cy5 to Cy5.5 or from Cy7 to 
Cy7.5 (Figure I-8) [50]. Cyanine probes demonstrate large molar extinction coefficients, in 
the order of 105 M-1cm-1, and considerably high fluorescence quantum yields including in the 
NIR range with values up to 30% (Table I-5). The dyes that have been chosen for 
development of the multimodal platform include Cy5 and IR-783, which represent two 
distinct regions of the spectrum in terms of the absorption/emission properties. The current 
experience of our group in applying Cy5 in the development of antibody bioconjugatable 
probes has been considerable (unpublished data) and hence has been envisioned to be 
extended to ligands for multifunctional gold nanoparticles. Nevertheless, it is of crucial 
importance to select the correct form of the dye for development of the theranostics. Different 
properties of the fluorescent dyes like lipophilicity, solubility, polarity/charge, etc. can have 
profound influence on the affinity of the ligand towards its target or properties of the 
multimodal platform that contains it. As a result, a prior understanding of these variables 
during the development can be of considerable importance. Highlighting this feature, 
Bunschoten et al., performed systematic assessment of the influence of the chemical 
modifications of the fluorescent dye on integrin targeted bimodal probes. They developed a 
matrix-based scoring system to demonstrate a large influence of relatively small changes in 
the chemical design of fluorescent labels. This approach not only resulted in an optimized 
αvβ3-integrin targeted hybrid tracer but also provides a systematic approach to the 
optimisation of such tracers [51]. 
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Figure I-8: Chemical structures of some NIR-emitting organic dyes and their derivatives. 
Compared to the widely used Cy5, studies with IR-783 has been limited in the applications 
pertaining to multimodality. Nonetheless, the versatile nature of the IR-783 and its 
implications in wide range of biological responses has been noteworthy ranging from imaging 
to photothermal therapy [52, 53]. IR-783 is a commercially available fluorescent NIR dye. 
This dye is peculiar not just in terms of physico-chemical properties but also its biological 
properties as it can be used as dual imaging and targeting agents. IR-783 and its derivative 
show preferential uptake in tumor cells but not normal cells as has been demonstrated in a 
variety of cancer cell lines, tumor xenografts, spontaneous mouse tumors in transgenic 
animals and human tumor samples and this is proven to be mediated by tumor hypoxia and 
organic anion-transporting polypeptides (OATPs) [54, 55]. These diverse properties make IR-
783 a probe of choice for the development of multimodal platforms. 
I-3.3 Targeting ligands for cancer: 
Cancerous cells express wide range of receptors on their surface which are different or 
expressed to a significantly greater extent compared to normal healthy cells. This difference 
mainly stems from the requirement of meeting the high growth and metabolic rate of the fast-
growing cancerous cells. This provides the possibility to differentiate the cancer cells from the 
normal ones and presents the opportunity to selectively target the cancer cells for the purpose 
Chapter 1. Introduction 
Multifunctional platforms for cancer theranosis   39
of diagnosis and/or therapy and forms the basis of active targeting.   Typically, these receptors 
on the cancer cells can be targeted by ligands that could be a small molecule (<500Da), 
peptide or protein/monoclonal antibody.  
I-3.3.1 Small molecular/Peptidic ligands: 
Small molecule based ligands present a viable and versatile option for the vectorization of the 
different kinds of tracers based on small chemicals, macromolecules and nanoparticles. 
Targeted tracers for theranosis based on such ligands has been one of the key areas of interest 
of our group in Dijon. Various chelators and fluorescent dyes have been linked alone or in 
combination to different targeting ligands like PSMA ligand, cRGDfk, folic acid, bombesin 
[56] and CXCR4 ligand [57] to name few. The most widely used ones therefore deserve a 
brief mention in this context (Figure I-9). 
 
 
 
Figure I-9: Commonly used targeting ligands in targeted cancer therapeutics and diagnostics 
(Blue is the site of conjugation). 
I-3.3.1.1 Folic Acid: 
Folic acid (FA) has been famously utilized as a ligand for the selective targeting and delivery 
of macromolecular drugs into tumor cells via membrane-bound tumor associated folate 
receptors. Folate receptor is glycosylphosphatidyinositol-linked membrane protein that binds 
to its ligands from the extracellular fluid and transposes them inside the cell via a non-
destructive, recycling endosomal pathway [58]. The overexpression of folate receptor (FR) on 
wide range of cancer cells qualifies it as a potential target for different types of ligand and 
antibody directed cancer theranostics. Folate receptors exist in three major forms; FR- , FR-
 , and FR-, of which FR-is overexpressed by many types of tumor cells including those of 
the ovary, brain, kidney, breast, myeloid cells and lung. The density of the  folate receptor 
appears to increase as cancer stage/grade progresses [59, 60]. Owing to the internalization of 
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the ligand, folic acid is particularly suitable for targeted drug delivery of anti-cancer 
compounds. The importance of FA as a targeting ligand for cancer research is evident from 
the fact that, five FA-based small molecule drug conjugates have been evaluated in clinical 
trials. European Medicines agency had approved ‘vintafolide’ and ‘etarfolide’ for women 
with platinum-resistant ovarian cancer, however its sponsor (Endocyte) later withdrew its 
application owing to inability to perform additional clinical investigation. Vintafolide is folate 
conjugated vinblastine, whereas etarfolide is a companion diagnostic based on SPECT 
imaging for assessment of the folate expression in patients (www.ema.europa.eu).Despite the 
setback, there is continued interest in the development of folate targeted therapeutics and 
diagnostics and approval of folate based tools in near future is very likely [61]. 
I-3.3.1.2 RGD peptide: 
Once tumors have surpassed the size of >1 mm3, diffusion alone is no longer enough to 
provide the tumors cells with sufficient amounts of oxygen and nutrients. To cater to this 
deficit, tumor develops additional new blood vessels (Angiogenesis). This process is a 
hallmark of tumor growth process and represents an interesting target, not only for imaging 
but also for therapy. Targets like Integrin (v3) and vascular endothelial growth factor 
(VEGF) have implications in the angiogenesis and have been exploited for cancer therapy and 
diagnosis. Cilengitide inhibits the integrin receptors αvβ3 and αvβ5 and has been approved for 
targeted antiangiogenic therapy whereas antibody bevacizumab (Avastin), targets and blocks 
the vascular endothelial growth factor (VEGF) [62, 63]. 
Integrin (αVβ3) is a cell adhesion receptor that is highly expressed on most of the tumor 
vasculature including the tumor cells in some cases. This receptor has high affinity with 
proteins and peptides containing the arginine-glycine-aspartate (RGD) sequence making it an 
important tumor marker. This has particular relevance in molecular imaging as the RGD 
conjugates can serve as tracers owing to their receptor mediated binding that results in 
preferential accumulation in tumor vasculature. Both linear and cyclic RGD peptides can be 
employed as targeting vectors to develop αVβ3-targeted imaging tracers. However, linear 
RGD peptides suffer from low binding affinity (IC50>100nM), lack of specificity towards 
αvβ3 and are vulnerable to rapid degradation by proteases in serum in comparison to cyclic 
RGD peptides. Moreover, it has been shown that cyclization of RGD peptides via linkers, 
such as S−S disulfide, thioether, and aromatic rings, leads to increased integrin binding 
affinity [64, 65]. This has led to increasing use of peptides like c(RGDfk) in developing RGD 
targeted tracers or nanoparticles for cancer theranosis [62, 66]. 
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I-3.3.1.3 PSMA ligand: 
Human prostate cancer cell line LNCaP for first time revealed the presence of the type II 
integral membrane glycoprotein called prostate-specific membrane antigen (PSMA) [6]. 
Majority of the prostate cancers exhibit significantly elevated expression of PSMA compared 
to benign prostatic tissue and low expression in non-target tissues. As a result, PSMA is 
considered to be an ideal target for both therapy and diagnosis [67]. Research efforts to 
develop the ligands based on monoclonal antibody led to approval of capromab pendetide 
(ProstaScint®) for SPECT imaging [68]. However, the inherent disadvantages of the full-
scale antibody and the quest for better and improved probes for imaging has generated 
substantial and continued interest in development of small molecule based ligands [69]. 
Current body of research indicates different chemical families of PSMA ligands; 
phosphorous-based (including phosphonate, phosphate and phosphoramidate), thiol-based, 
carbamate-based and urea-based ligands. Although phosphorous based PSMA ligands 
exhibited nanomolar inhibitory potency, these compounds are highly polar and manifested 
poor pharmacokinetic profile limiting the clinical translation. Thiol-based and carbamate 
agents were considered a good alternative, owing to their enhanced membrane permeability 
and oral bioavailability. These agents however suffered from poor metabolic stablility and 
selectivity receding their advancements [70]. Addressing these concerns, a series of novel 
urea-based PSMA ligands has been developed. Of these, the Glu-urea-Lys containing binding 
motif has been of particular interest and led to lead candidates based on optimal combination 
of radiolabel bearing moiety/chelator and linker [71]. The favourable properties of the Glu-
urea-Lys and the extensive experience of our group in developing Glu-urea-Lys based 
imaging agents makes it a compelling case to be used as targeting ligand for the building of 
multimodal theranostics for prostate cancer (Chapter III & IV).   
I-3.3.2 Monoclonal Antibody: 
Contributing to the major immunotherapeutic advances, monoclonal antibodies (mAbs) have 
been able to bring about a paradigm shift in the cancer treatment and care. mAbs target the 
specific receptors on the cancer cells and induce a cascade of events (e.g: antibody dependent 
cytotoxicity/ADCC) leading to cancer cell death. In addition to being used as a standalone 
medicine, monoclonal antibodies have also been used as a vehicle for delivery of highly 
potent anticancer molecules (e.g: maytansinoids) [72], radioisotopes (e.g: 177Lu for 
brachytherapy) and imaging tracers [73]. Use of the mAbs for the targeted delivery of cargos, 
necessitates the use of chemical biology based approaches to conjugate the molecule of 
interest to the mAbs (as described in detail in Chapter 5). The interest of our group in Dijon 
mainly lies in using monoclonal antibodies for imaging [43, 74]. The choice of the target is 
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critical to the selection of the monoclonal antibody. mAbs target several different receptors on 
the cancer cells like HER-2, EGFR, CD20, CD30 etc. to name few. Table I-6 enlists the 
mAbs that have been approved in oncology.  
Table I-6: Tumor-associated antigens targeted by monoclonal antibodies [75].  
 
I-3.3.3 How does the targeting using small ligand differ from the antibody based 
targeting? 
Use of targeting moieties is the basic premise on which the principles of active targeting is 
based. One of the basic questions that a chemist is confronted with is whether to use a small 
molecule based ligand or an antibody given the varied choice of molecules at disposal. 
Obviously, this choice is greatly influenced by the disease in question and its intended target. 
However, it is necessary to understand the differences between these two classes while 
employing them in theranosis. Most of the monoclonal antibodies are highly specific to a 
receptor expressed on the cancer cells and hence might be the only choice for the targeting. 
On the other hand, the number of small molecule based ligands specific to certain receptors is 
relatively limited. The principle difference between antibody and small molecules stems from 
their pharmacokinetic properties. The circulation half-life of monoclonal antibodies is quite 
high compared to the small molecules (3-4 days vs hours) [76]. This is due to the fact that the 
small molecules are excreted rapidly from the system due to their small size unlike 
macromolecular antibodies (except when the chemical ligand shows high protein binding). 
Since the penetrative power of the ligand depends upon its ability to diffuse rapidly across the 
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milieu of the cancerous tissue, this favours the chemical ligand over antibody. In the context 
of developing targeted nanoparticles, it is important to pay attention to the effect on the 
nanoparticle properties upon conjugation with antibody or a chemical ligand which can have 
drastic effect of the pharmacokinetics of the probe [77]. Limitations on the use of the organic 
solvent during targeted nanoparticle synthesis further narrows the choice of antibody for such 
applications. Besides this, use of antibodies can entail higher costs relative to chemical based 
ligands which are relatively much less expensive to synthesize. Thus, above considerations 
make chemical ligands more apt for the applications in imaging and theranosis. Nonetheless, 
the novel formats of the antibodies which are less bulky can overcome the hurdles associated 
with full scale antibody while realising such developments. Also, it might become imperative 
to use antibody or antibody fragments where corresponding chemical ligand for the receptor 
(disease) might not be available or yet developed. 
I-3.4 Conjugation Site and Chemistry: 
A conjugation site enables the multimodal platform to be grafted onto the protein 
(monoclonal antibody or its fragment) or the nanoparticle. Majority of the bioconjugation 
reactions that are used for this application have been summarized in Figure I-10. Typically, 
the nucleophilic site is present on the substrate/protein/nanoparticles. Lysine residues are 
present in abundance whereas cysteine residues can be generated via reduction of the 
endogenous disulfide bonds or can be engineered into the monoclonal antibodies. Likewise, 
the amino groups can be present on the nanoparticles (e.g: AGuIX) and thiol groups can be 
generated on its surface via thiolation reactions using Traut’s reagent. Chemical conjugation 
is an important step in appending the multimodal platform onto the antibody/fragment/protein 
and is expected to take place within short period of time under mild aqueous conditions. In 
order to graft the optimal amount of the platform the probe to protein/nanoparticle ratio needs 
to be optimized to obtain the desired stoichiometry.   
The chemistry that has been widely exploited for development of diverse set of gold 
nanoparticles includes the sulfur-Au chemistry.  Irrespective of the aliphatic or aromatic 
character and surface structures, sulfur bearing molecules are chemisorbed on Au by a strong 
thiol-Au bond (40-50 kcal.mol-1)[78]. This gives an opportunity to synthesize the 
multifunctional ligands bearing the sulfur atoms that can be grafted onto the gold surface. The 
strategy for development of the multifunctional gold nanoparticles described in Chapter III 
relies primarily on the use of lipoic acid as grafting moiety.  
Amide based conjugation reactions involve peptide coupling mechanisms. To realize the 
conjugation reaction based on peptide coupling, NHS esters have been hitherto used as a 
workhorse that entails conversion of the carboxylate group with a relevant coupling agent 
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(e.g: TSTU, carbodiimide plus NHS, etc.). NHS ester based compounds react with primary 
amines (nucleophilic substitution) under slightly alkaline conditions (pH 7.2 to 9) to yield 
stable amide bonds whilst releasing N-hydroxysuccinimide (NHS) as by-product. 
Alternatively, the NHS esters can be generated in-situ and coupling can be carried out in the 
same reaction mixture. Numerous fluorescent dyes, linkers, and chelating agents are 
commercially available as their NHS esters.  
Other conjugation chemistry harnessing the nucleophilicity of the amino group involves 
chemical functionalities like isocyanate or isothiocyanate.  Isocyanates are mostly used in 
polymer chemistry reactions taking place in organic solvents. Their application in aqueous 
conjugation reactions is very limited owing to water sensitive nature of isocyanate. On the 
other hand, isothiocyanates (NCS) are quite stable under aqueous conditions even compared 
to NHS esters and hence find application in acting as conjugation handles. NCS containing 
compounds normally undergo conjugation reaction at pH of 9 (or above) and hence might 
need due consideration when dealing with proteins/nanoparticles prone to degradation in 
alkaline conditions. On the similar lines, hydrazine/aminoxy group undergoes reductive 
amination reactions like oxime ligation and hydrazone formation based on its reaction with 
carbonyl compounds and these reactions have implication in bioconjugation [79]. 
Second to amino group, thiols have been widely explored for the bioconjugation applications. 
The unique nucleophilicity of thiols, particularly in its deprotonated thiolate form (–S-) 
enables it to undergo wide variety of reactions. The dissociation energy of sulfhydryl is 
substantially lower relative to the corresponding alcohols which provides it much higher 
acidity. The conjugation reactions involving thiols usually involve either a nucleophilic 
addition or displacement reaction with the thiolate anion acting as the nucleophile. Thiols 
undergo reactions with -halocarbonyl compounds, perfluoroaromatic molecules, Michael 
acceptors (maleimide and vinyl moiety), 2-cyanobenzothiazole, phenyloxadiazole sulfone etc. 
[80]. 
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Figure I-10: Chemical strategies for bioconjugation & nanoparticles functionalization [81]. 
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Ever since their first introduction by Friedmann, maleimide-mediated reactions (with thiols) 
represent as of today the most frequently used functional groups for bioconjugation and is one 
of the key Michael addition reactions. The optimal reaction conditions for maleimide-
mediated conjugation, are near neutral conditions (pH 6.5–7.5), to avoid the reaction of 
maleimide with amines, which usually need a relatively higher pH. Maleimides are prone to 
hydrolysis beyond pH 8 resulting in a mixture of isomeric non-strained maleamic acids 
unreactive toward sulfhydryls and can thus compete with thiol modification [82, 83]. The halo 
substitution and the Michael addition (involving maleimide) will be exploited in the current 
research work in realizing and applying the multimodal platform to theranosis.  
Owing to its versatile nature, click chemistry has influenced wide range of chemical fields 
like; drug development, and polymer chemistry, chemical biology and nanoscience. Click 
chemistry is quite relevant to the applications where the time is a limiting factor like 
bioconjugation reactions or radiochemistry owing to the sensitive nature of the protein or the 
limited half-life of the radioisotope. Click ligations are rapid and efficient that enables to 
maximize yield while being selective and clean obviating the post reaction work-up. Click 
reactions are mainly of three types; the Cu-catalyzed azide-alkyne cycloaddition (CuAAC), 
the strain- promoted azide-alkyne cycloaddition (SPAAC) and the inverse electron demand 
Diels-Alder reaction (iEDDA) [84]. CuAAC leads to formation of a 1,2,3-triazole ring which 
can be considered as a small and a rigid stereoisomer of an amide linkage causing least 
perturbation of the vector activity. On the other hand, despite its wide utility, SPAAC 
ligations can impregnate the probe structure with a hydrophobic and bulky 
benzocyclooctatriazole footprint which can lead to dramatic changes in the pharmacokinetics 
of the tracer and significantly impaired its uptake [85]. Nonetheless, click chemistry based 
cycloaddition reactions (CuAAC, SPAAC) are rapid and modular with higher yields and 
release nontoxic by-products, remain stable in physiological conditions and utilize benign 
solvents [86, 87]. Inverse Electron-Demand Diels–Alder (iEDDA) cycloaddition entails reaction 
between 1,2,4,5-tetrazines and trans-cyclooctene (TCO) was introduced in 2008 providing a 
marked improvement over the sluggish SPAAC ligation. iEDDA is currently being explored 
for varied applications owing to its extremely fast kinetics (k > 800 M−1.s −1, fastest 
biorthogonal reaction). However, it still leaves the tracer with a bulky bicyclic [6.4.0] ring 
system. One of the drawbacks associated with click reactions for bioconjugation is, solubility 
of the reagents like alkynes, DBCO and tetrazines in aqueous conditions, which can be to 
certain extent addressed by including hydrophilic moieties (e.g: PEG spacers) in the structure. 
Nevertheless, the commercial availability of a wide range of click chemistry tools; derivatives 
of azides, alkynes, DBCOs, tetrazine and TCO reagents has made these reactions a popular 
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choice for bioconjugation applications [88, 89].  
Silanization/silylation is one the widely used processes in functionalization or modification of 
the silicon surfaces in materials chemistry. The 3-aminopropyltriethoxysilane (APTES) is the 
most frequently used organosilane coupling agent in such treatments to generate amine 
functionalized surfaces [90]. Silanization is a condensation reaction taking place at the surface 
of the silica leading to formation of Si-O-Si bond. The silylation process is very complex and 
does not involve a single mechanism. Thus, many different intermediates are possible [91]. 
This chemistry has been also explored to alter the surface chemistry of the inorganic 
nanoparticles like iron oxide nanoparticles (SPIONs) or silica nanoparticles [92]. Developing 
organosilanes based on chelators represent an interesting avenue to functionalize the silica 
nanoparticles with the chelator of choice. It is using this organosilane based conjugation 
chemistry, we envisioned functionalization of AGuIX nanoparticles for multifunctionality 
(Chapter II).  
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I-4 Objectives of the research thesis: 
 
Figure I-11: Application of the monomolecular multimodal platform towards development of 
theranostics. 
In the current thesis, the multimodal platform has been exploited to synthesize the customized 
chemical moieties that can be applied across broad spectrum of systems as depicted in the 
Figure I-11. Chapter II entails development of the silane derivatives of the chelators that can 
be used for the synthesis and functionalization of the silica nanoparticles (AGuIX). It 
demonstrates the efficient use of precursors used for functionalization of AGuIX. It also sheds 
light on its physico-chemical and radiochemical properties along with investigation in TSA 
tumor model to underscore its importance in theranostics. Chapter III deals with development 
of the multifunctional ligands that can be used for fabrication of gold nanoparticles with 
varied properties and aspects. These include ligands for PET, PET-MRI and PET-Optical 
imaging as well as PSMA targeted ligands for SPECT imaging. Since gold is a high Z atom, 
the nanoparticles manufactured using these ligands can obviously be used for radio-
sensitizing applications giving rise to a sophisticated set of theranostic tools. Focussing on the 
tools useful for the prostate cancer management, Chapter IV highlights the state of the art in 
the PSMA targeted multimodal imaging agents. It focusses on the development of small 
molecule based PSMA targeted bimodal (PET-Optical) imaging agent. Along with the 
synthesis, it also delves into the suitability of this probe in terms of its photophysical, binding 
and radiochemical properties. In the last chapter, the focus has been to apply the multimodal 
platform in developing a versatile bimodal imaging probe that can be applied to the 
bioconjugation of monoclonal antibody fragments as well as functionalization of silica 
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nanoparticles. This has been supported by the characterization as well as examination of these 
systems in relevant animal model. The above objectives fit well in the context of the expertise 
available and research focus at Chematech/ICMUB as well as the goals of the ARGENT 
program that aims to focus on developing the processes and technologies catering to the 
improvement of breast, prostate and brain cancer management. 
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II-1 AGuIX Nanoparticles in cancer theranosis: 
Of the diverse inorganic components present in the nature, silicon or Si (IV) is one of the 
essential trace inorganic species having a biological significance. Although, it’s not clear what 
form of metabolism does silica undergo, under ordinary physiological conditions, Si(IV) is 
present as silica, hydrated silica, or hydrated silicate ions, and is taken into the cells for 
promoting the growth of the connective tissue like bone and cartilage. In-vitro experiments 
have revealed that silica/orthosilicic acid has influence on the differentiation and gene 
expression levels the osteoblasts. Cells have the innate ability to engulf particles with size less 
than a few micrometers through their cell membrane with a lipid-bilayer structure through a 
process called endocytosis. Silica or hydrated silica particles in the size range of nanometer to 
micrometer can not only get inside the cells but can also exert biological influence depending 
on its nature and can be harnessed to deliver a drug or an imaging tracer [93]. 
Stöber demonstrated the sol-gel synthesis method for the preparation of monodispersed 
spherical silica particles. This was performed by hydrolysis and condensation of 
tetraethylorthosilicate (TEOS) in ethanolic medium with ammonia as a base [94, 95]. Since 
then, Stöber method has been deployed in different ways for the synthesis of silica 
nanoparticles for various applications. The aqueous sol-gel process can be defined in simple 
terms as the conversion of a precursor solution into an inorganic solid via inorganic 
polymerization reactions induced by water. Typically, a sol-gel process consists of the 
following steps: i) Compounding of a homogeneous solution through dissolution of metal 
organic precursors in an organic solvent (miscible with water), or via dissolution of inorganic 
salts in water; ii) transformation of the homogeneous solution into a sol by treatment with a 
suitable reagent (in most cases, water with or without any acid/base); iii) Subsequent steps 
involve aging and thermal treatment (sintering)[96]. The primary step in a sol-gel reaction is 
the formation of an inorganic polymer induced by hydrolysis and condensation reactions, 
which results in the conversion of the molecular precursors into a crosslinked solid structure. 
Under the optimal conditions of the precursor concentration, solvent, pH and agitation, 
nanoparticles of desired particle size can be synthesized. 
AGuIX nanoparticles have been synthesized on same principle, wherein TEOS condensation 
in the presence of APTES gives rise to amino group bearing nanoparticles. The AGuIX is a 
hybrid nanoparticle based on a polysiloxane core and complexed gadolinium situated at the 
periphery. The concerted efforts of the team led by Prof. Tillement at Claude Bernard 
University, Lyon over a decade has led to the development of this platform. This platform 
represents a unique combination of silica and chelation chemistry making it one of its kind 
amongst myriad of nanoparticles currently explored in theranosis. These nanoparticles are 
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multimodal in that they can be used both as a positive contrast agent in MRI and as a 
radiosensitizing agent in cancer theranosis. This chapter will focus on the thesis work carried 
out in the context of these nanoparticles after a brief introduction of this platform technology. 
II-1.1 Synthesis and structure of AGuIX: 
 
Figure II-1. Structure of AGuIX nanoparticle. 
As can be seen from the Figure II-1, classical AGuIX nanoparticles are composed of a 
polysiloxane backbone surrounded by around ten DOTAGA ligands. 98-99% of these ligands 
are complexed with Gd3+ ions. A typical tetraazamacrocycle (DOTA/DOTAGA) provides 8 
coordination sites for the chelation of the Gd3+ ion.  Conventional DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) has four carboxylate arms, whereas 
DOTAGA provides an additional carboxylate group available from the glutaric arm that 
serves as an achoring point for synthesis of multimodal agents. This macrocyclic chelator has 
a very high complexing constant for the Gd3+ ion (logK = 25.6) and slow dissociation kinetics 
[97]. As a result, any release of Gd3+ ions into the body after injection of the particles is 
precluded, which otherwise would cause a toxic effect. The particles also have about fifteen 
primary amine functions at the surface that can be used for subsequent functionalization. On 
the other hand, these particles have an average hydrodynamic diameter of about 3-5 nm and a 
mass of about 10 kDa, making them amenable to renal elimination.  
Polysiloxane network (APTES/TEOS)
DOTA(Gd) (a kind of DOTAREM®)
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Figure II-2. Classical synthesis of AGuIX nanoparticles. a) core synthesis, b) polysiloxane 
shell synthesis, c) DOTAGA grafting, d) transfer to water, e) core dissolution, f) polysiloxane 
fragmentation. Figure adapted from [98]. 
The AGuIX nanoparticle synthesis involves a mixed bottom-up and top-down approach as 
explicated in the Figure II-2. The synthesis starts with the preparation of a core of gadolinium 
oxide via alkaline treatment of the GdCl3 salt, which is then encapsulated in a polysiloxane 
layer.  This is obtained by hydrolysis-condensation of tetraethoxysilane (TEOS) and 3-
aminopropyltriethoxysilane (APTES) on the surface of the Gd core. TEOS has been a 
chemical of choice to crosslink and densify the polysiloxane network as reported in majority 
of the silica nanoparticle based schemes whereas APTES enables to have the amine groups 
integrated with the siloxane core that remains at the surface of the particle and which can be 
used as appendage point for subsequent functionalization chemistry. Following the shell 
synthesis, DOTAGA is coupled to the surface amino groups via an amide bond. Presence of 
the DOTAGA groups on the surface increases the water dispersibility/solubility and the 
colloidal stability of the nanoparticles. Finally, the nanoparticles are transferred to water, 
during which the dissolution of the gadolinium oxide core causes the fragmentation of the 
polysiloxane layer, giving rise to ultrafine nanoparticles: AGuIX® nanoparticles. The 
released Gd3+ is subsequently chelated by the free DOTAGA causing it to be lodged at the 
periphery of nanoparticles [99]. The ultrasmall nanoparticles are then purified to remove the 
extraneous components using the ultrafiltration device. After purification, the AGuIX® 
nanoparticles are lyophilized to get a powder that can be stored at room temperature for more 
than one year. The AGuIX nanoparticles can be produced on a large scale in a reproducible 
Chapter II. Multifunctional polysiloxane (AGuIX) nanoparticles for cancer theranosis 
Multifunctional platforms for cancer theranosis   55
manner at the laboratory scale (~ 50 g of particles corresponding to ~ 50 mmol of Gd3+). A lot 
has been also produced under conditions of Good Manufacturing Practices (GMP) in 
partnership with Carbogen AMCIS (600 g) for the investigations pertaining to the human 
clinical trial.  
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II-2 Functionalization of AGuIX: 
Surface chemistry of the nanoparticles defines its ability to remain stable at physiological 
conditions and also its amenability to undergo surface alteration or functionalization. AGuIX 
nanoparticles are rich in surface composition in that they possess abundant silanol (from 
hydrolysed and uncondensed TEOS) and amino (from hydrolysed APTES) groups. Since, the 
silanol and amino groups have different acid–base properties, the surface amino groups also 
control the repulsive forces amongst the adjacent particles, and hence contribute to the 
stability. Some of the amino groups are also then used to attach a chelate (DOTAGA) that 
will ultimately form complex with gadolinium. Moreover, AGuIX nanoparticles offer further 
scope for its functionalization via availability of the active surface moieties like –NH2 (from 
APTES), -COOH (from the free uncomplexed carboxylate groups of DOTAGA) or –OH 
(silanols). In the previous work, Morlieras et al. demonstrated use of –COOH and –NH2 
groups for the functionalization of the nanoparticles with peptide ligand and fluorescent 
dye[35]. Truillet et al. exemplified synthesis of NODAGA functionalized AGuIX based on 
amide coupling employing the –NH2 of nanoparticle and the NHS ester of NODAGA[100]. 
However, this approach is not so lucrative as reaction conditions are not amenable to the 
stability and yield of the final product. In this chapter, we demonstrate for first time the 
functionalization of AGuIX with NODAGA employing the surface silane chemistry. Part of 
this work was performed during my secondment at Prof. Tillement’s group in Lyon and was 
result of the close collaboration with his team involving Dr. Lux François and Vulong Tran. 
The first step toward realization of this approach was to synthesize silane bearing chelates and 
then perform functionalization of AGuIX using the silane bearing chelators. 
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II-2.1 Nanoparticle synthesis and functionalization with silane chelators: 
II-2.1.1 Synthesis of the DOTAGA-Silane: 
 
 
        (1) Yield: 78% 
Figure II-3. Synthesis scheme of DOTAGA(tBu)4-APTES (1). 
DOTAGA-(tBu)4 was used as a starting point for the synthesis of DOTAGA-silane 
compounds. DOTAGA-(tBu)4 was first activated to form an ester using HBTU and HOBt, 
which was then peptide coupled with APTES ((3-aminopropyl)triethoxysilane) (Figure II-3). 
To get rid of the excess of the reagents and side products the product containing organic phase 
(dichloromethane) was successively washed with weakly acidic, basic and neutral aqueous 
solution. The product was obtained as a light brown viscous residue (1). The formation of the 
product was confirmed by HRMS (Figure II-4). The product was detected as M+Na+ species 
at m/z = 926.5. 
             
Figure II-4. Mass spectrum of DOTAGA(tBu)4-APTES (1): A) Experimental spectrum, B) 
Simulated/Theoretical spectrum. 
 
A) 
B) 
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(1)        (2) Yield: 81% 
Figure II-5. Synthesis scheme of the DOTAGA-Silane (2). 
Typically, deprotection of the t-butyl group can be brought about by treatment with TFA, 
however, the experience with simple macrocyclic compounds suggests that conc. HCl acts as 
an effective and fast deprotecting agent. As a result, deprotection of the compound (1) could 
be easily effected by a brief treatment with conc. HCl (36% HCl) (Figure II-5). Compound (2) 
was obtained with a yield of 81%as a light brownish brittle compound as a salt of chloride 
and HPF6 that tended to be hygroscopic when left at room temperature.  
II-2.1.2 Synthesis of the NODAGA-Silane: 
 
  (3) Yield: 99% 
Figure II-6. Synthesis scheme of NODAGA-(tBu)3-APTES (3). 
On the similar lines as followed for DOTAGA, synthesis of a silane derivative of NODAGA 
was attempted as NODAGA is a more efficient chelator for the PET based radioisotopes like 
64Cu and 68Ga and hence could be of significant value in development of variants of AGuIX 
with multimodal imaging capability. NODAGA-(tBu)3-APTESwas synthesized in a manner 
analogous to the compound (1),where in the t-butyl protected NODAGA (NODAGA-(tBu)3) 
was coupled to APTES using HBTU based coupling chemistry (Figure II-6). This 
intermediate protected compound (3) was obtained in good yield (99%) and could be detected 
as M+H+species at m/z =663.4 when analysed by HRMS (Figure II-8). Alternatively, the 
compound could also be characterized by proton and carbon NMR.   
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        (3)               (4) Yield: 96% 
Figure II-7. Synthesis scheme of the NODAGA-Silane (4). 
Deprotection of the compound (3) proceeded quickly in conc. HCl as expected (Figure II-7). 
The excess HCl was immediately evaporated off. The residue obtained was easily solubilized 
in water which upon lyophilisation afforded a light brown compound obtained as a salt of HCl 
and HPF6.  
 
Figure II-8. Mass spectrum of NODAGA-(tBu)3-APTES(3): A) Experimental spectrum, B) 
Simulated/Theoretical spectrum. 
Organic silanes in general are labile compounds as they have propensity to undergo inter-and 
intra-molecular condensation reactions, hence, the silanes depicted above can form and exist 
in dimeric or oligomeric form. As a result, an accurate characterization attributable to 
monomolecular species might not be always feasible.  Nonetheless, the complementary 
characterization tools enable to ascertain the analysis of the compounds synthesized here. 
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Moreover, adapting the process of the nanoparticles synthesis/functionalization to completely 
harness the utility of these silanes has delivered successful results and has been discussed in 
following sections. The silanes synthesized hereof have not just been used for 
functionalization of nanoparticles but also explored for the one pot synthesis of the silica 
nanoparticles (AGuIX).  
The one pot synthesis of the nanoparticles based on these silanes forms the part of research 
thesis of Vulong Tran, one of the ESRs within the consortium of ARGENT project at 
Université Claude-Bernard, Lyon. This highlights the collaborative and multidimensional 
value of the work described here.  
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II-2.1.3 Nanoparticle functionalization with silane bearing chelators: 
Silica surfaces can be treated with silane derivatives so as to have the materials with desired 
surface chemistry. For instance, treatment of the glass surface/silicon wafers with APTES can 
result in the formation of amine functionalized surfaces that can be used for varied application 
like enzyme immobilization or building antibody coated surfaces. Based on similar principle, 
we condensed the surface silanols present on the AGuIX surface with silane bearing chelators. 
 
 
 
 
Figure II-9. Functionalization of the AGuIX nanoparticles with the silane derivatives of 
DOTAGA and NODAGA.  
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The silane derivatives were briefly dissolved in alkaline aqueous solution so as to have the 
monomeric species present in the solution. Each type of chelator silane was mixed with 
AGuIX in molar ratio of Gd: silane-chelator = 10: 1.5 with the pH adjustment, if needed. The 
nanoparticle solution was stirred in light protected environment for overnight (16h) at the pH 
of 7.0-7.5 (Figure II-9). Furthermore, this process is currently undergoing optimization with 
respect to various process parameters and concentrations, so as to have optimally developed 
process yielding defined nanoparticle characteristics. 
The pH of the solution was adjusted to 2 by adding HCl solution before the purification to 
quench any further reactions/degradation. Then each solution was purified with tangential 
filtration through Vivaspin membranes (MWCO = 5 kDa) employing 9 cycles. Following 
this, pH of the solution was readjusted to 7.4 and solution was filtered through 0.2 µm 
membrane to remove dust and large impurities/microbes. Finally, the solution was lyophilized 
in vials to obtain the powder that could be stored for long time at room temperature. 
II-2.2 Physico-chemical properties of functionalized nanoparticles: 
 
Figure II-10. Dynamic light scattering measurement of AGuIX nanoparticles. 
Table II-1.  Physico-chemical properties of the functionalized nanoparticles. 
Sample AGuIX AGuIX-DOTAGA AGuIX-NODAGA 
Hydrodynamic Diameter (nm) 4.2 ± 0.8 4.5 ± 0.9 4.5 ± 0.9 
Zeta Potential 
(mV at pH 7.4) 
+8.15 -8.43 -13.7 
DLS measurements were performed on the native and the functionalized nanoparticles using 
Zetasizer Nano-S (633 nm He-Ne laser) from Malvern Instruments. Measurements was made 
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using 1 mL of the solution at around 5 – 10 g/L with a single use PMMA cuvette (Carl Roth 
GmbH, Germany) at 20 °C. For the Zeta potential, the lyophilized powder was re-dispersed in 
water to achieve 100 mg/mL solution and diluted to 10 mg/mL in an aqueous solution 
containing 5 mM NaCl and adjusted to the desired pH (7.4) just before each measurement. 
Zeta potential measurements were recorded at 20 °C within a DTS 1061 folded capillary cell 
(Malvern Instruments Ltd, USA). The zeta potential (ζ) was automatically calculated from 
electrophoretic mobility based on the Smoluchowski equation, ν = (εε0ζ /η)ζ, where ν is the 
measured electrophoretic mobility, η is the viscosity, ε is the dielectric constant of the 
electrolytic solution, ε0 ≈ 8.854 x 10-12 C2N-1m-2 is the vacuum permittivity. 
As has been routinely observed, AGuIX nanoparticles exhibited a hydrodynamic diameter 
(Dh) of 4.2nm, whereas functionalized nanoparticles displayed a slight increase amounting to 
the size of 4.5nm for both AGuIX-DOTAGA and AGuIX-NODAGA. This small increase in 
the size could be attributed to the appendage of the chelators on to the nanoparticles. This 
inference was compounded from the zeta potential measurement results, wherein the surface 
potential of the nanoparticles changed from positive to negative after grafting of the chelators 
on nanoparticles. In its native form, AGuIX has a slight positive charge owing to the presence 
of surface amino groups (+8.15mV). Upon functionalization, the surface charge turned 
negative with the value of -8.43mV and-13.7mV for AGuIX-DOTAGA and AGuIX-
NODAGA (Table II-1). Moreover, a monomodal symmetric peak/correlogram obtained after 
the DLS analysis (Figure II-10) suggests that the nanoparticles are monodisperse, despite the 
small particle size range.  
 
Figure II-11. Chromatographic analysis of the functionalized nanoparticles using HPLC at 
285nm. 
Although AGuIX are a class of nanoparticles, their unusual small size permits their analysis 
by reverse phase HPLC, which otherwise is not so common. As can be seen form the Figure 
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II-11, AGuIX exhibit a retention time of about 14min. The retention time of AGuIX-
DOTAGA was slightly shifted to right with retention time of 15.5min. Similar observations 
were made for AGuIX-NODAGA. In addition, a relative peak broadening was also observed 
which could be due to different size and charge characteristics of the functionalized 
nanoparticles in comparison to AGuIX. 
 
Figure II-12. Chromatographic analysis (RP-HPLC) of the Cu2+ complexed functionalized 
nanoparticles at A) 700nm and B) 375nm. 
To further verify that indeed the chelators have been grafted on the nanoparticles, AGuIX-
DOTAGA and AGuIX-NODAGA were complexed with Cu2+ (using molar excess of CuCl2) 
by incubating at pH 3 and 80°C for 2h. The Cu2+ labelled nanoparticles were analysed by 
HPLC with detection at 700nm as the copper chelate complex is blue coloured and exhibits 
max in this region. As can be seen from Figure II-12, pristine AGuIX exhibits almost a flat 
profile with a small spike at around 15min as the amount of free/uncomplexed DOTAGA 
present on AGuIX to chelate Cu2+ is only 1% of the total DOTAGA present on AGuIX. 
However, with the functionalised nanoparticles; AGuIX-DOTAGA and AGuIX-NODAGA 
there is distinct peak at 15min (at the same position as observed at 375nm) which indicates 
grafting of the free chelators which afford the nanoparticles the ability to complex Cu2+. 
Relaxometric studies were also performed on the nanoparticles to evaluate the effect on 
contrast properties by the measurements of the longitudinal and the transversal relaxivity 
(respectively r1 and r2). One of the common approaches to increase relaxivity is to decrease 
the molecular tumbling by attaching/integrating gadolinium complexes to a macromolecular 
structure through rigid linkages [101].  
The longitudinal relaxivity (r1) increased from 13.70 to 17.97 or 18.17 mM-1. s-1, (whereas, r2 
increased from, 19.15 to 25.44 and 25.84) indicating an increase in rotational correlation time 
A. B. 
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resulting from the grafting of a ligand. On the end, the ratio r2/r1 slightly increased but stayed 
around 1.4 indicating that the efficiency of the NPs as positive contrast agents was still 
maintained (Table II-2). 
Table II-2. Relaxometric properties of AGuIX, AGuIX-DOTAGA and AGuIX-NODAGA at 
37 °C (1.4 T & 60 MHz). 
Sample 
Concentration 
(mM) 
T1 r1 T2 r2 r2/r1 
AGuIX  100 0.73 13.70 0.52 19.15 1.40 
AGuIX-DOTAGA 76.3 0.729 17.97 0.515 25.44 1.42 
AGuIX-NODAGA 76.3 0.721 18.17 0.507 25.84 1.42 
 
Fourier Transform Infra-Red (FTIR) spectroscopy is an excellent tool for the qualitative 
assessment of the materials based on the functional groups present on it. The FTIR analysis of 
a compound or material generates a spectrum which acts as a signature of its structural 
information. This is due to the fact that different types of bonds, and thus different functional 
groups, absorb infrared radiation of different wavelengths. Although the analysis takes into 
account the absorbance by the materials, it is typically converted to transmittance and 
represented as plot of % transmittance against the wavenumber as has been depicted in Figure 
II-13. 
 
Figure II-13. FTIR Spectroscopy of the functionalized nanoparticles performed on lyophilized 
powder (at pre-lyophilisation pH of 2). 
There has been a slight increase in intensity of peak at 1730 cm-1 and 935 cm-1 that proves the 
appearance of free COOH groups. Strangely, in the case of AGuIX-NODAGA, peak at 1390 
cm-1 reduces. Probably, this peak is a combination of signals from COOH and NH2. This 
could be possibly due to the fact that NODAGA contains one COOH and one NH2 group less 
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than DOTAGA, the contribution of those peaks in the total spectrum is less than in the case of 
AGuIX-DOTAGA. Nonetheless, complementing other tools of characterization, FTIR data 
supports the successful grafting of the chelators onto the AGuIX. 
A)  
           AGuIX   AGuIX-DOTAGA  AGuIX-NODAGA 
B)  
Figure II-14. Eu+3 Phosphorescence based titration of the grafted macrocycle on the 
nanoparticles: A) Emission spectrum of Eu+3chelate of AGuIX-DOTAGA/NODAGA. B) 
Titrimetric determination of free chelator content based on inflection point employing 
phosphorescence. 
Estimation of the number of the free chelators is of utmost importance to ascertain the number 
of chelators grafted onto nanoparticles and for the overall characterization of nanoparticles as 
a tracer. Assay to quantify the number of free chelators present in the solution based on the 
spectrophotometric/colometric and luminescent analysis have been developed for the chelate 
functionalized nanoparticles [100, 102]. The colorimetric assay is based on the use of xylenol 
orange as an indicator which has the ability to form a coloured complex with Gd3+. Xylenol 
orange is a weaker ligand than chelator like DOTAGA. An aqueous solution of GdCl3is 
gradually added to a colloidal solution of nanoparticle containing free chelators. When there 
is no more accessible chelator, Gd3+ions are chelated by xylenol, thus modifying the UV-vis 
absorption spectrum of xylenol. At pH values between 2 and 4, the absorption spectrum of 
xylenol orange is characterized by a strong absorption band at 443 nm in the absence of Gd3+. 
When xylenol orange is coordinated to Gd3+, two main absorption bands are observed at 479 
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and 569 nm. The amount of the free chelators can then be retrospectively computed based on 
the amount of the Gd3+added to the nanoparticle solution, until there is change in the color of 
the solution or change in the spectrum. On the other hand, luminescence assay is based on the 
principle of phosphorescence observed with the complex of europium with chelator. 
Luminescence titrations are more sensitive and accurate compared to the colorimetric assays 
and hence can be employed when the colorimetric assays fall short of providing necessary 
information. The concept of this innovative tool for accurate chelate quantification arises 
from (i) the finger print of lanthanide luminescent centres with the chelating agent, (ii) the 
high sensitivity at relatively low sample concentrations and (iii) the exclusion of the parasitic 
signals coming from the background. Europium has several advantages that makes it the 
lanthanide of choice for this assay; (i) Close chemical reactivity to gadolinium ions (ii) 
Similarity of the stability constants for chelation (DOTAGA, NODAGA) to that of 
gadolinium (iii) Sensitivity of the luminescence spectrum to the ion environment enabling 
separation of each component and (iv) The fluorescence background of residual organic 
impurities can be overcome due to long lifetime allowing time-resolved assays. In the case of 
functionalized AGuIX described in this chapter, the free chelator content was determined by 
luminescence assay. As can be seen from Figure II-14, the excitation of the europium chelate 
complex at 395nm results in an emission spectrum with two peaks at 595nm and 616nm. 
Varying concentration of Europium was incubated with fixed amount of functionalized 
nanoparticles at 80°C for 48h at pH 5 (acetate buffer) following which phosphorescence 
measurements were done. The estimate of the free chelators grafted on AGuIX could be made 
based on the inflection point observed in the titration curves. Based on these titration curves, 
it was observed that the amount of the free chelators appended on the AGuIX were around 
10% in comparison to the pristine AGuIX (1-2% free chelators). This roughly translates to 
one free chelator on each nanoparticle that possesses approximately 10 DOTAGA-Gd 
chelates/complexes. 
 
  
Chapter II. Multifunctional polysiloxane (AGuIX) nanoparticles for cancer theranosis 
Multifunctional platforms for cancer theranosis   68
II-2.3 Radiolabelling and study of the stability of radiolabelled nanoparticles: 
AGuIX nanoparticles have the potential to act as multimodal imaging agents in addition to 
their radiosensitising potential. The presence of the residual free chelators like DOTAGA can 
be labelled with a suitable isotope like 111Infor SPECT-MRI imaging [103]. With the advent 
of the commercial FDA approved PET-MRI systems for clinical diagnosis, it has become 
possible to obtain the functional and the anatomical information necessary for the detailed and 
accurate diagnosis in single sitting. Despite the commonly used radionuclide for PET is18F 
(half-life 110 min), 68Ga (half-life 68 minutes) is gaining popularity owing to its ease of 
availability from a commercially available68Ge/68Ga generator system that can deliver the 
68Ga nuclide reliably for up to a year, without the need of a cyclotron. NODAGA 
functionalized AGuIX have been used for PET-MRI imaging and have been shown to be 
radio-labelled with 68Ga [100, 104]. Using the current novel scheme of functionalization, the 
NODAGA functionalized AGuIX have been demonstrated for first time to be radiolabelled 
with 64Cu.  Unlike 68Ga, the 12.7-hours half-life of 64Cu provides enough flexibility to image 
both smaller molecules and larger slowly clearing proteins and nanoparticles making it an 
isotope of choice for the proposed application. 
The AGuIX-NODAGA nanoparticles could be easily radiolabelled with a facile protocol. 
Nanoparticles were incubated with 64Cu in AcONH4 buffer (pH: 5.8) for 45min at 37°C. Post 
the incubation, the radiolabelled nanoparticles were analysed with SA-ITLC using 0.1M 
EDTA as a mobile phase. The radiochemical purity of the nanoparticles was found to be 
satisfactory (>95%). 
 
Figure II-15. Radio-chromatogram of the AGuIX-NODAGA(64Cu) performed by ITLC using 
0.1M EDTA as mobile phase. 
With the good radiochemical purity, it becomes necessary to assess the integrity of the 
radiolabelled nanoparticles under physiological conditions, wherein the radiolabelled 
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nanoparticles might potentially undergo any alteration owing to nanoparticle degradation or 
trans-chelation of 64Cu under the influence of endogenously present bivalent cations or 
chelating moiety. The radiolabelled nanoparticles were incubated with human plasma at 37°C 
for up to 48h. Moreover, EDTA challenge assay was performed at pH 7 in HEPES buffer to 
ascertain the resistance of the nanoparticle to trans-chelation by commonly employed 
chelating agent EDTA.  
 
Figure II-16. Stability of the radiolabelled nanoparticles in human plasma and EDTA. 
As can be seen from the above Figure II-16, the 64Cu complexed AGuIX-NODAGA were 
found to be stable over much longer duration. More than 98% of the 64Cu remained 
incorporated in the nanoparticles at end of 48h. The anticipated time spent by the 
nanoparticles inside the biological system (in vivo-mice) would be much shorter than 48h. 
EDTA challenge test revealed that more than 95% of the 64Cu remained incorporated in the 
AGuIX-NODAGA at end of 48h. The large excess of EDTA experienced by the nanoparticles 
as in the above experiments may not be relevant to conditions in vivo but still generates the 
confidence in stability of radiolabelled AGuIX-NODAGA. 
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II-3 Animal imaging in TSA tumor model: 
To evaluate the targeting potential and understand the pharmacokinetics of the nanoparticles 
the radiolabelled nanoparticles were intravenously injected into mice bearing TSA tumor 
(mammary adenocarcinoma). The dose of the nanoparticles was calibrated taking into 
consideration the amount of the nanoparticles needed for the radiosensitization during the 
radiotherapy based on the previous experience with these nanoparticles. The nanoparticles are 
currently under Phase I clinical trial in France for their radiosensitizing application. The 
nanoparticles were radiolabelled as explained earlier. 10mg of AGuIX-NODAGA(64Cu) 
nanoparticles in PBS corresponding to activity of 10 MBq was injected via tail vein in each 
mouse (n=3). The PET‐MR dual imaging was performed at 1 and 24 hours after the injection 
of the radiolabelled nanoparticles using a LabPET scanner (Trifoil Imaging) coupled in line 
with a small animal 3T MR small animal imaging system (MR Solutions) after anaesthesizing 
the mice with isofluorane (1.5‐3% in air)  [105]. After the last image acquisition, animals 
were sacrificed by isoflurane anaesthesia followed by pentobarbital overdose. Blood, tumour 
and organs were collected, weighed and radioactivity in these samples was measured with a 
gamma‐well counter. The counter was cross‐calibrated to the dose calibrator used to measure 
the injected dose and the linearity range was determined for all the geometries used in ex‐vivo 
counting. Data were then converted to percentage of injected dose and to percentage of 
injected dose per gram of tissue. 
 
Figure II-17. PET-MRI imaging in TSA tumor models at 1h and 24h after injection of 
AGuIX-NODAGA(64Cu). 
As can be seen from the axial and the coronal images (Figure II-17), the nanoparticles 
provided enhanced PET-MRI images with modest accumulation at the tumor site and major 
accumulation in kidneys and bladder at end of 1h.  At 24h, the decrease in the intensity of the 
signals was evident indicating excretion of the nanoparticle preferentially via renal route. This 
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was further compounded by the biodistribution analysis based on the gamma counting the 
signals received from the recovered organs (Figure II-18). 
 
Figure II-18. Biodistribution of AGuIX-NODAGA(64Cu) at the end of 24h. 
At the end of 24h, the nanoparticles were observed to be distributed into liver, tumor, lungs 
and spleen. However, these signals were relatively quite weak compared to the signals from 
the kidneys which could possibly indicate that the nanoparticles are in process of getting 
excreted.  
Moreover, at the end of 24h the nanoparticles are significantly cleared from the circulation 
with signals from blood almost nil. The accumulation in the tumor was not very high and 
several factors could be attributed to this including the tumor model/physiology and hence it 
could be interesting to evaluate this multifunctional system in other tumor models. 
Nonetheless, the studies highlight the fact that the nanoparticles can be cleared from the body 
via renal excretion and do not suffer from the problem of biopersistence in major organs as is 
observed with many other inorganic nanoparticles. This clearly demonstrates the value of this 
multifunctional nanoparticles in cancer theranosis.  
  
0
5
10
15
20
25
30
Blood Liver Tumor Muscle Lungs Brain Kidney Spleen
%
 I
D
/g
 Biodistribution of AGuIX-NODAGA(64Cu) 
Chapter II. Multifunctional polysiloxane (AGuIX) nanoparticles for cancer theranosis 
Multifunctional platforms for cancer theranosis   72
II-4 Conclusions: 
AGuIX are a novel and unique class of nanoparticles amongst several types of silica based 
nanoparticles reported in literature. These nanoparticles have exhibited an excellent 
theranostic value through their rigorous assessment in different pre-clinical models. 
Currently, these nanoparticles are undergoing clinical trials (Phase I) for their radiosensitizing 
application. The existing method of nanoparticle synthesis and functionalization is 
cumbersome and hence warranted new approaches for facile development. The works 
demonstrated in this chapter addresses this aspect as can be seen from below conclusions: 
1. Silanes based on DOTAGA and NODAGA have been synthesized based on the prior 
knowledge and experience with these chelators and have been characterized using 
NMR, elementary analysis and mass spectrometry.   
2. The chelator based silanes have been successfully demonstrated to be used for the 
functionalization of the AGuIX nanoparticles and these nanoparticles have been 
characterized qualitatively and quantitatively using various techniques. 
3. The NODAGA functionalized nanoparticles have been radiolabelled with 64Cu and the 
stability of the AGuIX- NODAGA (64Cu) assessed in human plasma and EDTA has 
been shown to be favourable until 48h. 
4. The NODAGA functionalized nanoparticles/ AGuIX- NODAGA (64Cu) have been 
investigated in TSA tumor model in mice for the PET-MRI application. 
Pharmacokinetic and biodistribution studies demonstrated moderate tumor 
accumulation and renal clearance of the nanoparticles at the end of 24h, highlighting 
the theranostic potential of these nanoparticles. 
The work performed in this chapter holds considerable value in terms of the applicability of 
the tools/approaches developed. The outcomes also highlight the strengths of the 
collaborative efforts between the teams in Dijon and Lyon. Further work encompasses, the 
optimization of the synthesis/functionalization processes in employing silanes to afford 
customized and well-defined materials as well as biological investigation in additional in-
vitro/in-vivo tumor models to better ascertain their theranostic value.
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III-1 Gold Nanoparticles for cancer theranosis: 
Inorganic nanoparticles possess unique physico-chemical, optical and/or electronic properties 
compared to nanoparticles made of organic materials. These attributes are particularly useful 
for the development of imaging agents or theranostics. Amongst this class, gold nanoparticles 
are widely investigated nanoparticles for diverse set of applications including computed 
tomography, radiotherapy, MRI/PET/SPECT, drug delivery, etc. Gold nanoparticles have a 
high X-ray absorption coefficient (at 100 keV Au=5.16 and I=1.94), amenability to surface 
functionalization, good tissue compatibility, special surface plasmon resonance properties and 
ability to passively target tumor.  The ease of functionalization of these nanoparticles make 
them unique as multifunctional nanoagents.  
Chematech and ICMUB have been able to develop unique ligands based on linear or 
macrocyclic chelator compounds particularly for nanomedicine. These ligands have been 
successfully used for functionalization of gold nanoparticles.  This has been achieved by 
harnessing the nanoparticle synthesis expertise of scientists led by Prof. Stephane Roux from 
UTINAM, Besançon. This collaboration is significant not just in terms of the institutional 
partnership but also within the framework of ARGENT as these gold nanoparticles will be/are 
being used and explored biologically for diverse cancer applications by the partners within 
this consortium.  
 
Figure III-1: Synthesis of gold nanoparticles based on DTDTPA. Adapted from [106]. 
The first-generation gold nanoparticles based on DTDTPA have been reported in 2008, 
DTDTPA was synthesized from diethylenetriaminepentacetic acid bis-anhydride and 
aminoethanethiol (Figure III-1)[107]. These nanoparticle (Au@DTDTPA-Gd) were found to 
be promising for MRI imaging.  Moreover, these nanoparticles have also been implicated in 
SPECT imaging and have been shown to be cleared from the body via renal excretion [106]. 
Owing to the presence of high atomic number atoms like Au and Gd, these nanoparticles have 
exhibited radiosensitizing properties in preclinical models of gliosarcoma and prostate cancer 
[108, 109]. These studies clearly stand the testimony to the multifunctionality of this class of 
gold nanoparticles. 
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Recently, gold nanoparticles based on macrocyclic chelators have been synthesized as an 
advancement over the DTDTPA based nanoparticles. Macrocyclic chelators have excellent 
chelating ability in terms of stability of the complexes with the heavy atom or radioisotope 
compared to the linear chelators like DTPA. In a recently published paper, gold nanoparticles 
based on macrocyclic ligands (Au@DTDOTA, Au@TA-DOTA and Au@TA-DOTAGA) 
have been shown to increase the lifespan of rats bearing 9L gliosarcoma owing to 
radiophysical effects after intravenous administration. It can also be noted that there were 
differences in the efficiency of radiosensitization amongst this class of nanoparticles which 
could be attributed to the structural changes associated with the macrocyclic ligands [110].   
 
Figure III-2: Functionalization strategies for gold nanoparticles. 
The nanoparticles mentioned above are limited in terms of further functionalization, for the 
purpose of imparting multimodality in the context of imaging or for active targeting. This 
stems from the absence of functional group that is easily amenable to grafting of a targeting 
ligand or an alternate chelating/contrast agent.  This necessitates the availability of site on the 
ligand that can be easily conjugated to agents mentioned above. Development of ligand 
bearing an amino function presents a rational approach in developing the gold nanoparticles 
that can be functionalized later in a post-functionalization approach (Figure II-2_A). 
Alternatively, the amino bearing ligand can be derivatized with desired agent (targeting 
ligand) and then can be employed for gold nanoparticle synthesis depicting a pre-
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functionalization approach (Figure III-2_B). Generation of an amino group containing ligand 
was based on developing a linker system that is capable of integrating the chelating moiety, 
gold binding moiety and an amino group. Following sections describe the approaches and the 
ligands that were synthesized towards achieving this objective, so as to develop diverse set of 
gold nanoparticles with a high value in cancer theranosis.  
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III-2 Development of DOTAGA based amine functionalized gold nanoparticle: 
III-2.1 Synthesis of DOTAGA-Lys-TA-NH2 
 
 
            (5) Yield: 73% 
Figure III-3: Synthesis scheme of DOTAGA-Lys-Fmoc-Dde (5). 
The development of an amine functionalized gold nanoparticle began with synthesis of 
DOTAGA-Lys-Fmoc-Dde. Synthesis of DOTAGA-Lys-Fmoc-Dde (Figure III-10) could be 
realized by coupling of DOTAGA-NH2 with activated NHS ester of Lysine-Fmoc-Dde. Since, 
the deprotected DOTAGA-NH2 was used, the reaction was carried in aqueous DMF solution, 
as DOTAGA-NH2 is only soluble in water. The NHS ester of Lys-Fmoc-Dde could be 
obtained in DMF solution and was verified by LC-MS following which DOTAGA-NH2 was 
added to the reaction mixture to perform an amide coupling. The resulting compound (5) was 
purified by flash chromatography with the yield of 73% and HPLC purity of 98%. 
Compound (5) was a crucial intermediate in terms of the orthogonality offered by the 
differentially protected lysine which can be explored in sequential manner to get the desired 
topology of the subsequent compounds. 
 
 
       (5)       (6) Yield: 77% 
Figure III-4: Synthesis of DOTAGA-Lys-Dde-NH2 (6). 
DOTAGA-Lys-Dde-NH2 was obtained by deprotection of the Fmoc group present in 
compound (5) by treating with diethylamine (Figure III-4). The reaction proceeds very 
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quickly and does not alter the stability of the dde group present on the epsilon amino group. 
The purified compound (6) was characterized by HR-MS that revealed the molecular peak at 
811.456 M+H+ and a purity of over 99%. 
 
  (6)       (7) Yield: 95% 
Figure III-5: Synthesis of DOTAGA-Lys-TA-Dde (7). 
In order to impart the ability to compound to be employed for the synthesis of gold 
nanoparticles, it is necessary to possess the functionality that will bind over the surface of the 
gold surface. A thiol bearing moiety is a function of choice in developing gold nanoparticles. 
DTDTPA is a chelator bearing two thiol groups that has been demonstrated previously to be 
useful in the development of first generation gold nanoparticles. However, the replacement of 
linear chelators by macrocyclic chelators appears to be a better alternative as the latter forms 
more stable and inert complexes with gadolinium ions. Thioctic acid represents a preferable 
handle for the attachment of the chelator to the gold surface as it possesses two sulfur atoms 
that can enforce stronger, monomolecular and uniform bond formation between gold and the 
chelator and prevent any potential inter-molecular polymer formation unlike DTDTPA. This 
was achieved by treating compound (6) with pre-synthesized thioctic acid-NHS ester in the 
presence of base (Figure III-5). Amide coupling resulted in compound (7) that was purified by 
flash chromatography and obtained in good yield (95%) and purity.   
The last step of the scheme entailed deprotection of the Dde group on the lysine side chain to 
obtain the anticipated compound containing the desired features. This was realized by 
adopting the deprotection strategy proposed by Bradley et al. [111]. 
 
  (7)        (8) Yield: 48% 
Figure III-6: Synthesis of DOTAGA-Lys-TA-NH2 (8) 
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Treatment of compound (7) with imidazole and hydroxylamine hydrochloride in DMF 
resulted in clipping off of the Dde resulting in the expected compound (8) (Figure III-6). The 
compound was readily soluble in water and was hence considered good candidate for 
synthesis of gold nanoparticles. It was purified as a white creamish powder using C18 
chromatography with a moderate yield of 48% and HPLC purity of 93%. 
III-2.2 Amine functionalized DOTAGA gold nanoparticle (Au@DOTAGA-Lys-TA-NH2): 
Gold nanoparticles were developed employing the bifunctional ligand (8) that was 
synthesized for the theranostic application as described in preceding section. Typically, the 
gold salts were reduced using NaBH4 in the presence of equimolar amount of the ligand (8). 
This experiment was performed at the lab of Prof. Stephane Roux in Besançon. The gold 
nanoparticles thus developed were stable in terms of the colloidal stability of the dispersion. 
The hydrodynamic diameter of these nanoparticles was around 5 nm as measured by DLS 
(performed in Besançon). This was in alignment with the previous observations made for the 
DTDTPA functionalized gold nanoparticles. Moreover, stability assessment of these 
nanoparticles was performed using UV-visible spectroscopy and the zeta potential 
measurements.  
 
Figure III-7: UV-visible spectra of the Au@DOTAGA-Lys-TA-NH2 nanoparticle solution 
and the zeta potential at different pH. 
As can be seen from the above Figure III-7, the dilute nanoparticle solution exhibited a unique 
spectrum in the range of 400-750nm, that remained unchanged for a pH ranging from 1 to 12. 
Moreover, the zeta potential values over same pH range revealed a net negative surface 
charge at the physiological conditions (-20mV at pH 7.4). This can be expected owing to the 
presence of surface carboxylate groups from the chelate moieties. The DOTAGA moiety can 
be partially complexed with Gd (for MRI) or any other radioisotope for nuclear imaging and 
this is not expected to alter the stability of nanoparticles. Above observations clearly 
demonstrate the ability of the ligands to yield stable gold nanoparticles that can be of value in 
theranosis (radiotherapy and imaging). 
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III-3 Development of gold nanoparticles for PET-MRI: 
III-3.1 Synthesis of DOTAGA-Lys-TA-NODAGA ligand 
With a proof of concept demonstrated, pertaining to the development of the amine 
functionalized DOTAGA containing gold nanoparticles, attempts were made to develop and 
harness the amine function for developing more advanced gold nanoparticles. In the following 
section, we describe the approach adopted in this direction towards development of 
nanoparticles for PET-MRI application.   
 
               (9) Yield: 48%  
Figure III-8: Synthesis of DOTAGA(tBu)4-NH2 (9). 
In order to develop the intermediates that be later used in a versatile manner for further 
addition of a functionality (e.g: chelator/targeting ligand), the protected form of the chelator 
was used, which otherwise would not be feasible with the unprotected chelator. The synthesis 
begins with DOTAGA(tBu)4 which has been a key starting compound in majority of the 
tetraazacyclododecane based imaging probes in our group. DOTAGA(tBu)4 is converted into 
its amine bearing form DOTAGA(tBu)4 -NH2 through classical coupling chemistry using 
HBTU and HOBt as coupling agents (Figure III-8). Possibility of the covalent dimers 
formation necessitates the use of the ethylene diamine in excess (eq. 50). Post reaction work-
up was necessary to get rid of the excess of the reagents. This involved washing of the organic 
phase (dichloromethane) successively with acidic, basic and neutral aqueous solutions 
followed by drying over MgSO4. The compound was finally purified by flash 
chromatography using C18 column using water (0.1%) and acetonitrile (0.1%) as eluents. The 
compound (9) was obtained in good yield of 48% as a TFA salt.    
 
          (non-isolated) 
Figure III-9: Activation of Lysine-Fmoc-dde using TSTU. 
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        (10) Yield: 45%  
Figure III-10: Synthesis of DOTAGA(tBu)4-Lys-Fmoc-Dde (10). 
The next step of the synthesis entailed the linker system which was based on lysine. Lysine-
Fmoc-Dde was first activated to its ester form using TSTU (Figure III-9).The activated NHS 
ester of lysine-Fmoc-dde was then coupled to DOTAGAtBu4-NH2 via amide coupling to 
obtain the compound (10) (Figure III-10). This compound is unique in that it features the 
differently protected functional groups that can be successively deprotected and coupled at 
desired site to have a control over the topology of final compound. 
 
(10)         (11) Yield: 94% 
Figure III-11: Synthesis of DOTAGA(tBu)4-Lys-Dde-NH2 (11). 
Deprotection of the Fmoc group via the treatment with 20% diethylamine in acetonitrile 
afforded compound (11) with excellent yield and purity (98%) (Figure III-11). The compound 
exhibited the mass peak corresponding to the molecular ion at 1257.775 M+H+ using HR-
MS. 
 
(11)              (12) Yield: 95%  
Figure III-12: Synthesis of DOTAGA(tBu)4-Lys-TA-Dde (12) 
Chapter III. Multifunctional gold nanoparticles for cancer theranosis 
Multifunctional platforms for cancer theranosis   82
As demonstrated using the deprotected form of DOTAGA, thioctic acid could 
be easily coupled at the alpha amino position of the lysine linker ( 
Figure III-12) to have a grafting function enabling attachment of this sophisticated system to 
the surface of the gold nanoparticle via the gold-sulphur interactions.   
 
(12)        (13) Yield: 72%  
Figure III-13: Synthesis of DOTAGA(tBu)4-Lys-TA-NH2 (13) 
In the second last step towards the generation of an important intermediate; compound (12) 
was deprotected to set the -amino group free using the equimolar ratio of imidazole and 
hydroxylamine hydrochloride in molar excess to that of the substrate (12). The reaction was 
carried out in solvent system containing ACN and water, to ensure that the polar (imidazole) 
and salt based (hydroxylamine hydrochloride) deprotection reagents were solubilized to elicit 
the reaction. Compound (13) was easily formed under the conditions indicated (Figure III-13) 
and was obtained in good yield (72%) after purification. Compound (13) represents the t-
butyl protected form of the compound (8). As demonstrated in earlier section, compound (8) 
could be used for development of the amine functionalized gold nanoparticles. This affirmed 
the feasibility of using the ligands derived from compound (13) for the synthesis of gold 
nanoparticles. Compound (13) can be used as a crucial intermediate, the amino group of 
which could be modified using the relevant functions (like a chelating agent or a targeting 
ligand) resulting in a multi-functional ligand that can be deployed for the synthesis of gold 
nanoparticles as a part of pre-functionalization strategy (Figure III-2_B).  Through this 
approach, the ligands bearing the relevant functions are used for the synthesis of gold 
nanoparticles that support dual functionality (bimodal imaging like PET-MRI or targeting) 
which are relatively easier for characterization unlike the post-functionalization of the gold 
nanoparticles. 
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(14) Yield: 69%  
Figure III-14: Synthesis of DOTAGA(tBu)4-Lys-TA-NODAGA(tBu)3 (14) 
The -amino group on the side chain of the compound (13) was derivatized with 
NODAGA(tBu)3 using its NHS ester (Figure III-14).  The resulting macromolecular 
compound (14) was obtained with a purity of 95% after flash chromatographic purification.  
 
 
       (14)       (15) Yield: 60%  
Figure III-15: Synthesis of DOTAGA-Lys-TA-NODAGA (15) 
The t-butyl protected compound (14) was subjected to deprotection using 1:1 mixture of 
dichloromethane and TFA (Figure III-15). Deprotection could also be effected by use of conc. 
HCl or TFA as demonstrated for some of the simpler forms of t-butyl protected chelate 
compounds but could be harsh for the macromolecular structure described above. As a result, 
the deprotection was performed under milder conditions that ensured the integrity of the 
molecule which remains unaltered as revealed by the mass analysis that showed molecular ion 
peak at 1192.559 M+H+ and HPLC purity of 91%. 
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III-3.2 Gold nanoparticles based on DOTAGA-Lys-TA-NODAGA for PET-MRI: 
Gold nanoparticles were developed employing the bifunctional ligand that was synthesized 
for PET-MRI application. Typically, the gold salts were reduced using NaBH4 in the presence 
of equimolar amount of the ligand (15). This experiment was performed at the lab of Prof. 
Stephane Roux in Besançon. The gold nanoparticles thus developed were stable in terms of 
the colloidal stability of the dispersion. The hydrodynamic diameter of these nanoparticles 
was around 8nm as measured by DLS with gold core amounting to the size of 2.3nm as 
evidenced by the TEM measurements (analysis performed in Besançon). This was in 
alignment with the previous observations made for the DTDTPA functionalized gold 
nanoparticles. Moreover, stability assessment of these nanoparticles was performed using 
UV-visible spectroscopy and the zeta potential measurements. The optical properties of the 
gold nanoparticles are dependent on its size. Gold nanoparticles exhibit surface plasmon 
resonance owing to interaction of light with electrons on the gold nanoparticle surface 
resulting in strong extinction of light (absorption and scattering). The particular wavelength, 
or frequency, of light where this occurs is strongly dependant on the gold nanoparticle size, 
shape, surface and agglomeration state [112, 113]. UV-visible spectroscopy has been widely 
used to characterize the gold nanoparticles. However, gold nanoparticles having size around 
2nm do not exhibit surface plasmon resonance and hence the UV-visible spectrum of the 
DOTAGA-Lys-TA-NODAGA nanoparticles appears without any sharp peak. Nonetheless, 
the changes in the UV-visible spectrum reflects a change in properties like size, shape and 
agglomeration state of the nanoparticles and serve as one of the stability indicating parameter. 
 
Figure III-16: UV-visible spectra of the Au@DOTAGA-Lys-TA-NODAGA nanoparticle 
solution and the zeta potential at different pH. 
As can be seen from the Figure III-16, the dilute nanoparticle solution exhibited a unique 
spectrum in the range of 400-750nm, which remained unchanged for a pH ranging from 1 to 
12. This property of the nanoparticle can also be useful for quantification of the nanoparticles 
in terms of the gold content once the extinction coefficient at a particular wavelength is 
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known or computed. To further assess and characterize the surface properties, zeta potential 
was measured over same pH range which confirmed the negative surface charge. A net 
negative surface charge of  -10mV was observed at the physiological conditions at pH 7.4, 
which is believed to impart the colloidal stability to the nanoparticles. This can be expected 
owing to the presence of surface carboxylate groups from the chelate moieties. The DOTAGA 
moiety can be partially complexed with gadolinium, to improve the MRI contrast as well as 
increasing the radiosensitizing properties of these probes. On the other hand, NODAGA in 
small traces can be used for complexing the PET radio-isotope as the high sensitivity of the 
PET precludes the use of large amount of radioisotope and this is not expected to significantly 
alter the stability of nanoparticles. This has also been proven for the first-generation gold 
nanoparticles based on DTDTPA [106]. Above observations clearly demonstrate the ability of 
the ligands to yield stable gold nanoparticles that can be of value in PET-MRI imaging. 
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III-4 Radiolabelling and stability of the radiolabelled nanoparticles for PET-MRI: 
 
Figure III-17: Radiochromatogram of Au@DOTAGA-Lys-TA-NODAGA(64Cu) as 
determined by ITLC using 0.1 M EDTA as mobile phase. 
Following the demonstration of the synthesis of the nanoparticles using the ligand (15) the 
next step towards establishing the applicability of the nanoparticles was to radiolabel them. 
The Au@DOTAGA-Lys-TA-NODAGA nanoparticles were radiolabelled with 64Cu in line 
with the strategy to use them as PET-MRI probe. Since, NODAGA forms rapid and stable 
complex with 64Cu at ambient conditions unlike DOTAGA, it can be anticipated that the 64Cu 
gets exclusively complexed by NODAGA. This holds true as well for gadolinium, however in 
opposite manner. Due to the presence of the abundant ligands (15) on the surface of the gold 
core in nanoparticles, the nanoparticles Au@DOTAGA-Lys-TA-NODAGA could be easily 
radiolabelled with 64Cu by incubating at 37°C for 45min in 0.1M NH4Ac buffer (pH 5.8). 
These conditions have been proven and observed to be optimal for radiolabelling with 64Cu 
based on previous experience. As can be seen from the (Figure III-17), Au@DOTAGA-Lys-
TA-NODAGA (64Cu) exhibited a radiochemical purity of >95%. The radiolabelling protocol 
of the nanoparticles was quite facile since no purification was required as the relative amount 
of chelating agent compared to the radioisotope was quite high taking into account the 
anticipated dose of nanoparticles. Moreover, the presence of DOTAGA affords the 
opportunity of nanoparticles to be complexed with Gd for improving the MRI contrast and 
radiosensitizing properties of these nanoparticles.  
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Figure III-18: Stability of Au@DOTAGA-Lys-TA-NODAGA(64Cu) in plasma and EDTA. 
To further investigate the stability of the Au@DOTAGA-Lys-TA-NODAGA(64Cu) 
nanoparticles, the radiolabelled nanoparticles were subjected to incubation in human plasma 
and EDTA solution (chelate challenge study) at 37°C (Figure III-18). The incorporation of the 
64Cu into nanoparticles was found to efficient as the radiolabelled nanoparticles were stable 
and retained more that 90% and 80% of the incorporated 64Cu at the end of 48h in plasma and 
0.1M EDTA challenge solution. These observations justified the biological evaluation of 
these nanoparticles in relevant tumor model to investigate their pharmacokinetic properties. 
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III-5 Animal imaging and biodistribution studies in TSA tumor model: 
 
Figure III-19: PET-MRI imaging in TSA tumor models at 1h and 24h after injection of 
Au@DOTAGA(Gd)-Lys-TA-NODAGA(64Cu). 
To evaluate the targeting potential and understand the pharmacokinetics of the nanoparticles 
the radiolabelled nanoparticles were intravenously injected into mice bearing TSA tumor. The 
dose of the nanoparticles was calibrated taking into consideration the amount of the 
nanoparticles needed for the radiosensitization during the radiotherapy based on the previous 
experience with this type of gold nanoparticles. The nanoparticles were radiolabelled as 
explained earlier. 1mg of Au@DOTAGA(Gd)-Lys-TA-NODAGA(64Cu) nanoparticles in 
PBS with activity of 10 MBq was injected via tail vein in each mouse (n=3). The PET‐MR 
dual imaging was performed at 1 and 24 hours after the injection of the radiolabelled 
nanoparticles using a LabPET scanner (Trifoil Imaging) coupled in line with a small animal 
3T MR small animal imaging system (MR Solutions) after anaesthesizing the mice with 
isofluorane (1.5‐3% in air)  [105]. After the last image acquisition, animals were terminated 
by isoflurane anesthesia followed by pentobarbital overdose. Blood, tumour and organs were 
collected, weighed and radioactivity in these samples was measured with a gamma‐well 
counter. The counter was cross‐calibrated to the dose calibrator used to measure the injected 
dose and the linearity range was determined for all the geometries used in ex‐vivo counting. 
Data were then converted to percentage of injected dose and to percentage of injected dose 
per gram of tissue. 
As can be seen from the axial and the coronal images (Figure III-19), the nanoparticles 
provided enhanced PET-MRI images with slight accumulation at the tumor site and major 
accumulation in kidneys and bladder at end of 1h.  At 24h, the decrease in the intensity of the 
signals was evident indicating excretion of the nanoparticle preferentially via renal route. This 
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was further compounded by the biodistribution analysis based on the gamma counting the 
signals received from the recovered organs (Figure III-20).  
 
Figure III-20: Biodistribution of Au@DOTAGA(Gd)-Lys-TA-NODAGA(64Cu) at the end of 
24h. 
At the end of 24h, the nanoparticles were observed to be mainly distributed into kidneys and 
to certain extent in liver, tumor, lungs and spleen. The stronger signals from kidneys 
(15.77.89 %ID/g) compared to the signals from other organs could possibly indicate that the 
nanoparticles are in process of getting excreted. The accumulation in the tumor was very 
minimal (0.590.11%ID/g) and many factors could be attributed to this including the tumor 
model/size/physiology and hence it could be interesting to evaluate this multifunctional 
system in other tumor models. Nonetheless, the studies highlight the fact that the 
nanoparticles can be cleared from the body via renal excretion and do not suffer from the 
problem of biopersistence in major organs as is observed with many other inorganic 
nanoparticles. This clearly demonstrated the value of this multifunctional gold nanoparticles 
in cancer theranosis.  
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III-6 Development of PSMA targeted gold nanoparticles: 
Due to the ease of its synthesis and the amenability to be grafted onto the macromolecular 
surface without significantly altering its properties, urea based PSMA inhibitors have been 
used for targeting nanoparticles for drug delivery [114, 115], macromolecular drug conjugates 
[116] and nanoparticles for imaging/brachytherapy [117-119]. Kasten et al., demonstrated 
feasibility of synthesis of the PSMA targeted gold nanoparticle wherein, the phosphoramidate 
peptidomimetic PSMA inhibitor was coupled to biotin and grafted non-covalently onto 
streptavidin coated gold nanoparticles using the streptavidin-biotin complex [120]. PSMA 
targeted gold nanoparticles containing a macrocyclic chelator can be of immense value in 
developing theranostic agents having value both as imaging (SPECT) and radiosensitizer.  
The monomolecular multimodal platform can be adapted to develop such novel tools as has 
been described in the following sections. 
III-6.1 Synthesis of the DOTAGA-Lys-TA-Glu-PSMA 
As an extension to the application towards the development of targeted gold nanoparticles 
based on pre-functionalization strategy, ligand bearing the targeting moiety and the 
macrocyclic chelator was synthesized utilizing the amino bearing 
intermediate/DOTAGA(tBu)4-Lys-TA-NH2 (13)(Figure III-13) and PSMA ligand. The 
approach entailed modification of the PSMA targeting ligand so as to develop a spacer and a 
coupling handle between the pharmacophore and the intermediate bearing the site of 
nanoparticle conjugation and the chelator. The PSMA ligand precursor was kindly provided 
by Dr. Victor Gonçalves. 
 
 
    (16) Yield: 76%  
Figure III-21: Synthesis of PSMA(tBu)3-Glutarate (16). 
As has been demonstrated in some of the reports earlier, a glutarate arm was introduced at the 
lysine residue of the urea based ligand. This could be easily achieved with commercially 
available glutaric anhydride. The translucent compound (16) was obtained in moderate yield 
(76%) and provided the carboxylate site that could be used for further amide coupling (Figure 
III-21). 
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     (16)            Yield: non-isolated 
 
          (17) Yield: 75%  
Figure III-22: Synthesis of DOTAGA(tBu)4-Lys-TA-Glu-PSMA(tBu)3 (17). 
The carboxylate bearing compound (16) was activated to its NHS ester form using TSTU and 
then treated with the amino bearing intermediate (13) to afford the compound (17) (Figure 
III-22). The course of the synthesis was verified by LC-MS analysis and the purification was 
made using flash chromatography with C18 column employing the mobile phase (water: 
acetonitrile) containing TFA as is the case for most of the compounds.   
 
 
   (17)              (18) Yield: 34%  
Figure III-23: Synthesis of DOTAGA-Lys-TA-Glu-PSMA (18). 
Mild deprotection conditions were used to deprotect the t-butyl protected compound (17) as 
described in preceding sections. (Figure III-23). The compound was finally recovered as a 
TFA salt in the form of a white powder after purification. The compound was readily soluble 
in water and hence is considered valuable in development of targeted gold nanoparticles. 
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III-6.2 Determination of the PSMA binding activity using the enzymatic assay: 
 
Figure III-24: Binding affinity of ligands (CC34 & 18) towards PSMA using enzymatic assay. 
To evaluate the binding affinity of this ligand we performed the NAALDase assay using the 
commercially available assay kits from R&D Systems. The assay employs recombinant 
human PSMA that has ability to hydrolyse the substrate N-acetyl-L-Asp-L-Glu into 
N-acetyl-L-Asp and L-Glu. The L-Glu product is measured by fluorescence after its 
derivatization by ortho-phthaldialdehyde. This enzyme also has the ability to hydrolyse the 
ureido derivatives containing L-Glu which have been reported in numerous articles involving 
PSMA based theranostic agents. The extent of the released L-Glu as detected by fluorescence 
in relation to the quantity of the theranostic probe (ureido derivative) indicates the binding 
ability/potency of the PSMA based probe.    
This assay has been routinely employed in our group particularly by Dr. Victor Gonsalves for 
evaluation of the PSMA based probes developed at ICMUB. CC34 is one such PET imaging 
probe which has shown a considerable promise born out of Master’s thesis of Coline Canovas 
and developed in collaboration with Prof. Helmut Maecke for clinical imaging. The details 
concerning this compound and its background will be discussed extensively in Chapter IV 
that exclusively focusses on PSMA. As a control for the experiment, we compared head to 
head, the activity of our ligand with that of CC34 and it was observed that the binding or 
inhibitory activity of (18) was very close to that of CC34 (Figure III-24). This paved the way 
for employing (18) in the synthesis of the gold nanoparticles targeted towards PSMA. 
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III-6.3 Gold nanoparticle based on DOTAGA-Lys-TA-Glu-PSMA: 
With the promising affinity towards PSMA, the ligand (18) was justified to be employed for 
the development of the targeted gold nanoparticles. Typically, the gold salts were reduced 
using NaBH4 in the presence of equimolar amount of the ligand (18). These experiments were 
performed in collaboration with Prof. Stephane Roux at Université de Franche-Comté, 
Besançon. The gold nanoparticles developed were found to be stable in terms of the colloidal 
stability of the dispersion. The hydrodynamic diameter of these nanoparticles was observed to 
be around 7nm as measured by DLS (analysis performed in Besançon). These results were in 
agreement with the previous observations made with nanoparticles based on (15) and 
DTDTPA (first generation) functionalized gold nanoparticles. The stability of these 
nanoparticles was assessed using UV-visible spectroscopy and the zeta potential 
measurements.  
 
Figure III-25: UV-visible spectra of Au@DOTAGA-Lys-TA-Glu-PSMA nanoparticle 
solution and the zeta potential at different pH. 
As can be observed from the above figure 4-5, the dilute nanoparticle solution exhibited a 
unique spectrum in the range of 400-750nm, that remained unchanged for a pH ranging from 
1 to 12. Moreover, the zeta potential values over same pH range revealed a net negative 
surface charge at the physiological conditions (-20mV at pH 7.4). This can be expected owing 
to the presence of surface carboxylate groups from the chelate moieties as well as the PSMA 
ligand. The DOTAGA moiety on the nanoparticles can be partially complexed with 
gadolinium, to impart the contrast enhancing properties for MRI and improving the 
radiosensitizing properties of the nanoparticles. Alternatively, the DOTAGA can also be used 
in smaller amounts for complexation with SPECT relevant radioisotope like 111In. This design 
of the ligand makes it versatile and indeed multi-functional yet meeting the criterion of 
stability as can be seen from above graphs. These observations justify the ability of the 
ligands to yield stable gold nanoparticles that can be of value in targeted imaging and therapy 
in prostate cancer management. 
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III-7 Radiolabelling and stability study of the PSMA targeted nanoparticles: 
 
Figure III-26: Radiochromatogram of Au@DOTAGA(111In)-Lys-TA-PSMA as determined 
by ITLC using 0.1 M EDTA as mobile phase. 
Having demonstrated the affinity of the ligand (18) towards PSMA and successful synthesis 
of stable gold nanoparticles using it, the nanoparticles were further radiolabelled with 111In.  
Radiolabelling with 111In was made keeping in mind the propensity of the chelate (DOTAGA) 
to form a stable complex with 111In, so that nanoparticles can be tracked and could find 
application in targeted SPECT imaging in prostate cancer.  Due to presence of the abundant 
ligands (18) on the surface of the gold core in nanoparticles, the nanoparticles 
Au@DOTAGA-Lys-TA-PSMA could be easily radiolabelled with 111In by incubating at 37°C 
for 1hin 0.1M NH4Ac buffer (pH 5.8).  As can be seen from the figure 4-6, 
Au@DOTAGA(111In)-Lys-TA-PSMA exhibited the radiochemical purity of >95%. The 
radiolabelling protocol of the nanoparticles was quite facile in that there was no purification 
needed as the relative amount of chelating agent compared to the radioisotope was quite high. 
Moreover, this relative abundance can also permit some of the chelate to be complexed with 
Gd for improving the MRI contrast and radiosensitizing properties of these nanoparticles. To 
further assess the stability of the Au@DOTAGA(111In)-Lys-TA-PSMA nanoparticles, the 
radiolabelled nanoparticles were subjected to incubation in human plasma and EDTA solution 
(chelator challenge study) at 37°C, as has been done with AGuIX nanoparticles in Chapter II.  
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III-8  Development of a PET-Optical ligand for gold nanoparticles: 
In another interesting application towards development of multimodal gold nanoparticles, 
ligands for the fabrication of gold nanoparticles were envisaged for PET-optical imaging. 
This entails development of a monomolecular multimodal platform that encompass; PET 
chelator, fluorescent dye and a gold conjugatable handle. Following section describes in a 
stepwise manner the realization of this ligand and its photophysical characterization.  
III-8.1 Synthesis of a PET-Optical ligand for gold nanoparticles 
 
        (19) Yield: 68%  
Figure III-27: Synthesis of NODAGA(tBu)3-NH2 (19). 
The synthesis commences with NODAGA(tBu)3 which has been a key starting compound in 
majority of the PET based imaging probes in our group. NODAGAtBu3 is converted into its 
amine bearing form NODAGA(tBu)3-NH2 through classical coupling chemistry using HBTU 
and HOBt as coupling agents (Figure III-27). Possibility of the covalent dimers formation 
necessitates the use of the ethylene diamine in excess (eq. 50). Post reaction work-up was 
necessary to get rid of the excess of the reagents. This involved washing of the organic phase 
(dichloromethane) successively with acidic, basic and neutral aqueous solutions followed by 
drying over MgSO4. The compound was finally purified by flash chromatography using C18 
column using water (0.1%) and acetonitrile (0.1%) as eluents. The compound (19) was 
obtained in good yield of 68% as a TFA salt.    
 
      Yield: Non-isolated 
Figure III-28: Synthesis of Lysine-Fmoc-Dde-NHS. 
The next step entails use of the appropriately protected lysine as a linker which in our case 
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has been Fmoc-Lys(Dde)-OH, as explained in preceding sections. The lysine (carboxylate) 
was activated to obtain an NHS ester (in-situ). The NHS ester formation could be easily 
verified by LC-MS as the ester is fairly stable during the course of chromatographic analysis.  
 
 (19)        (20) Yield: 44%  
Figure III-29: Synthesis of NODAGA(tBu)3-Lys-Fmoc-Dde (20). 
The activated Fmoc-Lysine-Dde was coupled to NODAGA (tBu)3-NH2 through formation of 
a peptide link. The compound could be recovered with the yield of 44% after C18 
chromatographic purification (Figure III-29). This compound (20) represents a very important 
intermediate owing to the presence of differently protected groups which could be exploited 
in diverse manner in order to achieve the desired placement of the functional moieties over 
the course of subsequent deprotection-coupling reactions.  
 
             (20)       (21) Yield: 48%  
Figure III-30: Synthesis of NODAGA(tBu)3-Lys-Dde-NH2 (21) 
As can be seen in Figure III-30, the -amino group on the lysine was set free by cleaving off 
the Fmoc through a deprotection step mediated by diethylamine to get compound (21) that 
was chromatographically purified and recovered as cream white powder with a yield and 
purityof 48% and 97% respectively. In a manner analogous to the previous approach, it was 
necessary to place an arm bearing the sulfur (thiol/disulphide) function between the chelator 
and prospective gold surface. This was achieved by attaching lipoic acid or thioctic acid to the 
alpha amino group that was generated in compound (21). The use of lipoic acid has been 
proven to be valuable in developing functionalized gold nanoparticles via a post synthetic 
functionalization approach [121].  
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(21)        (22) Yield: 81%  
Figure III-31: Synthesis of NODAGA(tBu)3-Lys-TA-Dde (22) 
In an attempt to develop an integrated molecule bearing the grafting function, compound (21) 
was amide coupled to thioctic acid by employing the pre-synthesized thioctic acid NHS ester 
(Figure III-31). Compound (22) was characterized by HR-MS and revealed the anticipated 
molecular peak at 1066.629 M+H+.  
 
  (22)        (23) Yield: 52%  
Figure III-32: Synthesis of NODAGA(tBu)3-Lys-TA-NH2 (23) 
Deprotection of the dde yielded the intermediate compound bearing the free amino group at 
the  position (Figure III-32).  This purified compound (23) was obtained as a TFA salt owing 
to presence of the TFA (0.1%) in the mobile phase with moderate yield and excellent purity 
of 97%.  This compound was further coupled to fluorescent dye (Cy5). 
Cy5 dye is a traditional far-red–fluorescent label for protein and nucleic acid conjugates used 
for imaging, flow cytometry, and genomic applications ideally suited for the 633 nm or 647 
nm laser lines. A significant advantage to using long wavelength dyes such as Cy5 dye over 
other fluorophores is the low auto-fluorescence of biological specimens in this region of the 
spectrum. Although less superior compared to the NIR dyes, Cy5 dye has relatively higher 
quantum yield and brightness and hence finds application in optical imaging. Cy5 was kindly 
provided by Prof. Anthony Romieu and was synthesized based on the scheme depicted in 
Figure III-33. The 2,3,3-trimethylindolenine is subjected to a nucleophilic substitution 
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reaction with 6-bromohexanoic acid and ethyliodide so as to develop two intermediates; one 
bearing the longer carboxylate side arm and the other short ethyl arm. The hexamethine chain 
was introduced between these two intermediates so as to obtain Cy5 that was purified over 
silica using flash chromatography to obtain the pure Cy5. 
 
Figure III-33: Synthetic scheme for the Cy5 fluorescent dye. 
 
     (non-isolated) 
 
(23)               (24) Yield: 20%  
Figure III-34: Synthesis of NODAGA-Lys-TA-Cy5 (24) 
Cy5 was activated to its NHS form using TSTU in DMF and treated with compound (23) to 
obtain an intermediate which was confirmed by LC-MS (Figure III-34). This intermediate 
was treated in-situ with TFA to deprotect the t-butyl group present on the chelator. Compound 
(24) was finally obtained after purification using semi-prep HPLC with a purity of 94%. 
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III-8.2 Photo-physical characterization of the PET-Optical probe (24): 
The photo-physical properties of (24) were studied in PBS at room temperature. The stock 
solution of compound 24 was prepared in DMSO and diluted into PBS for the analysis. The 
photophysical data has been summarized in (Table III-1). The PET-Optical probe displays 
long wavelength absorption and emission bands that match closely to that of disulfonated 
Cy5.0 (reference dye) in aqueous solutions. The compound has an absorption maximum of 
644 nm with a quantum yield of 10%, as a result it is well suited for imaging using currently 
available filter sets optimized for Cy5. The aqueous solution of the probe exhibited no 
indication of aggregation which otherwise would manifest itself as a second absorption band 
around 60nm shorter from the main peak. The short wavelength shoulder preceding the main 
peak in the absorption spectrum is a common feature of virtually all cyanine based 
fluorochromes and is even observed in less polar solvents such as DMSO and MeOH where 
there is least tendency for aggregation. The formation and presence of dimers or aggregates is 
undesirable as they likely result in intermolecular quenching of fluorescence emission [122]. 
 
Figure III-35: Absorption and emission spectrum of the purified compound (24) in PBS using 
UV-Vis and fluorescence spectroscopy. 
Table III-1: Photophysical properties of the trifunctional probe (24) in PBS at 298K. 
Compound abs (nm) em (nm)  (M-1.cm-1)  (%) 
24 644 665 120125 10 
The PET-Optical ligand (24) described above has the potential for synthesis or 
functionalization of the gold nanoparticles that can be used for multimodal imaging.  
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III-9 Development of amine functionalized NODAGA ligands for gold nanoparticle 
synthesis: 
 
Figure III-36: Synthesis of NODAGA-Lys-TA-NH2. 
In an attempt to develop amino functionalized gold nanoparticles for PET imaging, ligand 
was developed employing the NODAGA-NH2 as a starting compound as against the t-butyl 
protected NODAGA-NH2 i.e NODAGA(tBu)3-NH2. This approach is amenable when the 
gold nanoparticles based on post-functionalization strategy (Figure III-2_A) are being 
developed unlike the pre-functionalization route where is it is essential to have the chelate 
moiety protected as demonstrated previously for the synthesis of ligands for PET-MRI 
(DOTAGA-Lys-TA-NODAGA), PSMA targeting (DOTAGA-Lys-TA-Glu-PSMA) and PET-
Optical (NODAGA-Lys-TA-Cy5). Synthesis of NODAGA-Lys-TA-NH2 (28) using 
NODAGA-NH2 can be realized by using correct combination of solvent and appropriate 
sequence of coupling-deprotection (Figure III-36).  The overall yield of the process in terms 
of final compound was 37% which was considered very good. The purity of compound (28) 
as determined by HPLC was found to be 94%. This ligand (28) has been successfully 
demonstrated to be useful in development of multifunctional gold nanoparticles and will be 
employed in future projects encompassing targeted multimodal imaging in oncology as well 
as other disease areas.  
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III-10 Conclusions: 
The objective of this chapter was to develop novel multifunctional ligands that find 
application in fabrication of the gold nanoparticles for multimodal theranosis. This has been 
accomplished through multistep chemical synthetic schemes encompassing appropriate 
selection of chelator for PET/SPECT/MRI imaging, fluorescent dye, and/or a targeting ligand 
capitalizing on leveraging the expertise of Chematech and ICMUB in Dijon. Following are 
the highlights that summarize milestones achieved in this direction: 
 A novel PET-MRI ligand has been successfully synthesized and has been demonstrated to 
be useful in fabricating stable gold nanoparticles for cancer theranosis. These 
nanoparticles have been investigated for their pharmacokinetics and biodistribution 
properties in TSA tumor model using PET-MRI. 
 PSMA targeting multifunctional ligand has been synthesized that has been proven to be 
valuable in terms of its affinity for PSMA. Furthermore, this ligand could be applied in 
the development of targeted gold nanoparticles that demonstrated good colloidal and 
radiochemical stability for prospective theranostic applications.  
 A PET-Optical bimodal probe/ligand has been synthesized and characterized for its 
photophyical properties.  This probe can be of high value in synthesis or functionalization 
of gold nanoparticles for multimodal imaging/theranostics.  
 Amine bearing multifunctional ligands containing different chelators have been 
synthesized via diverse synthetic schemes that demonstrate versatility of the approach 
along with their application in developing amine functionalized gold nanoparticles. 
Above summary points clearly demonstrate the value of the developed multimodal ligands in 
developing gold nanoparticulate systems that find diverse applications in managing cancer. 
Moreover, this work further strengthens the interdisciplinary collaborative efforts between 
teams at Dijon and Besançon, as this work will also be useful in prospective joint research 
projects.
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IV-1 Introduction: 
Prostate cancer (PCa) is one of the most common malignancy observed in men, with an 
estimated 1.4 million incident cases diagnosed worldwide in 2013 and this has been projected 
to increase as the population ages [123].   
There are quite a few biomarkers associated with prostate cancer however, until recently 
diagnosis used to be typically based on the digital rectal exam and blood prostate-specific 
antigen (PSA) testing. PSA is secreted by the prostate cells and released into blood 
circulation. However, elevated serum PSA levels do not always necessarily correlate with 
malignancy, as it could be also due to condition other than prostate cancer.  As a result of 
these false negatives, there is a scepticism regarding the value of broad PSA testing in 
diagnosis of prostate malignancies [124][125]. Recently, PCa diagnosis and staging has 
moved to the morphologic imaging with computed tomography (CT) and magnetic resonance 
imaging (MRI), as well as analysis of bone metabolism with 99mTc- methylene diphosphonate 
scintigraphy [126].  
In order to address the anomalies that existing diagnostic toolkit presents, novel agents based 
on molecular imaging that will more accurately diagnose and stage prostate cancer are being 
developed. These tools must not only diagnose but also aid in monitoring therapy that will 
lead to a better treatment planning and result in improved patient outcome. PSMA based 
molecular theranostics represents one such arena. 
 
Figure IV-1: Schematic diagram of prostate-specific membrane antigen (PSMA) structure. 
Adapted from [127]. 
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IV-1.1 PSMA as a biomarker in prostate cancer: 
PSMA is a type II transmembrane glycoprotein which is negatively regulated by androgen 
and is observed to be significantly overexpressed in androgen-independent prostate cancer 
[128]. With a molecular weight of 100kD, it is composed of 750 amino acids and has three 
distinct parts: a 707-amino acid containing portion that orients in an extracellular region, 24 
amino acids region that spans the cell membrane and a short cytoplasmic tail which entails 19 
amino acids (Figure IV-1).  
PSMA has been found to be a key player in prostate carcinogenesis, glutamatergic 
neurotransmission and folate absorption.  Owing to the diverse functions and the varied tissue 
distribution, there are different terms attributed to this protein, the most widely used being 
glutamate carboxypeptidase II (GCPII). This protein also has capacity to metabolize the brain 
neurotransmitter N-acetyl aspartyl glutamate (NAAG), as a result it is also named as 
NAALADase. As a folate hydrolase FOLH1, it removes -linked glutamates from poly--
glutamated folic acid in the proximal small intestine. [129-132].  
Upon binding of the PSMA ligand to the cell membrane bound PSMA (target) it undergoes 
internalization through clathrin-dependent endocytosis [133]. This results in enhanced 
accumulation of ligand assembly (ligand conjugated chelate complexed radionuclides/drugs) 
into the cells in spite of the small volume of the afflicted site. This in turn enables high quality 
imaging for diagnostic procedures as well as high local dose for therapeutic applications [134, 
135].  
Recently, several monoclonal antibodies as well as small molecules with high binding affinity 
to the extra-cellular domain of PSMA have been developed [136]. Monoclonal antibodies, 
owing to their large size (150kD) and high blood circulation half-life, have poor tumor 
penetration that make them less attractive for molecular imaging unlike their small sized 
counterparts. In this context, the based small molecule inhibitors of PSMA have been 
observed to be quite promising owing to their suitable pharmacokinetic features and rapid 
blood clearance that improves the tumor to background signal [137]. So far, many bio-
distribution studies have been performed to optimize the protocols for imaging with this small 
molecule based contrast agents. 
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IV-2 PSMA inhibitors in prostate cancer theranosis: 
With the advanced ongoing investigations, the scientific community has been able to  better 
understand the molecular pathophysiology of prostate cancer in greater details. This 
knowledge has resulted in the development of the ligands that specifically targets the PSMA 
expressed on the prostate cancer cells. The ability of the PSMA to also act as an enzyme 
facilitates the in-vitro screening of such ligands using easy to perform biochemical assays. 
These ligands when coupled to a pertinent chelating moiety could be used for molecular 
imaging as well as therapy. Subsequent section highlights in the brief the approaches that 
have been developed in this direction. 
IV-2.1 Anti-PSMA monoclonal antibodies in prostate cancer theranosis: 
ProstaScint® (Capromab Pendetide) developed by Cytogen Corporation, Princeton, NJ, USA 
has been the first antibody-chelate conjugate approved for the prostate cancer diagnosis based 
on SPECT imaging. It comprises the monoclonal antibody (7E11-C5/ Capromab) conjugated 
to diethylenetriaminepentaacetic acid (DTPA) which is labelled with 111In. ProstaScint® has 
not found its widespread use as it binds to the intracellular domain of PSMA (the amino 
terminus) restricting its accessibility only to the necrotic cells and not the general population 
of cancer cells [138, 139].  
To overcome this hurdle, monoclonal antibodies binding the extracellular domain of PSMA 
have been developed. A humanized monoclonal antibodyJ591 has been conjugated to 
chelators like 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 
desferoxamine (DFO) which could be labelled with different radioisotopes for imaging 
(99mTc, 111In, 89Zr, 64Cu) as well as therapy (177Lu, 90Y)[140, 141]. Of these, 11In-DOTA-J591 
was found to be superior in terms of pharmacokinetics and tumor-to-blood signal ratios in the 
nude mice with PSMA-positive LNCaP tumors. This led to the drug being tested in clinical 
trials, where it was observed to be superior to ProstaScint® owing to its ability to unveil soft-
tissue and bone metastases [141, 142]. Attempts have been made to produce antibodies with 
better binding profiles for theranostic applications. However, despite the efforts the major 
drawback with monoclonal antibodies associated with their inherent properties still persists; 
longer turnover (circulation) time and slow clearance. This impedes the compliance in the 
clinical setting with respect to the time between the administration of the contrast agent and 
imaging session. This could be of more concern in therapeutic applications (177Lu/90Y) where 
extra-tumoral dose deposition needs to be controlled [143, 144]. In order to address the 
drawbacks associated with the full length antibodies, newer and shorter formats like antibody 
fragments (Fab, Fab’, ScFv), nanobodies, diabodies and minibodies have been employed 
[145]. These tools have improved tumor penetration and faster clearance resulting in excellent 
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tumor/background signals in relatively shorter period of time, allowing the imaging to be 
done in one setting or same day [146].  
Although with limited clinical success, immuno-imaging has been one of the pioneering 
approaches towards the prostate cancer diagnosis and necessitates further fine tuning to 
optimize the pharmacokinetics of the imaging agents. Table IV-1 summarises the list of the 
important developments in the antibody based PSMA imaging probes.  
Table IV-1: Antibody and antibody fragments based conjugates for PSMA theranosis 
Antibody/Protein 
Chelating 
agent 
Radionuclide Application Reference 
7E11/Capromab 
(MAb) 
DTPA 111In SPECT Imaging [138] 
J591 
DOTA 131I, 111In SPECT Imaging [147] 
DTPA 99mTc SPECT Imaging [140] 
DOTA 177Lu, 90Y 
Radiotherapy/SPECT 
imaging 
[148] 
 
DFO 89Zr PET Imaging [149] 
3/A12, 3/F11, 3/E7, 
3/A12-Fab, 3/A12-
F(ab)2 
(MAb) 
DOTA 64Cu PET Imaging [150] 
JVZ-007 (Nb) DTPA 111In SPECT Imaging [151] 
IAB2M (Mb based 
on J591) 
DFO 89Zr PET Imaging [146] 
 
IV-2.2 Small molecule based PSMA inhibitors in prostate cancer theranosis: 
Chemically synthesized low-molecular-weight PSMA-targeting radioligands have been 
shown to detect metastatic or recurrent PCa with high specificity and sensitivity. In 
comparison to mAbs, they are more potent and have excellent tissue penetration, half-life of 
circulation, and production-related costs [152, 153].  
With the advances in the in-silico tools, it has been possible to perform docking studies to 
identify the best fitting (affinity) PSMA inhibitors using a high-resolution crystal structure of 
PSMA/binding motif. The active site of PSMA comprises a binuclear Zn+2active site and the 
two sub-pockets namely S1 and S1′. The urea and carboxylate groups are primarily involved 
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in interactions at the Zn+2active site and the S1′ sub-pocket of PSMA. In addition to this, there 
is S1-accessory hydrophobic pocket that entails potential lipophilic interactions with the 
PSMA inhibitors. In the context of the above binding features, the glutamate−urea−lysine 
binding structural motif has been a building block for the synthesis of potent PSMA inhibitors 
[154-157].  
Urea based PSMA inhibitors were first synthesized and evaluated by Kozikowski and co-
workers in 2001[158]. Later in 2002, Pomper’s group from John Hopkins School of Medicine 
(Baltimore, MD, USA) for the first time published the synthesis and preclinical evaluation of 
radiolabelled urea-based PSMA inhibitor abbreviated as 11C-MCG, which refers to 11C-(S)-2-
[3-((R)-1-carboxy-2-methylsulfanyl-ethyl)-ureido]-pentanedioic acid [159]. Having published 
numerous articles, this group has been one of the major contributor toward development of 
PSMA based theranostics. 
Since the first report of the urea based PSMA inhibitors, different variants have been 
developed and labelled with radio-isotopes for imaging modalities like SPECT (99mTc, 111In) 
and PET (68Ga, 64Cu) as well as for therapeutics (177Lu). Some of these probes have even 
shown good clinical value after being tested in humans [160-162]. 
In order to label the urea-based PSMA precursors with radiometals, it is necessary to attach 
the chelator to the peptidomimetic structure of the PSMA inhibitors. However, as the active 
site of the PSMA/enzyme is hidden about 20 Å inside from its extracellular surface it is 
necessary to have a linker/spacer between the urea moiety and the sterically bulkier 
radiometal chelate complex. Introduction of the spacer/linker not only ensures the easy access 
of the PSMA inhibitor to the binding site but also gives an opportunity to alter the binding 
properties through the lipophilic interactions between the receptor and the inhibitor. 
Moreover, structural changes in the linker can influence lipophilicity, charge, plasma protein 
binding and molecular weight of the probes which have substantial effect on its 
pharmacokinetics. Thus, the overall potential of the PSMA based radiopharmaceuticals 
cumulatively depends on the relevant combination of the urea moiety, chelator moiety and 
particularly the nature of the spacer [71, 163]. Amongst several candidates that have been 
developed for PSMA theranosis below section will discuss some of the candidates that have 
shown promise at the preclinical and clinical level. 
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Figure IV-2: PSMA targeted probes for SPECT imaging (adapted from [153, 164]). 
Low and his group from Purdue University has done some significant work in developing 
PSMA based imaging probes for SPECT imaging. Using the computational docking studies, 
PSMA inhibitors were developed taking into account the receptor topology.  Figure IV-2 
depicts the 99mTc labelled Glu-Urea-Lysine-Peptides that have shown promising PSMA 
binding affinities in nanomolar range as well as good tumor localization in LNCaP xenografts 
in nude mice [153, 164].  
 
 
Figure IV-3: PSMA targeted probes based on single amino acid chelators (SAAC) for SPECT 
imaging (Adapted from [165]). 
On the similar lines as above, Hillier et al., developed SPECT imaging agents one bearing 
Glu-Urea-Lys and other bearing Glu-Urea-Glu as pharmacophoric moiety. These functions 
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have been coupled to the SAAC (single amino acids) chelators CIM (2,2’-(2,2’-
(azanediylbis(methylene))bis(1H-imidazole-2,1-diyl))diacetic acid) or TIM (2,2’, 2’’,2’’-
((2,2’-(2,2’-(azanediylbis(methylene))bis(1H-imidazole-2,1diyl)) bis(acetyl)) bis(azanetriyl)) 
tetraacetic acid). The two promising leads 99mTc-MIP-1404 and 99mTc-MIP-1405 have been 
tested in humans and were found to detect the bone metastatic lesions and soft-tissue PCa 
lesions including sub-centimeter lymph nodes [165, 166] (Figure IV-3). In addition to above, 
there have been few other 99mTc based PSMA inhibitors that have been reported which can be 
referred to in recent review [167].  
In recent years, PET imaging has gained a wide spread attention in oncology and PSMA has 
been no exception to this. Numerous preclinical and clinical studies have been published 
demonstrating use of PSMA based PET probes of which PSMA-11 (HBED-CC-PSMA), and 
PSMA-617 are the most promising ones.  
 
Figure IV-4: Rationally developed PSMA inhibitors for nuclear imaging and medicine by 
Eder and co-workers (Adapted from [168]). 
As demonstrated by Eder et al., PSMA-11 (HBED-CC-PSMA) has been developed by 
coupling the peptidomimetic structure Lys-urea-NH-Glu to the spacer 6-aminohexanoic acid 
(Ahx) and then functionalizing it with the chelator N,N′-dis[2-hydroxy-5-
(carboxyethyl)benzyl] ethylenediamine-N,N′-diacetic acid (HBED-CC) to obtain HBED-CC-
Ahx-Lys-urea-Glu (HBED-CC-PSMA or PSMA-11)(Figure IV-4). In addition to being a 
chelating agent HBED-CC also serves as a lipophilic moiety owing to the presence of the two 
phenolic rings. An aliphatic spacer such as Aca is sufficient for providing the requisite 
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lipophilicity and retaining the affinity of the ligand towards PSMA (Ki = 12.1 ± 2.1 nM)[169]. 
Based on the several clinical studies using PET/CT, 68Ga-PSMA-11 holds diagnostic value 
in PC patients having biochemical recurrence with curative treatment option, in primary 
staging of patients with a high risk for metastases (Gleason Score > 7 and PSA > 10 ng/mL) 
and in patients with a high suspicion of PC [170-174]. However, owing to the high 
selectivity of the complexing agent HBED-CC for 68Ga, the radiotracer (PSMA-11) is not 
suitable for radiolabelling with therapeutic radiometals such as 177Lu or 90Y.  
In order to mimic the proven additional biologic interactions of HBED-CC with the binding 
pocket, PSMA-617 was developed. PSMA-617 is the DOTA-conjugated PSMA inhibitor that 
has been sustainably refined and advanced with regards to its tumor-targeting and 
pharmacokinetic attributes by systematic chemical modification of the linker region. 68Ga-
PSMA-617 was found to be comparable with 68Ga-PSMA-11 in humans as PET diagnostic 
tracer, which paved the way for further exploration into radiotherapy [175]. Currently 
undergoing extensive investigations in human clinical trials, 177Lu-PSMA-617 has emerged as 
a promising new option for therapy of metastasized castration resistant prostate cancer [168, 
176-178]. The chelator moiety of PSMA-617 has been replaced with different chelators like 
DTPA, NOTA, NODAGA and CIM PCTA to give a series of compounds in a work 
demonstrated by Wüstemann et al [179].  
In an ongoing effort to develop novel PET traces in our group, CC34 has emerged to be a 
leading hit developed in collaboration with University of Freiburg (Figure IV-5). 
 
Figure IV-5: (R)-NODAGA-PSMA/CC34: A Versatile precursor for nuclear imaging of 
PSMA-positive tumors developed at ICMUB, Dijon (Adapted from [180]). 
CC34 is versatile in terms of its ability to be radiolabelled by 68Ga, 64Cu and 111In. 68Ga-CC34 
was found to be comparable to 68Ga-HBED-CC-PSMA in terms of tumor uptake and tumor to 
background tissue ratios. Moreover, 64Cu-CC34 enabled high contrast imaging of PSMA 
positive tissues characterized by elevated expression of PSMA. This could be of value when 
delayed imaging is required [180].   
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IV-2.2.1 Optical and PET-Optical imaging of PSMA: 
Optical imaging of prostate cancer based on high sensitivity fluorescence can be of 
considerable value in intraoperative prostate cancer imaging. In this context, quantum dots 
and more advanced dyes, such as indocyanine green (ICG), which emits in the near-infrared 
(NIR) region of the spectrum, enable reasonable tissue penetration of emitted (and detected) 
light. NIR region (>700 nm) facilitates deep-tissue imaging by improving the signal to 
background ratio through reduction in scattering events, as the NIR photons travel through the 
biological tissue.  
A typical approach in development of PSMA targeted fluorescent imaging agent involves 
conjugation of the fluorescent dye to an anti-PSMA antibody or chemical ligand.  
Monoclonal antibody J591 conjugated with a linkable ICG derivative was able to depict 
PSMA+ tumors with high contrast compared to PSMA tumors until 10 days after injection of 
low dose of reagent (0.25 mg/kg) in mice [181]. To overcome the longer tumor accumulation 
time associated with antibodies, Watanabe et al, conjugated ICG to anti-PSMA minibody 
which exhibited faster tumor penetration in around 6h [182] whereas,  conjugation of XX70 
to scFv has also been performed [183]. Using urea based small molecule ligands for optical 
imaging offers a smart and cost-effective approach as they are internalized into PSMA 
expressing cells just like their antibody counterparts however with better favourable 
pharmacokinetic features much suited in intra-surgical realms.  
 
Figure IV-6: PSMA targeted optical imaging probe based on YC-27 (adapted from [184]). 
Pomper’s group reported the synthesis of YC-27 (Figure IV-6) by coupling the urea based 
pharmacophore to activated NIR dye, IRDye800CW-NHS with a suberate-lysine spacer in 
between. YC-27 demonstrated a PSMA inhibitory activity of 0.37 nM and was able to 
generate tumor-to-normal tissue ratios of at least 10 in PSMA-expressing PC3-PIP beginning 
18h after injection [184, 185]. Moreover, it was demonstrated that such probes could be used 
for fluorescence guided laparoscopic surgery. Kularatne et al. likewise have synthesized 
fluorescent (fluorescein and rhodamine) urea derivatives that exhibited PSMA uptake in 
endosomes [164]. Recently, Bao et al. has reported a series of optical probes with a small 
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PEG spacer between the urea moiety of PSMA and the fluorescent dyes like Cy5.5, Cy7 and 
ZW800 for intraoperative assistance [186]. 
Although, quite a few fluorescent PSMA probes have been reported, the dual imaging 
modality in the context of PSMA has been less explored. A bimolecular approach has been 
revealed in which the extracellularly binding PSMA antibody (D2B) has been conjugated 
independently by DTPA (111In) and IRDye800CW for SPECT/Optical imaging [187]. This 
approach is not so elegant owing to complex conjugation protocol and heterogeneous species 
that are difficult to characterize. Our group has worked extensively in the development of 
monomolecular bimodal probes which could be employed in such applications.  
Owing to the complexity of the synthesis, only one example of monomolecular 
SPECT/Optical imaging probe with the small molecular PSMA inhibitor could be retrieved. 
Banerjee et al., in 2011 reported this dual imaging probe, which was synthesized through 
series of coupling and deprotection steps to arrive at a macromolecular structure as depicted 
in Figure IV-7. It encompasses a DOTA chelator and IRDye800CW (NIR dye) assembled 
through lysine based linker which in turn is linked to urea moiety. This study demonstrated 
efficient chemical and radiochemical synthesis of a dual modality PSMA-binding compound, 
that could provide sequential imaging by SPECT and NIRF at radiotracer levels in preclinical 
models [188].  
        
 
Figure IV-7: Bimodal probe for SPECT-optical imaging (Adapted from [188]). 
The objective of our project was to develop a PET-Optical imaging probe through the right 
combination of chelator and fluorescent dye. Subsequent sections of this chapter, details the 
approach and methodology adopted in achieving this goal.  
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IV-3 Synthesis of PSMA targeted monomolecular PET-Optical imaging probe: 
IV-3.1 Synthesis of chelator-linker moiety: 
The development of the bimodal probes began by the synthesis of lysine-chelator 
intermediate. This involved first, activation of Fmoc-dde-lysine-OH to its NHS ester, as also 
been the case for other synthesis in chapter III. The activated Fmoc-dde-lysine-OH was 
subsequently coupled to NODAGA-NH2 (Figure IV-8). Although, it might be more suitable 
to use the protected form of the NODAGA-NH2, we demonstrate here that even the 
deprotected form could be used to obtain the desired compound by the appropriate choice of 
solvent, during the course of synthesis. 
 
       (Non-isolated) Yield: 100% 
 
         (25) Yield: 68% 
Figure IV-8: Synthetic scheme for the NODAGA-Lys-Fmoc-Dde (25). 
Compound 25 was obtained in good yield and excellent purity of about 99%. This compound 
is valuable and versatile in terms of its amenability to be customized based on the topology of 
subsequent compounds desired. For instance, this compound has also been demonstrated to be 
of use in the synthesis of multifunctional ligands for gold nanoparticles as explained in 
chapter III. To introduce an extra space between the linker and the PSMA ligand, the Dde 
group on the amino group of lysine side chain was deprotected. Dde has been widely used as 
a protecting group for primary amines in peptide chemistry and is typically cleaved under 
nucleophilic conditions using 2% v/v hydrazine in DMF. Dde is stable under conditions used 
for deprotection of Fmoc and Boc, however, Fmoc is readily deprotected in the presence of 
2% v/v hydrazine in DMF, therefore defeating the potential of a dual Dde/Fmoc protecting 
group strategy. This necessitated the orthogonal deprotection strategy that involved use of 
hydroxylamine and imidazole (30 eq. of each)[111]. The orthogonal Dde deprotection could 
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be easily achieved within an hour or less and could be even carried out in an aqueous 
methanolic solution (Figure IV-9). The compound was further purified by flash 
chromatography.   
 
 
            (29) Yield: 94% 
Figure IV-9: Synthetic scheme for the NODAGA-Lys-Fmoc-NH2 (29). 
IV-3.2 Synthesis of PSMA ligand and its derivative: 
The design of the urea based pharmacophore has been reported widely in the literature. The t-
butyl protected Glu-Urea-Lysine was kindly obtained from Dr. Victor Gonçalves and further 
derivatized. 
 
           (30) Yield: 53% 
Figure IV-10: Synthetic scheme for the PSMA (tBu)3-Suberate (30). 
A suberate spacer was introduced between the lysine of the urea pharmacophore and chelator-
linker moiety. This will ensure steric flexibility and accessibility of the ligand to the binding 
region seated inside the PSMA/enzyme. An ideal approach in doing so would be to use 
suberate anhydride, but owing to its inherent challenges in the synthesis and characterization, 
we adopted another approach. Monofunctional NHS of suberate was synthesized by using one 
equivalent of TSTU and DIPEA, which was then coupled to protected PSMA ligand (Figure 
IV-10). As anticipated, dimers were also observed during synthesis which could be separated 
from the monosubstituted suberate of PSMA ligand using flash chromatography. Compound 
30 was obtained as a translucent semisolid with a purity and yield of 90% and 53% 
respectively. 
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IV-3.3 Synthesis of chelator-linker-PSMA ligand: 
 
 
  (30)              (Non-isolated) Yield: 100% 
 
 
        (29)      (31) Yield: 87% 
Figure IV-11: Synthetic scheme for the NODAGA-Lys-Fmoc-Sub-PSMA(tBu)3 (31). 
NHS ester of the compound 30 could be easily synthesized by TSTU coupling in the presence 
of base and was verified by LC-MS. Compound 29 was then coupled to the protected PSMA 
ligand via the available -amino group present on the chelate-linker moiety (Figure IV-11).  
The obtained product was purified using C18 based flash chromatography using water 
(0.1%TFA) and acetonitrile (0.1%TFA) as eluents. Compound 31 was recovered as a white 
powder after lyophilisation.  
 
   
(31)               (32) Yield: 67% 
Figure IV-12: Synthetic scheme for the NODAGA-Lys-Sub-PSMA(tBu)3-NH2(32). 
Compound 31 was subjected to Fmoc deprotection wherein, it was treated with 50% 
diethylamine in methanol (Figure IV-12). The deprotection was complete in 30min and the 
product was subjected to flash purification. Simple work-up was not possible with such a 
macromecular and amphoteric structure and hence chromatographic purification was 
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imperative. The product revealed a HPLC purity of about 98% and could be characterized by 
HRMS in which a molecular peak was evident at 1193.701 M+H+. 
 
 
     (non-isolated) Yield: 100% 
 
 
(32)             (non-isolated) Yield: 100% 
 
 
                  (33) Yield: 56% 
Figure IV-13: Synthetic scheme for the NODAGA-Lys-Sub-PSMA(tBu)3-PEG2-NH2(33). 
In the following steps, we decided to adopt a strategy that entailed use of a PEG spacer 
between the generated -amino group in compound 32 and the prospective fluorescent dye. 
This was accomplished by use of a hetero bifunctional PEG spacer; Fmoc-O2Oc-OH (Iris 
Biotech). Fmoc-O2Oc-OH was activated to its NHS ester again by its coupling with TSTU in 
presence of DIPEA and was then coupled to compound 32 (Figure IV-13). Taking cue from 
the previous Fmoc deprotection success, the Fmoc deprotection was attempted in a same 
reaction mixture. The resulting compound 33 could be easily obtained in a one pot process 
and with moderate yield of 56%. Compound 33 as can be seen from the structure is 
amphoteric with chelating moiety quite polar with three carboxyl groups whereas the PSMA 
ligand bears three t-butyl protected sites affording the lipohilicity. The presence of the 
protected groups ensured the molecule retained its amenability to chromatographic 
separation/purification. 
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     (33)                        (34) Yield: 60% 
Figure IV-14: Synthetic scheme for the NODAGA-Lys-Sub-PSMA-PEG2-NH2 (34). 
The deprotection of the t-butyl group was envisaged before the conjugation to the dye, in 
order to minimise the cycles of the reaction to which the dye could be subjected as the dye has 
been observed to be quite sensitive towards multiple reaction in terms of degradative stability. 
As a result, deprotection was performed before by using 1:1 mixture of dichloromethane: 
trifluoroacetic acid (Figure IV-14). The t-butyl groups on the PSMA ligand were cleaved off 
in an hour. The product was purified by semi-preparative HPLC to get the compound 34 
witha purity of around 96%. 
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IV-3.4 Synthesis of bioconjugatable IR-783: 
IR-783 is a commercially available NIR dye. Unlike most of the other NIR dyes like for 
example IRDye800CW, IR-783 is not very expensive. However, in its native form it lacks 
any bioconjugatable group and has to be chemically modified to have functional groups like –
COOH/NH2. Achilefu et al. demonstrated that Suzuki coupling could be employed to 
introduce carboxy phenyl moiety through a C-C bond formation at the meso carbon of the 
heptamethine chain of the NIR dye (Figure IV-15) [189, 190]. In another approach, aryl ether 
modified cyanine derivatives have been synthesized through the nucleophilic substitution at 
the chloro position [191]. These carboxylates bearing NIR dye could be then used to attach a 
peptide/protein through coupling chemistry. Although these modified NIR dyes are water-
soluble, such fluorophores containing an additional aryl group show an increased tendency to 
aggregate in aqueous solution and the aryl-ether linkage in some of these fluorophores is 
vulnerable to cleavage [192].  
 
 
 
Figure IV-15: Suzuki coupling mediated derivatization of IR-783. Adapted from [189]. 
In order to overcome the drawbacks associated with the presence of an extra aryl ring, use of 
an alkyl chain was envisaged. As demonstrated by Hilderbrand and co-workers, IR-783 could 
be easily modified into its alkyl-thio ether derivatives through nucleophilic substitution 
reaction at the meso position. Such fluorophores were directly labelled to a vascular cellular 
adhesion molecule-1 (VCAM-1) targeting peptide. This enabled monitoring of Endothelial 
cell internalization of the VCAM-1 targeted phage via near-infrared fluorescence microscopy 
[48]. 
Following the similar approach compound 35 has been synthesized. The reaction was quite 
straight forward with the product being obtained by overnight stirring of IR-783 with 3-
mercaptopropionic acid in the presence of a base (Figure IV-16). The compound was purified 
by semi-preparative HPLC to get a purity of 99%.   
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             (35) Yield: 66% 
Figure IV-16: Synthetic scheme for the IR-783-Propionic Acid (35) 
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IV-3.5 Synthesis of chelator-linker-PSMA ligand-IR783: 
The carboxy functionalized IR-783 was activated through TSTU in the presence of 
triethylamine to get the activated form of the dye (NHS ester), which could be then coupled to 
compound 34 (Figure IV-17). 
 
 
     (35)               (Non-isolated) Yield: 100% 
 
 
   (34)         (36) Yield: 32% 
Figure IV-17: Synthetic scheme for the PSMA-Suberate-NODAGA-Lys-PEG2-PA-IR783 
(36) 
The presence of several carboxylate groups in compound 34 necessitated use of large amount 
of the base to have the reactive amino group that could participate in coupling reaction. 
However, conducting the reaction under such conditions resulted into inexplicable 
degradation of the dye in DMF as solvent. In order to mitigate the degradative potential, we 
performed the coupling reaction in partially aqueous solution. As indicated in the reaction 
scheme the coupling was carried out in DMF and Borate buffer at pH 8. This significantly 
reduced the in-situ degradation of the dye and the compound 36 could be obtained in 
moderate yield of around 32% with excellent purity profile (Figure IV-18). 
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Figure IV-18: HPLC spectrum of the purified compound 36 at 780nm. 
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IV-4 Characterization of the PET-Optical probe 
IV-4.1 Photophysical characterization of the PET-Optical probe: 
In order to evaluate the potential of the optical probe, it is essential to estimate its 
photophysical parameters; abs-max, em-max, molar extinction coefficient () and quantum yield 
(). When the photon traverses through the fluorophore it induces a molecular electronic 
transition from a lower electronic state, usually the lowest in energy (ground state, S0), to a 
state of higher energy (excited states, S1, S2,...). Experimentally, the efficiency of light 
absorption at a fixed wavelength by a fluorophore is characterized by the molar extinction 
coefficent ε(λ) (commonly expressed in L.mol-1.cm-1) and follows the Beer-Lambert law 
where A(λ) represents the absorbance at the wavelength λ, l, the absorption path length (in 
cm) and c, the concentration (in mol.L-1). 
A (λ) = ε (λ). l. c 
Quantum yield (ΦF), is another important parameter which compares the photon input and 
output and represents the fraction of excited molecules that return to the ground state S0with 
the emission of fluorescence photons. The product of the two parameters ε(λ) and ΦF, results 
in the other important parameter; brightness, which relates to the absorption and emission 
capacity of the fluorophore. These parameters enable comparative analysis of different 
fluorophores at the same wavelength.  
 
Figure IV-19: Absorption and emission spectrum (at exc of 740nm) of the purified compound 
(36) in PBS (pH 7.4) using UV-Vis and fluorescence spectroscopy. 
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Table IV-2: Photophysical properties of the PET-Optical probe in PBS at 298K 
Compound abs (nm) em (nm)  (M-1.cm-1)  (%) 
36 785 819 197350 2.5 
The photophysical properties of 36 were studied in PBS at room temperature. The data has 
been summarized in Table IV-2. The bimodal fluorophore displays long wavelength 
absorption and emission bands that match closely to that of ICG in aqueous solutions (Figure 
IV-19). The compound has an absorption maximum of 785 nm, as a result it is well suited for 
imaging using currently available filter sets optimized for ICG. The quantum yield of the 
probe was computed to be 2.5% which is characteristic of ICG like dyes. Although, this is 
relatively lower compared to other dyes like Cy5, the NIR window compensates for this by 
providing high signal to noise ratio (low auto-fluorescence). The aqueous solution of the 
probes revealed no indication of aggregation which otherwise would manifest itself as a 
second absorption band around 70nm shorter from the main peak. The short wavelength 
shoulder preceding the main peak in the absorption spectrum is a common feature of virtually 
all cyanine based fluorophores and is even observed in less polar solvents such as DMSO and 
MeOH where there is least tendency for aggregation. The formation and presence of dimers 
or aggregates is undesirable as they likely result in intermolecular quenching of fluorescence 
emission [122]. 
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IV-4.2 Radiolabelling and stability of the PET-Optical probe: 
 
Figure IV-20: Plasma stability of the bimodal probe 36 at 37°C evaluated by HPLC at 780nm.  
The bimodal probe is expected to remain stable in terms of its optical/fluorescent properties as 
well as radiochemical properties after complexation at the physiological conditions. The 
stability of the bimodal probe was assessed by incubating the probe in human plasma at 37°C 
at the concentration of 0.5mg/mL over a period of 48h. Aliquots were withdrawn at t0, t8, t24 
and t48 and extracted into equal volume of methanol. This analysis represents the typical 
approach for the bioanalysis of the drugs during the pharmacokinetics studies, wherein the 
plasma recovered from the subjects is treated with a suitable organic solvent to precipitate the 
serum proteins and extract the drug into a solvent system that can be quantified 
chromatographically. 
Sowell et al., have demonstrated that IR-783 has propensity to bind to HSA with a binding 
affinity of around 6.5 x 106 M-1[193]. Although there has been structural modification of the 
dye IR783 in the bimodal probe, it can still be expected to have binding behaviour similar to 
that of the native dye IR783. Extraction of the plasma by methanol ensures serum protein 
precipitation and release of the probe that can be analysed by HPLC. The probe was found to 
be stable in plasma at 37°C over a period of 48h as can be seen from the overlaid 
chromatograms (figure 3-20) that depict no change in the retention time of the probe or 
appearance of new peaks when the absorbance was measured at 780nm. The peaks 
corresponded to the molecular species of the probe as confirmed by the mass analysis (LC-
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MS). This ensured that the optical/fluorescent properties of the probe remained unaffected at 
the physiological conditions. 
 
Figure IV-21: Radiochromatogram of the 64Cu labelled bimodal probe obtained after ITLC-
SA using 0.1M EDTA as a mobile phase. 
Stability studies were also performed to further understand the probe stability under 
radiolabelled conditions (with 64Cu) with end-point being radiochemical purity. 
Radiolabelling of the compound 36 was performed using 64Cu, as it is one of the most suitable 
radio-isotope for PET imaging. The chelator NODAGA exhibits excellent complexation 
properties for 64Cu and 68Ga and hence this probe could be also useful in PET studies with 
68Ga. The complexation was performed by incubating (37°C) the compound with 64Cu in 
ammonium acetate buffer at pH 5.8 for 45min. The quality control of the radiolabelling was 
performed by radio ITLC. Briefly, a micro-droplet was spotted onto the ITLC plates (ITLC-
SA) and the chromatography was performed by using 0.1M EDTA as a mobile phase. The 
ITLC plates were read using the radio-scanner. Figure IV-21shows the radio-chromatogram 
of the 64Cu complexed probe at t0 which exhibits a good radiochemical purity of around 99%. 
The radiolabelled probe was further subjected to EDTA challenge study and plasma stability. 
The EDTA challenge protocol involved incubating the labelled probe in HEPES buffer (pH 7, 
0.5M) containing EDTA (50mM). This enables to have an insight into the resistance of the 
labelled probe toward trans-chelation by the potential sequestering agents present in the 
physiological fluids. The radiolabelled probe was found to have an excellent stability towards 
trans-chelation as the radiochemical purity remained above 90% with no change in the 
retention time of the peak or emergence of new peak over a period of 48h. Similar results 
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were obtained also for the plasma stability experiments over a period of 48h when incubated 
at 37°C. The cumulative stability studies as described above justifies the utility of the probe 
for its bimodal imaging potential. 
IV-4.3 Binding affinity measurements using NAALDase assay: 
(A)  
 
(B)  
Figure IV-22: Enzymatic activity of the PSMA/NAALADase A) Breakdown of the enzyme 
substrate/NAAG (Adapted from [136]). B) Binding affinity measurements of the PSMA 
based diagnostic probes using in-vitro assay. 
In order to understand the tumor localization and the binding potential of the probe towards 
PSMA receptors, it is essential to perform the in-vitro studies using appropriate cell models 
that express the PSMA receptors at adequate levels. For instance, LNCap cells have been 
widely used as reported by several research groups working in this arena[167].  Alternatively, 
biochemical assays based on enzymatic activity could be performed which can be an excellent 
tool to reflect the PSMA targeting ability of the PSMA inhibitors. The binding affinity of the 
compound 36 towards PSMA was found to be very good based on the NAALDase assay. The 
assay is based on the principle that PSMA hydrolyses the substrate N-acetyl-L-Asp-L-Glu 
into N-acetyl-L-Asp and L-Glu. The L-Glu product is measured by fluorescence after its 
derivatization by ortho-phthaldialdehydewhich was performed based on the protocol provided 
by the vendor (R&D Systems, Bio-Techne Ltd, UK).  Typically, rhPSMA (recombinant 
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human PSMA) at the concentration of 0.4g/mL is mixed with the bimodal probe/inhibitor in 
HEPES buffer (50mM, pH 7.5) and incubated for 1h at 37°C. The reaction is stopped by 
transient heating at 95°C for 5 min, followed by addition of ortho-phthaldialdehydecontaining 
buffer. The resulting solution is incubated at room temperature for 10min and then analysed 
by fluorescence spectrometry at the excitation and the emission wavelengths of 330nm and 
450nm respectively in an endpoint mode. The specific activity of PSMA is then calculated as 
below: 
Specific	Activity
Adjusted	Fluorescence	 RFU Conversion	factor	 pmol/RFU
Incubation	time	 min 	amount	of	enzyme g
 
#Adjusted fluorescence – adjusted for blank substrate 
Conversion factor – derived from the calibration standard L-glutamic acid. 
The above analysis was performed with various concentrations/dilutions of the substrate and 
the resulting activity of the PSMA was used to calculate a plot between the two parameters. 
As can be seen in the Figure IV-22, a sigmoidal curve was obtained which is typical of an 
enzyme activity v/s substrate concentration curve or a pharmacodynamics dose response 
curve. As the concentration of the inhibitor increases the activity of the enzyme decreases 
proportionally and then reaches a plateau where there is a saturation and all the active sites on 
the enzyme are blocked. The mid-point of the linear region of the curve is a useful indicator 
for the interpretation of such sigmoidal relationship. In this context, it is referred to as IC50 or 
Inhibitor Concentration50 which is defined as the concentration of the inhibitor that is needed 
to reduce the activity of the enzyme to half or 50% of its initial activity. Figure IV-22 depicts 
two-sigmoidal curve one representing the bimodal probe and the other CC34 which has been 
used here as a reference compound. The curves were obtained by plotting the activity of 
PSMA versus the logarithms of molar concentration and fitting of the data points using non-
linear regression employing GraphPad Prism software.  The IC50 of the bimodal probe was 
observed to be 3.26 x 10-8 M or 0.326 nM which was around 14 times lower to the reference 
compound CC34 (4.47 x 10-9 M or 4.47 nM). Nonetheless, the bimodal probe can be 
considered to be significantly potent towards its PSMA binding affinity that reflects the 
PSMA targeting potential of this bulky probe. The lower affinity compared to CC34 could be 
because of its bulky macromolecular nature partly afforded by the fluorescent dye which in 
turn could induce or alter the nonspecific interactions between the probe and the PSMA.   
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IV-5 Conclusions: 
The objective of this chapter was to develop a new bimodal imaging probe targeted towards 
PSMA for prostate cancer theranosis. This has been realized through a multistep chemical 
synthesis encompassing appropriate selection of chelator for PET imaging and NIR 
fluorophore capitalizing on the collective expertise of Chematech and ICMUB in Dijon. 
Following aspects represent the conclusive remarks towards accomplishing this objective: 
 The PSMA targeted PET-Optical imaging probe has been successfully developed through 
strategic synthetic schemes and chromatographic purifications, with moderate yields and 
excellent purity and spectroscopic characterization. 
 The bimodal probe has been evaluated for its photo-physical characteristics that 
demonstrate its equivalence with ICG dye which has been the only FDA approved NIR 
dye for imaging in humans. 
 The radiolabelling protocol using 64Cu for this probe has been facile and efficient and 
affords a stable compound in terms of the radiochemical purity and this could also be 
adapted for other PET isotopes like 68Ga.  
 The probe has exhibited to have very good stability at the physiological conditions 
through determination of its stability in human plasma at 37°C up to 2 days for its optical 
as well as radio-chelating properties. 
 In-vitro enzymatic assay for PSMA/NAALDase inhibition revealed a good binding 
affinity of the probe towards the PSMA receptor highlighting its potential for targeting 
PSMA positive prostate cancer. 
Moreover, the approach described in this chapter could easily be adapted to other cancer 
targeting ligands. Biological investigation of this probe in the PSMA positive xenograft 
rodent model represents the immediate perspective of this project to truly realize the 
theranostic potential of this system. 
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V-1 Multimodal imaging probes for bioconjugation: 
Design of the multi-modal contrast agents has been one of the thrust areas of the research in 
the imaging sciences. Combination of the two imaging modalities can be really advantageous 
if they complement each other in revealing the correct biological information for preclinical 
and clinical use. This approach has given rise to hybrid imaging modalities like PET/MRI, 
SPECT/CT, PET/OI and PET/CT. Hybrid imaging helps in retrieving the information that 
otherwise would not be available with individual modality. For instance, a combination of 
functional information (from PET) and anatomic/spatial information (obtained by CT) into a 
single image provides an advanced diagnostic [29, 194]. To successfully leverage such 
symbiosis, it is necessary to develop tracers that can have dual/multiple functionality. Tracers 
coupled to the antibodies/peptides/chemical ligands enable molecular and tissue level 
investigations. These tracers could be a radioisotope/heavy metal complexed by chelator 
moiety, metals in colloidal form (nanoparticles), an organic fluorescent dye or a combination 
of any of these. Realization of the above systems necessitates chemical synthesis of structures 
which encompass tracers that support different imaging modalities (PET-MRI, PET-OI, MRI-
OI etc.) and could be grafted onto antibodies/antibody fragments/peptides or nanoparticles. In 
a PET-OI arena, using a same bimodal probe for PET imaging for diagnosis and later for 
intra-operative surgical assistance based on the optical imaging presents a more rational and 
valuable approach than development of probes independently. In the context of 
bioconjugation, the sequential conjugation with two different probes, which can present many 
process and characterization related challenges can be overcome using the bimodal probes. 
Our research interests particularly lie in developing such probes and has been testified by our 
previous work in this arena. 
Bimodal probes based on BODIPY and DOTA have been developed by our group for 
targeted SPECT/Optical imaging of neuroendrocrine tumors and lipopolysaccharide 
detoxification [195, 196]. To capitalise and extend application of such probes, Maindron et 
al., developed a SPECT-Optical probe for conjugation to trastuzumab using an isothiocyanate 
handle. The compound was called TBK-686 for TrisDOTA-BODIPY-Lysine- 686 nm. It 
comprises of a central bodipy which is linked to DOTA and conjugation site (-NCS) on one 
side (via click chemistry), whereas on the other side it bears two additional DOTA molecules 
(Figure I-1). The accumulation of the bioconjugate of this probe in HER-2 expressing tumors 
in mice demonstrated by both in vivo and ex vivo SPECT/optical imaging provided for the 
potential of such probes in bimodal imaging [197]. Another probe that has been developed at 
Chematech/ICMUB for PET-Optical imaging is NODAGA-Lys-Cy5-NCS. Use of NODAGA 
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as chelating agent makes it suitable for radiolabelling with PET radio-isotopes like 64Cu and 
68Ga. This probe has been deployed for conjugation with monoclonal antibody that targets 
Aspergillus Fumigatus within the purview of another European project MATHIAS. Thus, 
developing bimodal probes involves synthesis of complex chemical molecules that can cater 
to diagnosis of broader set of disease conditions. 
 
Figure V-1: Bimodal probes developed at ICMUB, Dijon for bioconjugation applications. 
Although challenging, this integrated approach enables development of unique tracer 
combinations having potential value in multimodal imaging. In the following chapter, we 
discuss the development of PET-Optical imaging tracer based on the Monomolecular 
Multimodal Imaging Probe (MOMIP) platform that has been one of the mainstays of the 
research conducted in our group at ICMUB and Chematech, Dijon. The central theme in 
developing this multimodal platform has been to develop first a linker system which is 
typically an amino acid or a short peptide and then subsequently extending this system by 
functionalizing it with a chelator, fluorescent dye and a bioconjugatable handle which enables 
this platform to be appended to a protein/peptide or a nanoparticle. In the sections following 
the synthesis, this probe has been further demonstrated to be valuable in site specific 
conjugation of the antibody fragments as well as the functionalization of the nanoparticles. 
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V-2 Synthesis of trifunctional probe for PET-Optical imaging: 
V-2.1 Synthesis of bifunctional chelating agent: 
The synthesis begins with NODAGA(tBu)3 which has been a key starting compound in 
majority of the PET based imaging probes. NODAGA(tBu)3 is converted into its amine 
bearing form NODAGA(tBu)3-NH2 through classical coupling chemistry using HBTU and 
HOBt as coupling agents (Figure V-2). Possibility of the covalent dimers formation 
necessitates the use of the ethylene diamine in excess (eq. 50). Post reaction work-up was 
necessary to get rid of the excess of the reagents. This involved washing of the organic phase 
(dichloromethane) successively with acidic, basic and neutral aqueous solutions followed by 
drying over MgSO4. The compound was finally purified by flash chromatography using C18 
column using water (0.1%) and acetonitrile (0.1%) as eluents. The compound (19) was 
obtained in good yield of 68% as a TFA salt.  This compound was synthesized in the same 
manner as the one indicated in Chapter III. 
 
(19) Yield: 68% 
Figure V-2: Synthesis of NODAGA(tBu)3-NH2 (19) 
V-2.2 Synthesis of the linker system bearing chelator and conjugation site: 
The next step in the synthesis was to build a building block containing a maleimide 
(bioconjugation site) and linker system bearing appropriately protected site. Choice of a 
suitable lysine derivative is very crucial while dealing with maleimide as it is very sensitive 
and prone to be attacked by variety of the reagents employed in deprotecting reactions used 
typically in peptide chemistry.  
 
                 (Non-isolated) Yield: 100%  
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         (37) Yield: 96% 
Figure V-3: Synthesis of 6-Maleimidohexanoic-Lysine-Boc (37). 
In this context, 6-maleimidohexanoic acid (6-MHA) was first reacted with Boc-lysine-OH, 
wherein the carboxylate group over 6-MHA was activated to NHS ester by TSTU which was 
then amide coupled with the -NH2 of Boc-lysine-OH (Figure V-3). The compound (37) was 
purified via C18 flash chromatography that led to a pure compound with HPLC purity of 
around 97%.    
 
           (Non-isolated) Yield: 100% 
 
 
 
           (38) Yield: 55% 
Figure V-4: Synthesis of 6-Maleimidohexanoic-Lysine-Boc-NODAGA(tBu)3 (38). 
As depicted in the scheme above (Figure V-4), the maleimide-lysine linker system was further 
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integrated with the chelator bearing moiety NODAGA(tBu)3-NH2. The carboxylate functional 
group on the maleimide-lysine system was activated using TSTU to afford an intermediate 
NHS ester (in-situ). Once the ester formation was verified (by LC-MS) it was appended onto 
the amino group of NODAGA(tBu)3-NH2, that resulted in a product bearing a maleimide, 
protected NODAGA and t-butoxy carbonyl (Boc) protected -amino group (38). 
 
 
        (38)            (39) Yield: 76% 
Figure V-5: Synthesis of 6-Maleimidohexanoic-Lysine-NODAGA-NH2 (39) 
To set free the protected - amino group present on the compound (38), it was treated with 
TFA (Figure V-5). Treatment with TFA not just enabled deprotection of the t-butoxy group 
but also deprotection of the tert-butyl group present on NODAGA. Thus, this step 
strategically afforded deprotection of two different sites in one step to yield a compound 
which was purified by flash chromatography to obtain the pure product (39). This compound 
was observed to be quite hygroscopic and hence needed to be stored away from moisture. 
V-2.3 Synthesis of a trifunctional probe using bioconjugatable IR-783: 
 
 
           (40) Yield: 68% 
Figure V-6: Synthesis of IR-783-Hexanoic Acid (40) 
The third aspect of developing a trifunctional probe involved the development of near infrared 
dye (NIR dye). The NIR dye used to address this part, entailed use of the commercially 
available dye IR-783.  As has been demonstrated earlier, IR-783 can be exploited for 
bioconjugation applications by introduction of the carboxylate group at the meso position on 
cyclohexyl ring using Suzuki coupling [198] or using thiol mediated nucleophilic substitution 
reactions [48]. Owing to simple work up and ease of purification we adopted the second 
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approach. The chloro- group on the cyclohexyl ring was displaced by 6-mercaptohexanoic 
acid by overnight stirring in the presence of triethylamine/TEA (base) (Figure V-6). The 
product was purified by semi-preparative HPLC to afford the product (40) with a purity of 
around 98%. 
 
 
   (40)       (Non-isolated) Yield: 100% 
 
 
         (41) Yield: 32% 
Figure V-7: Synthesis of 6-Maleimidohexanoic-Lysine-NODAGA-HA-IR783 (41) 
Introduction of the carboxylate function improves the bioconjugatability of the compound 
(40) in terms of the peptide chemistry. This function could be easily activated by the coupling 
agent TSTU to afford the NHS ester of the compound (40) as has been verified by LC-MS. 
The next critical step involved the final assembly of the molecule by forming a peptide link 
between the activated (40) and the amine bearing (39).Initial attempts to perform this reaction 
in DMF alone caused a significant degradation of the dye, possibly due to base promoted 
degradation in DMF. This could be alleviated considerably by performing the reaction in 
partially aqueous conditions [199]. 
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As can be observed in Figure V-7, the peptide coupling was performed in a 50:50 mixture of 
DMF and borate buffer (0.5M, pH 8). Immediately after the reaction was complete the final 
compound was purified by semi-preparative HPLC to obtain the pure product (41) with a 
purity of around 99% as detected by HPLC at 780nm (Figure V-8).   
 
 
 
Figure V-8: HPLC chromatogram at 780nm and HR-MS spectrum of the purified compound 
(41). 
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V-3 Photo-physical characterization of the trifunctional probe: 
The photo-physical properties of (41) were studied in PBS at room temperature. The data has 
been summarized in (Table V-1). The bimodal fluorochrome displays long wavelength 
absorption and emission bands that match closely to that of ICG in aqueous solutions (Figure 
V-9). The compound has an absorption maximum of 785 nm with a quantum yield of 2%, as a 
result it is well suited for imaging using currently available filter sets optimized for ICG. The 
aqueous solution of the probe exhibited no indication of aggregation which otherwise would 
manifest itself as a second absorption band around 70nm shorter from the main peak. The 
short wavelength shoulder preceding the main peak in the absorption spectrum is a common 
feature of virtually all cyanine based fluorochromes and is even observed in less polar 
solvents such as DMSO and MeOH where there is least tendency for aggregation. The 
formation and presence of dimers or aggregates is undesirable as they likely result in 
intermolecular quenching of fluorescence emission [122]. 
 
Figure V-9: Absorption and emission spectrum of the purified compound 41 in PBS using 
UV-Vis and fluorescence spectroscopy. 
Table V-1: Photophysical properties of the trifunctional probe (41) in PBS at 298K. 
Compound abs (nm) em (nm)  (M-1.cm-1)  (%) 
41 785 811 178470 2 
Having demonstrated the development of this multimodal probes based on the well-designed 
synthetic schemes, purification protocols and pertinent characterization, it was necessary to 
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justify the applicability of this probe in diverse situations. Subsequent chapter deals with the 
applications covered in the context of antibody bio-conjugation and nanoparticle 
functionalization.  
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V-4 Chemical biology of the antibody drug conjugates: 
Antibody–drug conjugate (ADC) encompasses a recombinant monoclonal antibody (mAb) 
which is covalently linked to a cytotoxic moiety through a synthetic linker system. Such an 
integrated modality combines the potency of highly cytotoxic anti-cancer compounds 
(typically 200-1000 Da) with the high selectivity and stability of mAbs [79]. Using this 
approach of targeted delivery, the eradication of the tumor cells can be realized whilst sparing 
the normal cells which have not been targeted by the antibody. Thus, mAbs provide an ideal 
delivery platform based on a magic bullet concept for molecular targeting of tumor cells. 
However, the realization of this theory has taken decades to implement and it is only recently 
that there has been surge in the number of ADCs that are in clinical development with only 
handful of market approvals hitherto [200]. The concept of ADCs can be equally extended to 
imaging or radiotherapy by conjugating a chelating moiety capable of sequestering a 
radioisotope that has implications in nuclear imaging/radiotherapy. Diverse strategies have 
been developed for chemical conjugation of the monoclonal antibodies with cytotoxic 
payloads or imaging probes which will be summarized in following sections (Figure V-10). 
 
Figure V-10: Antibody–drug conjugate (ADC) products of random conjugation comprise 
chemically heterogeneous species (a), whereas site-specific conjugation methods produce 
homogeneous product profiles (b). Adapted from [201]. 
V-4.1 Non-specific Conjugation through Native Residues 
The most common naturally occurring amino acids such as lysine and cysteine are attractive 
reactive sites for antibody conjugation. A typical IgG antibody has over 80 lysines of which 
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about 20 residues are found at solvent-accessible sites.  Unlike lysine, cysteine residues are 
less abundant in IgGs but are more uniformly and symmetrically distributed. In an IgG 
antibody there are 16 cysteine pairs that arise from 12 intra-chain and 4 inter-chain disulfide 
linkages. The four inter-chain disulfide bonds are the main targets for conjugation owing to 
their solvent accessibility and apparent ease of reduction [202, 203].  
The prime advantage of linkage via the native lysine residues is the ease of reactivity and 
obviation of prior processing/modification of the antibody. However, conjugation at these 
natural sites results in variability and heterogeneity of the resulting conjugates with a wide 
range of drug to antibody ratios (DAR). Moreover, the non-specific conjugation often results 
in alteration of electrostatic properties (with corresponding change in pI) and hydrophobicity 
of the parent antibody [204, 205]. It has been reported that most of the solvent-accessible 
lysine residues are localized in the CH2 domain and conjugation at these sites can have 
destabilizing effect on the antibody making it susceptible to aggregation [206].  
Presence of a reactive thiol group is the prime feature of the amino acid cysteine which serves 
the essential roles in the structure and function of several proteins. Conjugation of thiol-
reactive probes to proteins via the cysteine residues has been a practised method for protein 
labelling, and has also been extended to the generation of ADCs. Using the native cysteine 
residues for ADC synthesis involves partial reduction of inter-chain disulfide bonds and 
results in a heterogeneous mixture of ADCs that differ in terms of conjugation site, DAR and 
number of intact inter-chain disulfide bonds [207]. 
Although use of the cysteine residues for the conjugation entails processing of the antibody to 
chemically reduce the disulfide bonds, this approach yields ADCs that are less heterogeneous 
compared to ADCs generated via lysine conjugation. This is apparent owing to the limited 
number of potential sites (8 sites) making it easier to characterize the resulting products. 
Cysteine conjugated ADCs can thus have favourable implications on the pharmacokinetics 
and pharmacodynamics due to reduced variability amongst the heterogeneous species [207, 
208]. 
Despite the inherent challenges associated with the use of the native residues, the clinically 
approved ADCs viz. gemtuzumab ozogamicin (Mylotarg), trastuzumab emtansine (Kadcyla) 
and brentoximab vedontin (Adcetris) utilize native lysines or cysteines. On the similar lines, 
antibody conjugates like 90Y-Ibritumomab tiuxetan (Zevalin) and 131I-Tositumomab (Bexxar) 
have also been approved for targeted immuno-radiotherapy. 
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V-4.2 Conjugation through genetically engineered sites 
In order to overcome the inherent heterogeneity associated with non-specifically conjugated 
ADCs, antibodies have been engineered to possess reactive sites or amino acids that can be 
readily used for bioconjugation. Attesting to this concept, THIOMABs platform has been 
developed by Junutula and co-workers, wherein cysteines residues are engineered onto 
antibody to enable thiol conjugation at these specific sites. Such ADCs based on site specific–
drug conjugates are much superior compared to their conventional counterparts as these 
conjugates exhibit uniform spatial distribution of the linker-drugs over the antibody surface 
and display superior safety profiles. On the flip side, a reduction step prior to conjugation 
might be necessary along with the liability of aggregation caused by disulfide bridging 
between antibodies [209-211].  
On the similar lines, Jeffrey et al. (Seattle Genetics, USA) have recently reported an anti-
CD70−pyrrolobenzodiazepine linked through engineered cysteine residues. Previous attempts 
to prepare the conjugates employing the reduced hinge cysteine residues led to significant 
ADC aggregation owing to the combination of higher DARs and hydrophobicity of the 
pyrrolobenzodiazepines. These problems could be circumvented by using the engineered 
cysteine residue that limited the DAR to 2 [212]. Many ADC candidates based on the 
engineered cysteine residues are currently under clinical development and can be traced in a 
recent review published by Beck and co-workers [79]. 
V-4.3 Enzymatic Bioconjugation: 
 
Figure V-11: Transglutaminase mediated protein cross-linking. Adapted from [213]. 
The ability of an enzyme to catalyse bond formation has been utilized in the development of 
site-specific conjugation. Enzymes like transglutaminases and glycotransferases have been 
found to be quite valuable for these applications.  
Typically, microbial transglutaminase (MTGase) catalyses an isopeptide bond formation 
between the γ-carbonyl amide group of glutamines and the primary amine on the linker/drug 
(Figure V-11). Microbial transglutaminase has been utilized to modify antibodies, including 
synthesis of homogeneous ADCs [214, 215]. MTGase has also been used to produce 
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homogeneous trastuzumab-MMAE conjugate using a chemo-enzymatic conjugation strategy 
that involved at the first, use of peptide-N-glycosidase F (PGNase F) to clip-off the glycan 
attached to asparagine residue (N297) in the vicinity of conjugation site, glutamine 295 
(Q295). This was followed by MTGase treatement, to mount the azide handle on the antibody 
that could be later used for strain-promoted azide-alkyne cycloaddition (SPAAC) chemistry 
involving alkyne derivated auristatin (MMAE) [213].  
In another interesting amalgamation of polymer chemistry, radiotherapy, and enzymatic 
conjugation deployed on antibody, Grünberg et al., enzymatically conjugated DOTA (1/3/5) 
functionalized short length (10 amino acids) polylysine to the heavy chain of chimeric 
monoclonal anti-L1CAM antibody chCE7agl. These immunoconjugates were radiolabelled 
with 177Lu for exploring the potential of these systems for radiotherapy [216]. As a 
commercially viable technology, ADCs developed based on MTGase have been in clinical 
development under joint collaboration of ETH, Switzerland and Marseille, France. 
Glycoengineering of the antibody/protein enables to alter the antibody through its glycan 
regions. Modifications at the glycan site reduces the risk of alteration of the binding affinity 
which otherwise could be possible with Lysine/cysteine based conjugations. Chemical 
oxidation of cis-glycol groups of the glycans (galactose/sialic acids) using sodium periodate 
(NaIO4) results in the generation of an aldehyde moiety, that could be used for coupling with 
nucleophilic ligands/drugs [217, 218]. To prevent the lack of specificity with the chemical 
oxidation, glycotransferases could be used to graft a chemically active sugar moiety to a 
glycosylation site on an antibody. Glycotransferases encompasse a family of proteins that 
play a role in the synthesis of oligosaccharides and transfer of a sugar residue from an 
activated sugar nucleotide to a sugar acceptor or glycoprotein/lipid.  
The glycans attached to N-glycosylation site Asn-297 of the Fc fragment can be 
degalactosylated so as transfer C2-keto-Gal onto it through enzymatic action of mutant 
glycotransferase. The C2-keto Gal then serves as an anchoring point to which biomolecules 
can be coupled. Boeggeman et al., developed fluorescent conjugates of trastuzumab using this 
methodology by employing aminooxyacetamide derivative of Alexa Fluor 488 [219]. 
Likewise, Zhou et al., have demonstrated the synthesis of MMAE based ADCs through 
enzymatic remodelling of trastuzumab mediated via galactosyl and sialyltransferases [218]. A 
recent review by Pradman Qasba summarises the use of glycosyltransferases in antibody drug 
conjugation [220].  Several other enzymes like formylglycine generating enzyme, sortase, 
protein farnesyl transferase, biotin ligase, etc. have been implicated in the development of 
conjugates via enzymatic/chemo-enzymatic approaches [221]. 
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V-4.4 Labelling strategies in antibody conjugation: 
Table V-2: Labelling chemistries for antibody conjugates. Adapted from [200]. 
 
Some of the major reaction chemistries that govern the bio-conjugation of the drugs or 
imaging/chelating agents to the monoclonal antibodies or proteins have been depicted in 
Table V-2. Chemical conjugation is a crucial step in appending a detectable tracer or drug to 
an antibody/fragment/protein and should proceed quickly with high efficiency under moderate 
aqueous conditions. Moreover, resulting immune-conjugate should result in optimal tracer to 
antibody ratio and must be stable under in vivo conditions.  
NHS esters are widely used in labelling proteins and are typically formed by activation of 
carboxylate group with a relevant coupling agent (e.g: TSTU, carbodiimide etc.). NHS ester 
based compounds react with primary amines (nucleophilic substitution) under slightly 
alkaline conditions (pH 7.2 to 9) to yield stable amide bonds whilst releasing N-
hydroxysuccinimide (NHS) as by-product. The payload on the approved ADC Kadcyla 
(Trastuzumab emtansine) has been conjugated to antibody using this approach via a 
heterobifunctional linker SMCC. Likewise, several fluorescent dyes and chelating agents are 
available commercially as their NHS esters.  
Thiol reactive chemistry has been extensively used for conjugation reactions wherein the 
unique nucleophilicity of thiol enables it to undergo reactions with -halocarbonyl 
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compounds, perfluoroaromatic molecules, Michael acceptors (maleimide and vinyl moiety), 
2-cyanobenzothiazole, phenyloxadiazole sulfone, etc [80]. Although, maleimide-thiol 
conjugates are potentially vulnerable to exchange reaction with free thiol present on the 
endogenous albumin it’s unclear if it is significant in terms of kinetics to have an impact on 
the pharmacokinetics/dynamics.  [222].  Nonetheless, the Michael addition reaction between 
thiol from the cysteine residues and the maleimide have a special place in ADC chemistry as 
most of the site-specific approaches rely on use of cysteine residues. The EMA (European 
Medicines Agency) and FDA (Food and Drug Administration) approved ADC, Adcetris 
(brentuximab–vedotin) has been manufactured through this methodology. In addition to the 
conventional Michael reaction, derivatives of maleimides like dibromomaleimides have 
shown promise as disulphide bridging agents with better control over DAR without impairing 
the integrity of the antibody chains [223-225]. Click chemistry has found widespread 
applications in conjugation of tracer molecules to monoclonal antibodies. Click chemistry 
based cycloaddition reactions (CuAAC, SPAAC) are rapid and modular with higher yields 
and nontoxic by-products, remain stable in physiological conditions and utilize benign 
solvents [86, 87]. Inverse Electron-Demand Diels–Alder (iEDDA) cycloaddition has been the 
recent addition to the toolbox of bioorthogonal chemistry for ADCs. Reaction between 1,2,4,5-
tetrazines and trans-cyclooctene (TCO) was introduced in 2008 and is currently being 
explored for varied applications owing to its extremely fast kinetics (k > 800 M −1.s−1, fastest 
biorthogonal reaction). Moreover, the recent commercial availability of a wide range of 
tetrazine and TCO reagents has made iEDDA reactions a popular choice for bioconjugation 
applications. On the flip side tetrazines could be susceptible to degradation in biological 
environments and TCO can have the tendency to get buried in the hydrophobic pockets of the 
protein that could influence the efficiency of the conjugation [88, 89]. Since the labelling 
strategies are driven by the chemistry approaches, they can also be employed for the surface 
functionalization of nanoparticles, as has been demonstrated in the following sections.  
V-4.5 Difference between conjugates of mAb fragmentsand full scale mAb? 
Monoclonal antibodies/IgGs have a distinct structural feature with each structural sub-unit 
having a specific function. This modular nature of the immunoglobulins has enabled to 
engineer “customized” platforms for the optimized pharmacological applications. Pharmco-
kinetics/dynamic aspects like; half-life, biodistribution, valency, affinity, tissue penetration 
and apparently bioactivity could be varied and controlled by selection of appropriate 
molecular domains or genetic features, allowing a control over both safety and efficacy of 
antibody products. Certolizumab pegol (Cimzia) and Ranibizumab (Lucentis) are the antibody 
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fragment based products currently approved by FDA. Cimzia is Fab fragment indicated for 
Crohn’s disease, rheumatoid/psoriatic arthritis and ankylosing spondylitis, whereas Lucentis 
is a PEGylated Fab’ fragment indicated for age related macular degeneration [226]. 
Table V-3: Different antibody formats and their properties. Adapted from [227]. 
 
Choice of an antibody or its fragment for therapeutic purpose is influenced by the 
pharmacology desired while treating the disease. Likewise, the selection of an antibody or 
antibody fragments has considerable influence on the properties of the imaging tracer 
developed from them. Many therapeutic antibodies could be of value in imaging due to 
similarities in the desired characteristics of targets like high expression in disease state and 
low expression in normal tissue, but not all therapeutic targets will be ideal for imaging, and 
vice versa. It is preferable that an imaging agent be biologically inert and this can be to certain 
extent possible as the expected antibody concentration for imaging is several folds lower than 
that needed to elicit therapeutic effect. In terms of the pharmacokinetics and biodistribution, 
therapeutic antibodies should achieve significant concentrations at the target site/tissue over 
time (high area-under-the-curve) whereas, imaging agents need to achieve high contrast in 
shorter time frame. Extended serum half-lives (1–3 weeks) of intact antibodies serves to be a 
major impediment to successful use of antibody as an imaging agent as several days will be 
needed to achieve a good signal to noise ratio (disease site to normal tissue background) and 
also result in exposure of the organism or patient to radioactivity for an extended amount of 
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time [228].  
This can be addressed by harnessing protein engineering strategies that enable generation of 
the smaller and modular formats or by employing the antibody fragments developed from the 
parent antibody like Fab, F(ab’)2, Fab’, scFv, etc [228, 229]. Table V-3exemplifies various 
antibody based formats along with their characteristics and properties. Reformatted or 
enzymatically modified antibodies have Fv (fragment variable) domain that preserves the 
antigen binding properties, but typically lack the Fc region, eliminating complement- and 
effector cell-mediated immune interactions. Excision of the Fc region also prevents recycling 
that is mediated through the neonatal Fc receptor (FcRn) pathway, which facilitates 
visualization of targeted/diseased sites via faster target site penetration, rapid blood clearance 
and improved contrast.  
The radiation exposure to the patient also can be minimized together by deploying 
radionuclides that decay more rapidly and the expedited clearance of antibody fragments. 
Typically, lower-molecular weight antibody fragments and proteins (below ~50 kDa) undergo 
elimination via renal clearance as their size is lower than the renal threshold [230].  
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V-5 Activatable fluorescent molecular imaging probes based on antibody/antibody 
fragments: 
Molecular imaging with target-specific activatable “smart” probes, that yield fluorescence 
only at the intended target, enables sensitive and specific cancer detection. Different strategies 
have been employed to accomplish this viz. enzymatic activation of the fluorescent probe at 
the pathological site, pH mediated fluorophore activation or exploiting the fluorophore-
protein interactions. The last strategy being the most facile in that it harnesses the natural 
phenomenon of dimerization of some of the fluorescent dyes.   
Dimerization and quenching of fluorescent probes has been observed to occur in concentrated 
aqueous solutions. When conjugated to proteins, fluorophore dimerization and quenching can 
still occur at low concentration and this phenomenon could be exploited as a mechanism for 
fluorescence activation. Upon conjugation to the monoclonal antibodies/proteins, the 
fluorophores tend to dimerize owing to steric closeness as fluorophores are localized onto 
proteins. These fluorophore-antibody conjugates exhibit minimal fluorescence owing to 
quenching. However, upon injection into body, when these conjugates are internalised by the 
cancerous cells the catabolism/metabolism of the protein causes changes in the conformation 
of the proteins leading to activation of the fluorophore [231]. This phenomenon has been 
leveraged in the development of in-vivo activatable fluorescent conjugates (Figure V-12). 
 
Figure V-12: Quenching and activation mechanism involving H-dimer formation after 
binding to the protein [231]. 
Nakajima et al., have demonstrated development of monoclonal antibody conjugate of 
indocyanine green (ICG) for in vivo activatable smart probes for molecular imaging of PSMA 
positive cancers. Before binding to PSMA and cellular internalization, the conjugate yielded 
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minimal light however, after  binding and subsequent internalisation an 18-fold activation 
was observed enabling the specific detection of PSMA+ tumors up to 10 days after injection 
with a dose as low as (0.25 mg/kg) of the conjugate [232]. 
mAb-ICG/ICG like dye conjugates have drawback that inspite of purification, there could be 
some dye remaining non-covalently bound to the mAb. This non-covalent fraction when 
released from the mAb into the circulation could lead to higher nonspecific background 
signals, particularly in the liver and the intestine. To address this, a short polyethylene glycol 
(PEG) spacer was inserted between ICG and the minibody which diminished the background 
signals in a mouse PSMA xenograft model. However, the flip side of this could be altered 
binding affinity of the minibody, which needs to be taken into account [233].  
Given the complexity of the synthesis of the bimodal probe for bioconjugation, the objective 
of this piece of work was to develop the bimodal probe for PET-Optical imaging (as 
described earlier) and apply it to the site-specific labelling of the antibody fragment.  The 
bimodal conjugate developed based on the antibody fragment can be considered to be the first 
of its kind in terms of the bimodality combined with its bioactivatable features. Following 
sections describe the approach and methodology used in accomplishing this objective 
including the physico-chemical and biological characterization. 
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V-6 Development of HER-2 targeted bimodal probe based on antibody fragment: 
Breast cancer is one of the most commonly occurring tumors in oncology. In 20% of cases, 
tumors overexpress the HER-2 transmembrane receptor (Human Epidermal Growth Factor 
Receptor 2). At the clinical level, HER-2 positive tumors are associated with an increased risk 
of local or regional recurrence and impaired overall survival [234]. In order to effectively 
locate the lesions, it becomes imperative to observe the spread of the malignancy across the 
region using a suitable imaging technique. Moreover, it can be of considerable value for 
oncologist to provide delineation of the cancer tissue from the normal ones for effective 
surgical resection. An ideal probe must not only provide the spatial information of the tumor 
during the diagnostic assessment but also offer imaging (optical) guided operative assistance 
during surgery. 
Although quite a few studies report the development of trastuzumab based probes for PET or 
SPECT or Optical imaging as a standalone monomodal probes, the number of bimodal probes 
reported for HER-2 has been very limited. Group led by Eva M. Sevick-Muraca, has reported 
development of trastuzumab based bimodal probes based on sequential conjugation for 
SPECT-Optical imaging [235, 236]. However, there are barely any reports of bimodal 
trastuzumab conjugates based on the monomolecular approach (except one developed by our 
group for SPECT-Optical (Figure V-1)). The development of a HER-
2targetingmonomolecular bimodal probe essentially aims to address this lacuna, compelling 
the need for the proposed work. Aligning with this objective, our aim is to site specifically 
label the F(ab’) fragments of trastuzumab with the monomolecular bimodal probe, so as to 
develop HER-2 targeted PET-Optical probes that accumulate rapidly into the tumor. 
The first part of the work involves synthesising the fragments from the full-scale antibody. 
Obtaining the fragments of the antibody is quite common in a typical drug discovery set up, 
wherein, to investigate the distinct regions of an immunoglobulin, it is necessary to cleave 
them with proteolytic enzymes. To examine the effects mediated by specific binding of 
antibody to cells in vitro or to localize antibodies to certain organs in vivo, it might be 
necessary to get rid of the nonspecific effects of Fc-receptor binding. The affinity of antibody 
for an antigen on the surface of viable cells can only be gauged accurately using monovalent 
antigen-binding fragments (Fab)[237].  
Typically, the fragmentation of the antibody to the monovalent Fab fragment is carried out 
using papain digestion whereas, the bivalent F(ab’)2 fragment is obtained by pepsin digestion. 
Papain digestion produces Fab fragments from IgG of all subclasses from all species, 
however pepsin does not exert its action universally. While employing pepsin or papain for 
Chapter V. Bimodal imaging probes for bioconjugation to antibody fragments and 
nanoparticle functionalization 
Multifunctional platforms for cancer theranosis   152
first time on an antibody, pilot experiments are necessary to determine the optimal reaction 
conditions [238]. 
V-6.1 Synthesis of F(ab’)2 of trastuzumab: 
 
Figure V-13: Synthesis scheme for Trastuzumab-F(ab’)2. 
Trastuzumab (drug substance) was recovered from the marketed formulation - Herceptin 
(Roche) by reconstituting the lyophilisate with minimal quantity of phosphate buffer (20mM, 
0.05% NaN3). The reconstituted solution was desalted by using HiTrap desalting column on 
the AKTA Explorer purification system. The fractions were collected based on the position of 
the protein peak detected at 280nm. The fractions were pooled and concentrated using 
Vivaspin (5mL, MWCO-30kD) to get the concentration of around 20mg/mL measured using 
UV spectrophotometer. The F(ab’)2 formation was verified by mass analysis using MALDI.  
Trastuzumab F(ab’)2 was generated by enzymatically cleaving the monoclonal antibody at the 
hinge region. 10mg of trastuzumab was buffer exchanged in 20mM sodium acetate buffer pH 
4.5 and incubated with pepsin at 37°C for 12h (Figure V-13). After the digestion was 
complete the enzyme was inactivated by addition of Tris buffer pH 8.0. The reaction mixture 
was purified using ProteinA affinity chromatography based on ‘bind and elute’ principle. 
During the ‘binding’ phase of the chromatographic step, the Fab binding region exclusively 
binds to the protein A, whereas the digested Fc region is washed-off. The ‘elution’ phase 
conditions (pH 3) causes the release of the F(ab’)2 from the chromatographic media with good 
purity. The relevant fractions were pooled and concentrated using ultrafiltration and buffered 
exchanged in phosphate buffer.  
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V-6.2 Reduction of F(ab’)2 fragments: 
 
Figure V-14: SDS Gel electrophoresis of the A) F(ab’)2 and the effect of reduction using 
different concentration of 2-MEA. B) Fab’-conjugate without and with fluorescent detection. 
Reduction of the disulphide bonds present in the antibody can be brought about to generate 
individual antibody chains. However, for the synthesis of conjugates it is preferable that only 
the disulphide bonds in the hinge region are reduced. This can be realized by using mild 
reducing agent and by optimising the concentration of the reducing agent. The intra-chain 
disulphide bonds are generally more stable to reduction compared to the once present between 
the antibody chains. Hence, reduction performed under optimal conditions is less likely to 
cause any conformational damage to the antibody or its domains. Various reducing agents 
like DTT (Dithioerythritol), TCEP, 2-mercaptoethanol, cysteine and 2-mercaptoethylamine 
could be used in protein chemistry each with its own merits and demerits. Dithiothreitol is a 
popular reducing agent for many protein research applications and is most commonly used in 
reducing polyacrylamide electrophoresis (SDS-PAGE). TCEP has been widely used in ADC 
chemistry as it is odour free, effective at room temperature, efficient at lower concentrations, 
stable and compatible with wide range of solutes which makes it possible to perform 
reduction and conjugation in same reaction mixture. Of the all reducing agents mentioned 
above, 2-mercaptoethylamine (2-MEA) is a relatively mild reducing agent and finds 
application in the instances where only the hinge disulphide are needed to be reduced. 2-MEA 
is particularly suitable for reduction of the F(ab’)2 for the generation of Fab’ fragments. Zhou 
et al reported the  reduction of the F(ab’)2 using 2-MEAto develop Doxorubicin-PEG-anti-
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CD20 Fab′conjugates [239].  Fab’ fragment of the trastuzumab was generated by treating 
1mg/mL of the F(ab’)2 in the phosphate buffer with 10mM of 2-MEA and incubating at room 
temperature for 1h (Figure V-13). In order to arrive at this optimal concentration, F(ab’)2 was 
treated with varying concentration of 2-MEA (5-50mM) and gel electrophoresis was 
performed to verify the Fab’ formation. As can be seen from the Figure V-14, the 
concentration of 10mM of 2-MEA was found to be optimal in complete reduction of the 
F(ab’)2 with the generation of Fab’ band at around 55kD, whilst generating minimum of low 
molecular weight species. 
V-6.3 Conjugation of the bimodal probe to Fab’ fragment: 
 
Figure V-15: Development scheme for trastuzumab-F(ab’)-conjugate of the trifunctional 
probe (41) 
Following the reduction of the F(ab’)2, the reaction mixture was purified by HiTrap desalting 
column. The Fab’ fragment was recovered from the identified fractions and concentrated to 
around 1mg/mL and treated with 20-fold excess of the bimodal probe and incubated at room 
temperature for 2h. The conjugate was purified by protein A chromatography and the relevant 
fractions were pooled and buffered exchanged into phosphate buffer (20mM, pH 7.2) at the 
concentration of around 1mg/mL. Alternatively, purification can also be performed by Size 
Exclusion Chromatography. The purified conjugate was further characterized using MALDI 
spectroscopy, gel electrophoresis/SDS-PAGEand UV-Visible spectroscopy. As a positive 
control for the experiment, Fab’ fragment was also treated with iodoacetamide in a manner 
analogous to bimodal probe. Iodoacetamide reacts irreversibly with the thiol groups on the 
reduced fragments via nucleophilic substitution reaction generating the Fab’ fragments that 
cannot undergo re-oxidation to F(ab’)2, thus serving as useful control during analysis 
(particularly mass analysis). 
V-6.4 Characterization of the bimodal conjugate: 
In order to identify the number of probes conjugated to antibody or its fragment, it is essential 
to analyse the PAR (probe to antibody ratio), which is analogous to DAR (drug to antibody 
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ratio). This can be assessed by UV-Visible analysis, mass analysis or hydrophobic interaction 
chromatography. In this case, MALDI analysis was performed to evaluate the PAR using 
sinnapinic acid as a matrix and the mass spectroscopic parameters typically used for the 
biological proteins like monoclonal antibodies. As can be seen from Figure V-16, 
trastuzumab shows a peak at 148441 Da, that corresponds to its Mw, whereas the F(ab’)2 
exhibits a peak at 97496 Da demonstrating the digestion of the Fc region of the antibody. 
F(ab’)2 that was optimally reduced with 2-MEA and subsequently capped with idoacetamide 
showed a peak corresponding to 48744 Da. Absence of any F(ab’)2 peak in the iodoacetamide 
capped F(ab’)sample/spectrum proves that conjugation protocol was satisfactory. Similar 
observations were made for trastuzumab Fab’-bimodal probe conjugate, wherein the 
conjugate peak was observed at 51958 Da, this translates to the probe to fragment ratio of 2, 
as calculated below: 
PAR
Molecular	weight	of	the	conjugate molecular	weight	of	iodoacetamide	capped	F ab’
Molecular	weight	of	bimodal	probe
 
This demonstrates that the two thiol groups present at the hinge region of the F(ab’)have been 
successfully conjugated to the bimodal probe in a site-specific manner. This was further 
compounded by the results from the SDS-PAGE analysis. SDS-PAGE analysis revealed main 
band/peakcorresponding to the conjugate at around 50kDwhich was easily detected using 
coomassie blue staining and was also verified using fluorescent detection. 
Figure V-16: MALDI analysis of the trastuzumab Fab’-bimodal probe conjugate. 
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Figure V-17: UV-visible spectrum of the Fab’-bimodal probe in phosphate buffer (with or 
without 1% SDS). 
A UV-visible spectrophotometric analysis of the conjugate was performed in phosphate 
buffer in the presence and absence of SDS. As can be seen from the Figure V-17, the 
conjugate spectrum in phosphate buffer revealed three peaks; one at 280nm corresponding to 
the protein absorption and the other two at 710nm and 786nm corresponding to the 
fluorescent dye peak. However, the peak at 710nm exhibits higher absorbance compared to 
the ones at 786nm. As explained earlier, this is due to the phenomenon of quenching/dimer 
formation mediated by interactions of the fluorescent dye with the protein as well as the other 
dye molecules conjugated to protein in its vicinity. When the spectrum was recorded in the 
presence of 1% SDS (in phosphate buffer) these interactions were found to disappear as 
evident from the spectrum that revealed only two peaks one for the protein (280nm) and 
another for the fluorescent dye (795nm). This observation is in line with those described in 
the literature for a potential bioactivatable probe. 
It could be expected that an analogous effect might be observed under physiological 
conditions, wherein the internalized antibody fragment conjugate would be catabolized so as 
to digest the antibody fragment/protein releasing the fluorescent dye which under the 
activated state will exhibit its fluorescence.    
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V-7 Animal imaging in breast cancer model: 
Pilot imaging studies were performed in BT-474 xenograft tumor model in NOD-SCID mice 
(n=3). The bimodal probe was injected intravenously and the optical imaging scans were 
recorded with 760/845 nm filters at 1h, 4h and 24h. At the end of 24h animals were sacrificed 
and the organs were retrieved to see the probe distribution in the organs. 
 
Figure V-18: Optical imaging scans performed on the mice at 1h, 4h and 24h demonstrating 
localization of the probe in tumor. 
BT-474 xenograft tumor model can be useful to evaluate the theranostics targeting the HER-2 
positive breast cancer as it expresses the HER-2 receptors. As can be observed from images 
(Figure V-18), the conjugate was rapidly localized in the tumor and the kidneys. Unlike the 
full antibody, the Fab’ fragment is rapidly cleared from the circulation as its Mw is closer to 
the renal threshold. Signals from the liver were also observed to be strong. This was evident 
from the images at the end of 1h and 4h. At the end of 24h, the collective broad signals 
reduced in its intensity, owing to possible excretion of the conjugate.  These observations 
were consistent with the results reported for the 111In labelled DTPA conjugated Fab 
fragments of trastuzumab wherein, relatively high tumor uptake (7.8% ID/g) and 
tumor/background ratios (>25:1) were recorded [240].  
Typically, the optical/radioactivity in kidneys is high when conjugates are based on antibody 
fragments as the fragment tends to have higher renal uptake. This can be mitigated by 
administration of cationic amino acids (e.g., l/d-lysine or l-arginine) so as to competitively 
inhibit the charge interactions between Fab and renal tubular cell membranes. Alternatively, 
administration of total parenteral nutrition (TPN) solutions that include l-lysine could help in 
reducing the renal uptake of the antibody fragment based conjugates [241]. 
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Figure V-19: Biodistribution of the bimodal probe based on the fluorescence/optical signals 
observed from the retrieved organs. 
Our observations were further augmented by the biodistribution studies, that entailed imaging 
analysis of the organs retrieved at the end of 24h. As can be seen from the Figure V-19, the 
fluorescent signals were still noticeable in the tumor, in addition to the ones seen in kidneys 
and liver. However, it was difficult to quantify the organ wise biodistribution of the probe 
owing to the inherent variability/sensitivity of the fluorescent signals unlike the radioactivity 
based imaging modalities. Nonetheless, above imaging data clearly validate the tumor 
targeting ability of the bimodal probe. 
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V-8 Development of the multifunctional nanoparticles: 
Nanomedicine has played a seminal role in diagnosis and therapy of varying types of cancer 
as evidenced through the approval of diverse set of nanoparticles by the regulatory health 
authorities across the world [242]. By virtue of the enhanced permeability and retention effect 
(EPR effect), nanoparticles have been able to traverse the leaky vasculature and target the 
cancer tissue. To further understand the targeting potential of the nanoparticles, they have 
been functionalized with targeting ligands like chemical ligands, peptides, antibody or its 
fragments. Nanoparticles bearing multiple functionalities can have wider implications in 
terms of addressing the diagnostic and therapeutic concerns employing a single modality. In 
this context, silica nanoparticles represent one of the versatile platforms for imaging and drug 
delivery applications. Multifunctional silica nanoparticles have been described in literature as 
contrast agents that combine diverse imaging modalities: like optical imaging and positron 
emission tomography (PET), optical imaging and MRI, and optical imaging with both MRI 
and computed tomography [243-245]. In the arena of theranostics, these systems have been 
demonstrated to combine imaging and therapy: MRI and gene delivery, optical imaging and 
drug delivery, and optical imaging and photodynamic therapy [246-248].  
As described in detail in Chapter II, AGuIX nanoparticles are one of the most advanced silica 
nanoparticles in terms of its efficacy at the pre-clinical and clinical stages (Phase I) for 
imaging and radio-sensitizing applications. Owing to its rich surface chemistry, diverse 
functionalization strategies have been investigated to conjugate targeting ligands [35, 249], 
fluorescent dyes [35], photosensitizers [250] and chelating agents [251] onto the AGuIX 
nanoparticles. Multi functionalization of the nanoparticles is a multistep process that entails 
grafting of one modality after other in a sequential manner. This makes it difficult to exert 
control over the precision of process and accurate characterization of the macromolecular 
system. To address this, we capitalized on the monomolecular imaging platforms (MOMIPs) 
developed in our group and synthesized a trifunctional probe containing PET chelator and 
NIR dye and grafting functionality – maleimide that could be used to append it to the AGuIX 
nanoparticles, resulting into a multifunctional system capable of PET-MRI-Optical imaging 
and radiosensitization. 
The following sections describe the development and characterization of an advanced 
multifunctional modality based on AGuIX platform by functionalizing the AGuIX 
nanoparticles with the bimodal PET-Optical probe described at the beginning of this chapter. 
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V-9 Chemical functionalization of AGuIX using bimodal probe: 
V-9.1 Thiolation of the AGuIX: 
 
 
Figure V-20: Thiolation of the AGuIX nanoparticles using Traut’s reagent. 
The surface chemistry of the AGuIX nanoparticles enables it to be chemically conjugated to 
different tracers. Typically, AGuIX nanoparticles possess –NH2 groups that stem from the 
APTES group that occupy the nanoparticle surface. Alternatively, there are also surface –
COOH groups from free chelators which can be employed as a conjugation site. The amide 
coupling at this site can be performed by classical carbodiimide chemistry or employing pre-
activated ligands [35, 252].  In order for the trifunctional probe to be grafted on the 
nanoparticles based on thiol-maleimide chemistry, it was necessary to thiolate the 
nanoparticles. The thiolation was perfomed by treatment of the nanoparticles with Traut’s 
reagent using 10-fold excess to the gadolinium at pH 8 for 1h (Figure V-20). The 
nanoparticles were purified by 6 ultrafiltration cycles using the Vivaspin (MWCO -3kD). The 
purified nanoparticles were characterized by Ellman’s assay, T1 measurements, and DLS 
measurements.   
 
Figure V-21: Determination of the thiol content by the Ellman’s reagent. 
Ellman's Reagent (5,5'-dithio-bis-[2-nitrobenzoic acid])/DTNB can be used to determine the 
amount of sulfhydryl groups present in a sample (nanoparticles/protein/aminoacids) using the 
standard curve generated by of a sulfhydryl-containing compound such as cysteine or by 
R.T, 1h
pH = 8.0
+
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employing the extinction coefficient of TNB (14,150M-1.cm-1 at 412nm). Ellman's Reagent 
(DTNB) reacts with sulfhydryl groups, to form mixed disulfides and colored TNB, whose 
color can be measured at 412nm the extent of which reflects the number of thiols present in 
sample. 
A series of DTNB:Nanoparticles (Gd) ratios were tested to arrive at an estimate of the thiol as 
can be seen from Figure V-21. The thiol content of the nanoparticles was found to be around 
2.5 thiols per nanoparticle, which was considered optimal for further conjugation as excessive 
thiolation might potentially cause nanoparticles to clump by inter-particulate disulphide 
bridging. 
V-9.2 Conjugation of the bimodal probe to AGuIX: 
 
Figure V-22: Bioconjugation of the bimodal probe to the thiolated nanoparticles via thiol-
maleimide/Michael addition reaction. 
After the purification of the thiolated nanoparticles, the nanoparticles were immediately 
treated with the trifunctional probe at the pH of 7 (Figure V-22). Thiol maleimide conjugation 
works well in the pH range of 6.5-7.5 and results in the formation of stable thioether linkage. 
The thiol:maleimide or nanoparticle:trifunctional probe were taken in equal stoichiometric 
ratio and the reaction mixture was incubated at room temperature protected from light. Unlike 
NHS esters, the maleimide moiety is stable towards hydrolysis and molar excess was 
unnecessary. Moreover, the higher concentration of the reaction mixture ensured that reaction 
proceeded quickly to completion without any degradation. The functionalized nanoparticles 
were purified by 5 ultrafiltration cycles using the Vivaspin (MWCO-3kD) and lyophilized to 
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a green powder with a yield of around 50%. The purified nanoparticles were characterized by 
T1 measurements, DLS, HPLC and UV-Vis measurements.   
V-10 Characterization of the functionalized nanoparticles: 
V-10.1 Physico-chemical characterization of nanoparticle properties: 
Nanoparticles that are currently approved for diagnosis and therapy have varied sizes and 
most of them are over 100nm [242]. AGuIX nanoparticles are unique in this regard as they 
are relatively smaller and have a size of about 5 nm and correspond to Mw of 8-10,000 
Daltons. These physico-structural features make AGuIX suitable for the imaging applications 
as they are rapidly localized into tumor and cleared from the circulation through renal 
clearance [6, 100].  
 
Figure V-23: Dynamic light scattering analysis of the nanoparticles. 
The hydrodynamic diameter of the nanoparticles was measured using Dynamic Light 
Scattering (DLS) studies. The size of the pristine AGuIX nanoparticles was found to be 4.6 ± 
0.9nm whereas the thiolated nanoparticles exhibited a resembling size of 4.5 ± 0.9 nm (Figure 
V-23). Upon grafting of the macromolecular probe the DH of nanoparticles increased to 12.1 
± 3.0nm. Relaxometric measurements revealed that r1 increased significantly after thiolation 
and slightly after grafting with the probe. r2 increased significantly in both steps leading to a 
significant change in r2/r1.The relative content of Gd reduces considerably and this is 
reasonable given the bulky structure of the probe.  
Chromatograhic analysis of nanoparticles is quite unusual and daunting task. Nonetheless, 
HPLC analysis of the nanoparticles revealed valuable information upon the structural changes 
caused to the nanoparticles (Figure V-24). AGuIX nanoparticles typically exhibit a retention 
time of 13nm at 295nm. Upon grafting the nanoparticle retention time shifted to right with 
elutionat 18nm, and this could be due to increase in its hydrophobicity.  
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Figure V-24: HPLC analysis of the nanoparticles at 295nm and 700nm. 
The presence of the small peak before the main peak of functionalized nanoparticles could be 
due to the residual underivatized nanoparticles. Furthermore, this was verified by performing 
the analysis at 700nm which clearly demonstrated the functionalization of the nanoparticles. 
In addition to the chromatographic analysis, battery of tests was conducted to further 
characterize the functionalized nanoparticles. The hydrodynamic size (diameter) of the 
nanoparticles increased from 4.6 ± 0.9nm to 12.1 ± 3.0nm after the functionalization owing to 
apparent increase in the size of the nanoparticles due to the bulky nature of the bimodal probe. 
The hydrodynamic size of the nanoparticles was least affected after thiolation of the 
nanoparticles. Increase in the relaxivity (r1) and the corresponding increase in r2/r1of the 
functionalized nanoparticles indicate increase in the rotational correlation time resulting from 
the grafting of a probe. The overall functional properties of the nanoparticles were not 
affected after the functionalization, which justifies the feasibility of synthesis of such multi-
functional probes. Table V-4 & Table V-5 summarise the characteristics of the nanoparticles. 
Table V-4: Summary of the characteristics of the pristine/functionalized AGuIX nanoparticles 
Features Methods 
AGuIX 
(FR30) 
AGuIX-SH 
AGuIX-
NODAGA-
IR-783 
DH (nm) DLS 4.6 ± 0.9 4.5 ± 0.9 12.1 ± 3.0 
Relative quantification of 
SH 
Ellman’s assay - Gd : SH ~ 10 : 2 - 
r1 (mM-1.s-1) 
r2/r1 
Relaxometry 
13.51 
1.35 
16.82 
1.39 
16.91 
1.83 
Retention time (min) 
Purity (%) 
HPLC 
13.4 
80.2 
N/A 
18 
95.7 
Content of Gd (µmol/mg) ICP-OES 0.8903 - 0.3185 
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Table V-5: Summary of the relaxometric characteristics of the nanoparticles at 37 °C (1.4 T & 
60 MHz). 
Sample 
Concentration 
(mM) 
T1 r1 T2 r2 r2/r1 
AGuIX (FR30) 200 0.37 13.51 0.274 18.25 1.35 
AGuIX-SH 70.78 0.84 16.82 0.604 23.39 1.39 
AGuIX-NODAGA-IR-783 45.83 1.29 16.91 0.705 30.94 1.83 
 
V-10.2 Photophysical characteristics of the functionalized nanoparticles: 
 
Figure V-25: Absorption and emission spectrum of the functionalized nanoparticles in PBS 
using UV-Vis and fluorescence spectroscopy. 
Table V-6: Photophysical characteristics of the functionalized nanoparticles in PBS. 
Compound abs (nm) em (nm)  (%) 
AGuIX-NODAGA-IR783 792 815 0.4 
The functionalized nanoparticles were very readily dispersible in PBS. The photophysical 
measurements were performed by serially diluting the stock solution of 1mg/mL in PBS. The 
abs and em were observed to be 792nm and 815nm respectively (Figure V-25). Values for 
molar extinction coefficient could not be calculated as the functionalized nanoparticles 
represent a complex macromolecular structure without any assignable molecular weight. The 
shoulder peak at 725nm might signify the presence of inter-nanoparticulate interactions. 
Nonetheless, these functionalized nanoparticles have photophysical similarities to ICG 
making it a valuable candidate for imaging. 
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V-11 Radiolabelling and stability of the functionalized nanoparticles: 
The functionalized nanoparticles bear three different modalities; viz Gadolinium complexed 
DOTAGA chelates, NIR dye and NODAGA, a PET chelator. The nanoparticles were 
radiolabelled with 64Cu as its decay characteristics (t1/2 = 12.7 hours; β+, 0.653 MeV [17.8 %]; 
β−, 0.579 MeV [38.4%]) are well suitable for PET imaging [253]. The functionalized 
nanoparticles were dispersed in AcONH4 Buffer (pH 5.5) and incubated with 64Cu at 37°C for 
45min. The radiochemical purity of the radiolabelled nanoparticles was found to be >95% as 
determined by ITLC using 0.1M EDTA as a mobile phase (Figure V-26).  
 
Figure V-26: Radio chromatogram of the 64Cu labelled AGuIX-NODAGA-IR783 obtained 
after ITLC-SA using 0.1M EDTA as a mobile phase. 
 
Figure V-27: Stability of the radiolabelled nanoparticles AGuIX-NODAGA -IR783 (64Cu) in 
human plasma and EDTA. 
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Furthermore, stability investigations at 37°C in human plasma and EDTA (EDTA challenge) 
revealed that the radiolabelled nanoparticles are stable over a period of 48h as can be seen in 
Figure V-27.  This evaluation at in-vitro stage is very important to assess the ability of the 
nanoparticles to retain the radioisotope incorporated into it. Moreover, it is also reflective of 
the stability of radiolabelled nanoparticles at physiological conditions before proceeding to in-
vivo experiments. 
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V-12 Animal imaging in breast cancer model: 
Imaging studies were performed in TSA xenograft tumor model in NOD-SCID mice (n=3). 
The 64Cu radiolabelled nanoparticles/AGuIX-NODAGA-IR783 (64Cu)(10MBq) were injected 
intravenously and the optical imaging and PET-MRI scans were recorded. 
Optical imaging was done with 760/845 nm filters at 1h and 24h, whereas PET/MRI scan was 
done using PET/MRI machine as described earlier. At the end of 24h animals were sacrificed 
and the organs were retrieved to see the probe distribution in the organs. 
 
Figure V-28: Optical animal imaging TSA tumor models at 1h and 24h after injection of 
AGuIX-NODAGA-IR783(64Cu). 
 
Figure V-29: PET-MRI imaging in TSA tumor models at 1h and 24h after injection of 
AGuIX-NODAGA-IR783(64Cu). 
As can be seen from the images, AGuIX-NODAGA-IR-783 can be used for PET-MRI-
Optical trimodal imaging. Owing to the sensitivity of the fluorescent probes and limited depth 
penetration of the NIR light, the localization of the AGuIX-NODAGA-IR-783 into tumors 
could be easily traced (Figure V-28). This can be of a high value for the intra-operative 
surgical guidance. On the other hand, PET-MRI images could provide information about the 
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global distribution of these nanoparticles as can be seen from the improved MRI contrast and 
bright PET signals. The substantial decrease of the bright signals from the kidneys from 1h to 
24h, signifies renal excretion of these probes. Moreover, these observations were in line with 
the biodistribution data (Figure V-30).  
 
Figure V-30: Biodistribution of AGuIX-NODAGA-IR783 (64Cu) at the end of 24h. 
At the end of 24h the nanoparticles were observed to be mainly distributed into kidneys 
(35.763.87 % ID/g) indicating the renal clearance as major means of clearance like the 
pristine AGuIX nanoparticles. In addition, the nanoparticles also accumulated into liver 
(14.381.48 % ID/g) and spleen. This behaviour was slightly different from the AGuIX 
nanoparticles reported in Chapter II. This could be possibly due to the presence of relatively 
bulky ICG like macromolecule; IR783 on the nanoparticle, where the hepatic/biliary 
clearance could be another means of clearance [254]. The accumulation in the tumor was 
quite modest (1.80.15 % ID/g) owing to a relatively small tumor size. Nonetheless, this 
information gives a valuable insight into the pharmacokinetic behaviour of these complex 
multifunctional probes and their potential for multimodal imaging.  
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V-13 Conclusions: 
The objective of this chapter was to develop new trifunctional imaging probe that could be 
used for bioconjugation of antibody Fab’ fragments and functionalization of nanoparticles. 
This has been achieved through a multistep chemical synthesis encompassing appropriate 
selection of chelator for PET imaging and NIR fluorophore leveraging on the expertise of 
Chematech and ICMUB in Dijon. Following aspects represent the conclusive remarks 
towards accomplishing this objective: 
 The novel trifunctional imaging probe has been successfully developed through strategic 
synthetic schemes, chromatographic purifications with moderate yields and excellent 
purity and spectroscopic characterization. 
 The trifunctional probe has been evaluated for its photo-physical characteristics that 
demonstrate its equivalence with ICG dye which has been the only FDA approved NIR 
dye for imaging in humans. 
 The trifunctional imaging probe has been demonstrated to be site specifically 
bioconjugated to Fab’ fragments of trastuzumab and used in functionalization of the 
AGuIX nanoparticles towards development of multifunctional theranostics. 
 The PET-Optical bimodal conjugate of Fab’ fragment of trastuzumab has been evaluated 
in BT-474 xenograft tumor model to ascertain the tumor targeting potential of this probe 
using optical imaging. 
 The functionalized nanoparticles were radiolabelled with 64Cu and were found to be stable 
under physiological conditions. Moreover, these multifunctional nanoparticles were 
evaluated in TSA tumor model using PET-MRI-Optical imaging. 
Above achievements  clearly  demonstrate  the  versatility of  the  application of  the complex 
multimodal  probes  to  bioconjugation  and  functionalization towards  development of 
multifunctional  systems.
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Nuclear Magnetic Resonance Spectroscopy  
The 1H and 13C NMR spectra were recorded at 298 K, 300 K or 330 K on 300 MHz Bruker 
Avance, 500 MHz Bruker Avance DRX, 600 MHz Bruker Avance II spectrometers using 
perdeuterated solvents as internal standard. Measurements were carried out at the “Welience, 
Pôle Chimie Moléculaire de l’Université de Bourgogne (WPCM)”.  
Mass Spectrometry  
Matrix-Assisted Laser Desorption Ionization - Time of Flight (MALDI-TOF) mass 
spectrometry was carried out using a Bruker Ultraflex II LRF 2000 spectrometer. High 
Resolution Mass Spectrometry – ElectroSpray Ionisation (HRMS-ESI) was carried out using 
a Thermo LTQ Orbitrap XL. Liquid Chromatography – Mass Spectrometry (LC-MS) was 
carried out using a Bruker Amazon SL coupled to a Dionex HPLC Ultimate 3000 RSLC 
equipped with a columm C18Inertsil ODS-3, 5 μm, 1 × 15 mm. Measurements were carried 
out at the “Welience, Pôle Chimie Moléculaire de l’Université de Bourgogne (WPCM)”.  
Elemental Analysis  
Elemental analysis was performed with a Thermo CHNS/O Electron Flash EA 1112 Series. 
Measurements were carried out at the “Welience, Pôle Chimie Moléculaire de l’Université de 
Bourgogne (WPCM)”.  
UV-Visible Spectroscopy  
UV-visible spectra were recorded on a Jasco V630Bio spectrophotometer (with an automatic 
thermostated 6-position Peltier cell changer), at 20°C using quartz cuvette (1 cm, 3 mL). 
Measurement were performed in a solution of Phosphate Buffer Saline (PBS) + 0.05 % NaN3 
or PBS. The sample concentrations were chosen to obtain an absorbance included between 
0.08 and 1.  
Photophysical Characterization 
Phosphate buffered saline (PBS, 100 mM phosphate + 150 mM NaCl, pH 7.4) was prepared 
using water purified with a PURELAB Ultra system from ELGA (purified to 18.2 M.cm). 
Indocyanine Green (ICG, IR-125, laser grade) and DMSO (+99.9%, for spectroscopy) were 
purchased from ACROS Organics. 
UV-visible spectra were obtained on a Varian Cary 50 scan (single-beam) spectrophotometer 
by using a rectangular quartz cell (Hellma, 100-QS, 45 × 12.5 × 12.5 mm, pathlength 10 mm, 
chamber volume: 3.5 mL), at 25 °C (using a temperature control system combined with water 
circulation). Fluorescence spectra (emission/excitation spectra) were recorded with an 
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HORIBA Jobin Yvon Fluorolog spectrophotometer (software FluorEssence) at 25 °C (using a 
temperature control system combined with water circulation), using a standard fluorometer 
cell (Labbox, LB Q, 10 mm). Emission spectra were recorded in the range 755-900 nm after 
excitation at 740 nm (shutter: Auto Open, excitation slit = 5 nm and emission slit = 5 nm). 
Excitation spectra were recorded in the range 400-825 nm after emission at 825 nm (shutter: 
Auto Open, excitation slit = 5 nm and emission slit = 12 nm). All fluorescence spectra were 
corrected until 850 nm.Fluorescence quantum yields were measured at 25 °C by a relative 
method using ICG (F = 10.6% in DMSO) as a standard (dilution by a factor of 3 between 
absorption and fluorescence measurements). The following equation was used to determine 
the relative fluorescence quantum yield: 
F(x) = (AS/AX)(FX/FS)(nX/nS)2F(s) 
where A is the absorbance (in the range of 0.01-0.1 A.U.), F is the area under the emission 
curve, n is the refractive index of the solvents (at 25 °C) used in measurements, and the 
subscripts s and x represent standard and unknown, respectively. The following refractive 
index values were used: 1.479 for DMSO and 1.337 for PBS. Stock solution (1.0 mg/mL) of 
24 was prepared in DMSO whereas for 36 and 41 was prepared in ultrapure water and 
subsequently diluted with PBS for UV-vis absorption and fluorescence measurements. Stock 
solutions of AGuIX-NODAGA-IR-783 were prepared directly in PBS. 
Compound Purifications  
Flash Chromatography was performed using the Grace Automatic RevelerisFlash 
Chromatography System equipped with a multiple channel detection: UV (214 nm and/or 254 
nm) and Evaporative Light Scattering Detection (ELSD). Reveleris C18 12/25/40/80/120 g 
cartridges were used reversed phase liquid chromatography.  
Semi-preparative RP-HPLC were performed on a Thermo Scientific Dionex Ultimate 3000 
system equipped with UV-Vis detection using Ultimate 3000 diode array detector at 214, 254, 
280, 650 and/or 780 nm. semi-preparative RP-HPLC (Thermo Beta Basic C18 column, 30 x 
150 mm) linear gradient from 100 to 0 % (2 min) and 100 % [H2O/0.1 % TFA (2 min)] at a 
flow rate of 15.0 mL.min-1.  
HPLC Analysis  
The purity of the chemical compounds was determined by RP-HPLC on a Thermo Scientific 
Dionex Ultimate 3000 system with a photodiode detector according to the following methods: 
 RP-HPLC: (Phenomenex Kinetex C18 column, 50-2.1 mm) with CH3CN and H2O + 0.1 % 
TFA as eluents. 5 % CH3CN (2 min), followed by linear gradient from 5 to 100 % (5 min) of 
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CH3CN, 100 % CH3CN (1.5 min), a return to initial conditions by linear gradient from 100 to 
5 % (0.1 min) and 5 % CH3CN (1.4 min) at a flow rate of 0.5 mL.min-1. UV-vis detection 
with an Ultimate 3000 diode array detector at 201, 214, 220, 254, 650 and/or 780nm. 
AGuIX nanoparticles: For UV−vis detector, the detecting wavelength was set at 295 nm 
where organic chelators can highly absorb for characterizing empty NP and at 700 nm where 
copper (Cu) complex of DOTAGA specifically absorb for characterizing Cu incorporated NP. 
Fluorescence detector (λex = 274 nm, λem = 312 nm) was used to when characterizing Gd 
incorporated NP. The column temperature was maintained at 30 °C. Linear gradient LC 
elution was carried out with two mobile phases: (A) Milli-Q water/TFA 99.9:0.1 v/v and (B) 
acetonitrile (CH3CN)/TFA 99.9:0.1 v/v. Each time, an amount of 20 μL of sample was loaded 
to an injection valve and injected into a Jupiter C4 column (150 mm × 4.60 mm, 5 μm, 300 Å, 
Phenomenex) at a flow rate of 1 mL/min. Then the elution was programmed as follows: 1% 
of solvent B in 7 min to elute the reactive and fragments, then a gradient from 1% to 90% in 
15 min to elute the nanoparticle. The concentration of B was maintained over 7 min. Then, 
the concentration of solvent B was decreased to 1% over 1 min and maintained during 8 min 
to re-equilibrate the system for a new analysis. Before the measurement of each sample, a 
baseline was obtained under the same conditions by injecting Milli-Q water. The purity is 
calculated by dividing the area under the peak of the particle to the total area under the peaks 
of the particle and the impurities. 
Relaxivity Measurements: 
Relaxivity measurements were performed on a Bruker® minispec mq60NMR analyzer 
(Bruker, USA) at 37 °C at 1.4 T (60 MHz). 300 μL of samples were measured at a specific 
Gd3+ concentration (mM), measured from ICP-OES. The longitudinal relaxation time T1 and 
the transverse relaxation time T2 (s) were measured. 
FTIR Spectroscopy: 
Infrared spectra were performed with ‘IRAffnity-1 Shimadzu’. Transmittance mode was used 
with Happ-Genzel apodization function, 30 scans, 4 cm-1 resolution in a range between 400 
and 4000 cm-1. pHs of the solutions were adjusted to 2 before being lyophilized. The spectra 
were recorded on the obtained powders. 
Dynamic light scattering (DLS) and zeta potential (for AGuIX nanoparticles) 
Measurement was taken on 1 mL or 0.5 mL of the solution with a single use PMMA cuvette 
(Carl Roth GmbH, Germany) at 20 °C. Attenuator and position were optimized by the device.  
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Fast mode was enabled to enhance the precision for the measurement of particles with 
hydrodynamic diameter less than 10 nm. For most of samples, lyophilized powder 
wasredispersed in water to achieve 100 mg/mL solution and diluted to 10 mg/mL in an 
aqueous solution just before each measurement. 
Zeta potential measurements were recorded at 20 °C within a DTS 1061 folded capillary cell 
(Malvern Instruments Ltd, USA). The zeta potential (ζ) was automatically calculated from 
electrophoretic mobility based on the Smoluchowski equation, ν =(εε0ζ /η)ζ, where ν is the 
measured electrophoretic mobility, η is the viscosity, ε is the dielectric constant of the 
electrolytic solution, ε0 ≈ 8.854 x 10-12 C2N-1m-2 is the vacuum permittivity. Lyophilized 
powder was redispersed in water to achieve 100 mg/mL solution and diluted to 10 mg/mL in 
an aqueous solution containing 5 mM NaCl and adjusted to the desired pH (7.4) just before 
each measurement. 
Materials:  
All the macrocyclic compounds used as starting materials for synthesis were provided by 
CheMatech. All chemicals were purchased from Acros and Aldrich unless otherwise 
mentioned and were used without further purification. Peptide-grade DMF and all the Fmoc-
amino acids were purchased from Iris Biotech or Novabiochem. Organic solvents were 
removed under reduced pressure using rotary evaporator (Buchi, Switzerland). Water was 
removed by lyophilisation using freeze dryer (Labconco, USA).  
Radiochemistry:  
64Cu was obtained as Copper (64Cu) chloride in 0.1N Hydrochloric acid (Cuprymina 925 
MBq/mL) from SPARKLE S.r.l, Italy.Radiochromatograms were carried out with a Raytest 
miniGITA-Star γ radiochromatograph (Raytest, Straubenhardt, Germany) or with a Bioscan 
AR-2000 radio-TLC Imaging Scanner (Bioscan Inc., Washington, DC). 
Animal Imaging: 
All animal studies were conducted in accordance with the legislation on the use of laboratory 
animals (directive 2010/63/EU) and were approved by accredited Ethical committee (C2ea 
Grand Campus n°105). Female NMRI Nude mice (6-8 weeks, Janvier Labs, France) were 
subcutaneously injected with 2 x107 TSA cells (murine mammary adenocarcinoma).  Mice 
were maintained in ventilated housing units under controlled conditions of temperature (22 ± 
2°C), photoperiod (12h light/12h dark) with free access to food and drink. Three to five weeks 
after tumor cells injection, TSA tumor bearing-mice (n=3) were administered radiolabelled 
nanoparticles in PBS corresponding to radioactivity of 10 MBq by intravenous injection.  
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For the HER-2 tumor model, balb/c nude mice (n = 3; 6−8 weeks old, purchased from Charles 
River, France) were subcutaneously injected the flank with 2 × 107 BT-474 human breast 
carcinoma cells. After tumor growth, the bimodal bioconjugate was injected intravenously in 
the lateral tail vein as a ~1 mg/mL solution in PBS (100 μL). For all imaging procedures, 
mice were anesthetized under isoflurane.  Imaging experiments were performed using the 
imaging instruments available at the imaging platform of   CGFL, Dijon. 
PET-MRI Imaging: 
Simultaneous MRI-PET imaging was performed at 1 and 24 hours after the injection of the 
radiolabelled nanoparticles on a fully integrated system (MR Solutions, Guilford, UK) 
consisting of a 7T dry magnet (Powerscan MRS-7024-PW) coupled with a SiPM dual-ring 
PET-I-802 insert. Mice were anaesthetized with isoflurane (2 % in oxygen) and positioned in 
a dedicated heating cradle. MRI and PET acquisitions were performed simultaneously. 
Animal respiration was monitored with abdominal pressure sensor and dedicated software 
(PC Sam, SAII, Stony Brook, US). List-mode data were collected in the PET system during 
30-60 minutes. Images were reconstructed with the 3D ordered subset expectation 
maximization (OSEM) algorithm implemented in the system using 2 iterations, 32 subsets 
and an isotropic voxel size of 0.28 mm. An energy window of 250-750 keV and a coincidence 
time window of 8 ns were applied to the list-mode data. The algorithm takes into account 
normalization, random and decay corrections. No attenuation correction was applied. T1 and 
T2 weighted fast spin echo MR images were acquired with respiratory gating and sequences 
in axial and coronal plans. T1 sequences were acquired with time of repetition (TR) of 1000 
ms, time of echo (TE) of 11 ms. T2 sequences were acquired with TR of 4000 ms, TE of 45 
ms. Following parameters were used for both T1 and T2: flip angle of 90°, 4 signal averages, 
1 mm slice thickness, 0.15x0.15 mm² transaxial pixel size and 256x256 pixels matrix. The 
PET-MR fusion image was obtained using VivoQuant (Invicro, Boston, US). Each scan was 
then visually interpreted. For the gamma counting of the organs, the counter was cross-
calibrated to the dose calibrator used to measure the injected dose and the linearity range was 
determined for all the geometries used in ex-vivo counting. Data were then converted to 
percentage of injected dose and to percentage of injected dose per gram of tissue. 
Optical Imaging: 
The optical imaging/fluorescence signal was monitored using the Perkin Elmer Ivis Lumina 
III system. Whole body imaging was acquired at 1 h, 4h and 24 h time points using 
appropriate excitation/emission settings. All imaging data were analysed with the Living 
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Image® software. Values are reported as radiant efficiency, allowing direct comparison of 
images from each experiment. After the last imaging, the mice were euthanized and organs 
collected for ex-vivo imaging at 24 h post-injection. Fluorescence intensities were measured 
and normalized to photon per second per cm2 using the region of interest (ROI) function of 
the Living Image® software. The ROI cover the entire tissue.
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Chemistry 
 
DOTAGA(tBu)4-APTES (1) 
 
 
 
Chemical Formula: C44H85N5O12Si 
Molecular Weight: 904.27 
 
DOTA-GA(tBu)4 (0.9g, 1.284 mmol) was weighed in 100mL round bottom flask and was 
dissolved in 20mL of DCM under the hood with stirring. DIPEA (1.14mL, 6.55mmol) was 
added into above solution followed by coupling agents viz. HBTU (0.52g, 1.37 mmol) and 
HOBt (0.18g, 1.37 mmol) and the solution was left for stirring at room temperature for 
15min. APTES (0.3g 1.37mmol) was added to the above solution directly using the 1mL 
syringe and solution was stirred further at room temperature for 60min after which the 
product formation was confirmed through MS. The above solution was mixed with 50mL of 
citric acid solution (pH: 2.5-3) in a separating funnel and the organic layer was recovered. 
The organic layer was further mixed with 50mL of 5% NaHCO3 in a separating funnel and 
the organic layer was recovered. The DCM solution was stirred with 5g of MgSO4 for 10min 
and filtered using sintered funnel to receive the dry and clear DCM solution. Organic phase 
was evaporated under vaccum at 30°C to get a viscous brownish residue, as an intermediate 
product (Yield: 1.05g, 78%). 
 
HRMS: Calculated for C44H85N5O12Si:926.585 M+Na+; Obtained: m/z = 926.584 M+Na+ 
 
1H NMR (500 MHz, CDCl3-d) δ 0.4 – 0.7 (m, 2H), 0.7 – 0.8 (m, 1H), 1.0 (dd, J = 9.0, 6.7 Hz, 
1H), 1.1 – 1.2 (m, 9H), 1.3 – 1.5 (m, 32H), 1.5 (p, J = 7.8 Hz, 2H), 1.7 (d, 1H), 1.9 – 2.1 (m, 
1H), 2.1 – 2.3 (m, 1H), 2.4 – 3.4 (m, 29H), 3.5 – 3.7 (m, 1H), 3.7 – 3.8 (m, 4H). 
 
13C NMR (126 MHz, CDCl3) δ 7.5, 7.8, 18.3, 20.4, 23.5, 25.9, 26.8, 27.8, 27.8, 27.9, 27.9, 
27.9, 28.2, 28.3, 29.7, 33.0, 38.6, 42.1, 47.6, 49.8, 58.4, 63.6, 80.8, 82.3, 171.1, 173.2. 
 
Elemental Analysis:  
Calculated for C44H85N5O12Si. 0.9HPF6 (%): C: 51.03, H: 8.36, N:6.76. 
Observed (%): C: 51.86, H: 8.91, N: 8.38. 
 
--------------------------------------- 
 
Experimental Section 
 
Multifunctional platforms for cancer theranosis   179
DOTAGA-Silane (2) 
 
 
 
Chemical Formula: C22H41N5O12Si 
Molecular Weight: 595.68 
 
DOTAGA(tBu)4-APTES (1g) was weighed into a 100mL round bottom flask and was mixed 
with 5mL of concentrated hydrochloric acid and stirred for 10min. Later, the acid was 
evaporated under vacuum at 35°C in 5-15min to get a dried residue. The above dried residue 
was dissolved in 10mL of water and lyophilized to get a light brown coloured powder (Yield: 
850mg, 81%).  
 
1H NMR (500 MHz, D2O) δ 0.5 – 0.8 (m, 2H), 1.2 – 1.3 (m, 1H), 1.4 – 1.6 (m, 1H), 1.6 – 1.8 
(m, 1H), 1.8 – 2.2 (m, 1H), 2.3 – 4.5 (m, 26H). 
 
HRMS: Calculated for C22H41N5O12Si:596.259 M+H+; Obtained: m/z = 596.261 M+H+ 
; 618.242 M+Na+ 
 
Elemental Analysis:  
Calculated for C22H41N5O12Si. HPF6. 2HCl (%): C: 32.44, H: 5.44, N:8.60. 
Observed (%): C: 32.17, H: 6.54, N: 9.39. 
 
--------------------------------------- 
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NODAGA(tBu)3-APTES (3) 
 
 
 
Chemical Formula: C36H70N4O10Si 
Molecular Weight: 747.06 
 
NODA-GA(tBu)3 (1.0g, 1.84mmol) was weighed in the 100mL round bottom flask and was 
dissolved in 20mL of DCM under the hood with stirring. DIPEA (1.3 mL, 7.5mmol) was 
added into above solution followed by coupling agents viz. HBTU (1.0g, 1.95mmol) and 
HOBt (1.0g, 1.95mmol) and the solution was left for stirring at room temperature for 
15min. APTES (0.43g, 1.95mmol) was added to the above solution directly using the 1mL 
syringe and solution was stirred further at room temperature for 60min after which the 
product formation was confirmed through MS. The above solution was mixed with 50mL of 
citric acid solution (pH: 2.5-3) in a separating funnel and the organic layer was recovered. 
The organic layer was further mixed with 50mL of 5% NaHCO3 in a separating funnel and 
the organic layer was recovered. The DCM solution was stirred with 5g of MgSO4 for 10min 
and filtered using sintered funnel to receive the dry and clear DCM solution. Organic phase 
was evaporated under vacuum at 30°C to get a viscous brownish residue, as an intermediate 
product (Yield: 1.5g, 99%). 
 
HRMS: Calculated for C36H70N4O10Si:926.585 M+Na+; Obtained: m/z = 926.584 M+Na+ 
 
1H NMR (500 MHz, CDCl3-d) δ 0.5 – 0.6 (m, 2H), 1.0 – 1.1 (m, 1H), 1.1 – 1.2 (m, 7H), 1.4 
(d, 25H), 1.5 – 1.6 (m, 2H), 1.8 (d, J = 8.8 Hz, 1H), 1.9 – 2.1 (m, 1H), 2.2 – 2.5 (m, 2H), 2.6 – 
3.3 (m, 22H), 3.7 – 3.8 (m, 4H), 6.2 (d, 1H). 
 
13C NMR (126 MHz, CDCl3) δ 7.8, 18.3, 18.4, 23.1, 26.2, 28.1, 28.2, 28.3, 29.7, 33.4, 38.6, 
42.0, 53.7, 55.9, 58.4, 80.8, 165.7, 171.7, 172.8. 
 
Elemental Analysis:  
Calculated for C36H70N4O10Si. 0.6HPF6 (%): C: 51.81, H: 8.53, N: 6.71. 
Observed (%): C: 52.58, H: 9.13, N: 8.85. 
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NODAGA-Silane (4) 
 
 
 
Chemical Formula: C18H34N4O10Si 
Molecular Weight: 494.57 
 
NODAGA(tBu)3-APTES was weighed into a 100mL round bottom flask and was mixed with 
5mL of concentrated hydrochloric acid and stirred for 10min. Later, the acid was evaporated 
under vacuum at 35°C in 5-15min to get a dried residue. The above dried residue was 
dissolved in 10mL of water and lyophilized to get a light brown coloured powder (Yield: 
1.2g, 96%).  
 
1H NMR (500 MHz, D2O) δ 0.41 – 0.80 (m, 2H), 0.93 – 1.28 (m, 2H), 1.39 – 1.59 (m, 2H), 
1.84 – 2.18 (m, 2H), 2.27 – 2.46 (m, 2H), 2.73 (s, 5H), 2.97 – 3.18 (m, 5H), 3.19 – 3.45 (m, 
7H), 3.48 – 3.75 (m, 1H), 3.79 – 4.10 (m, 4H). 
 
HRMS: Calculated for C18H34N4O10Si:495.211 M+H+; Obtained: m/z = 495.212 M+H+ 
; 517.191 M+Na+ 
 
Elemental Analysis:  
Calculated for C18H34N4O10Si. HPF6. HCl (%): C: 31.93, H: 5.36, N: 8.28. 
Observed (%): C: 31.74, H: 6.64, N: 8.81. 
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DOTAGA-Lys-Fmoc-Dde (5) 
 
 
 
Chemical Formula: C52H72N8O14 
Molecular Weight: 1033.19 
 
Lysine-Fmoc-dde (500mg, 0.938mmol) was weighed into a 50mL RBF to which 2mL of 
DMF was added, solubilized followed by addition of DIPEA (0.34 mL, 1.92mmol) and 
stirring for 5min. TSTU (303mg, 1mmol) was added to the above reaction mixture and the 
reaction was stirred for 30min. The activated lysine formation was verified by LC-MS. 
DOTAGA-NH2 was weighed into glass tube and dissolved in DMF: Water - 3mL: 
1mL followed by addition of DIPEA to it. The above solution was added to the activated 
lysine solution and the reaction was left stirred at room temperature for 1h. The solvents were 
evaporated at 40°C to get a pale yellow viscous solution. The residue was purifed by flash 
chromatography (C18) using water (0.1%TFA) and acetonitrile (0.1%TFA). Appropriate 
fractions were identified, collected, evaporated, frozen and lyophilized to get the creamish 
white powder (Yield: 700mg, 73%). 
 
HRMS: Calculated for C52H72N8O14:1033.524 M+H+; Obtained: m/z = 1033.527 M+H+, 
1055.505 M+Na+ 
 
HPLC: tR= 3.93min, Purity= 97.93% 
 
1H NMR (500 MHz, D2O) δ 1.0 (d, 6H), 1.2 – 1.9 (m, 5H), 1.9 – 2.1 (m, 1H), 2.3 (m, 9H), 2.8 
(s, 2H), 3.0 – 4.7 (m, 33H), 5.0 (s, 1H), 7.3 (s, 4H), 7.5 – 8.0 (m, 4H). 
 
13C NMR (126 MHz, D2O) δ 17.7, 22.7, 27.3, 29.4, 31.3, 33.0, 38.0, 38.6, 43.1, 46.7, 51.6, 
53.5, 54.8, 55.3, 66.6, 107.4, 112.8, 115.2, 117.5, 119.8, 125.1, 127.2, 127.7, 140.7, 143.5, 
143.8, 157.0, 162.4, 162.7, 162.9, 163.2, 173.9, 174.1, 174.8, 178.7, 199.1 
 
Elemental Analysis:  
Calculated for C52H72N8O14. 2.2 TFA (%): C: 52.76, H: 5.82, N: 8.73. 
Observed (%): C: 52.53, H: 6.11, N: 8.96. 
 
------------------------------------------------------- 
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DOTAGA-Lys-Dde-NH2 (6) 
 
 
 
 
Chemical Formula: C37H62N8O12 
Molecular Weight: 810.95 
 
DOTAGA-Lys-Fmoc-Dde (600mg) was weighed into a 50mL round bottom flask and 
dissolved in 5mL each of DMF and DEA and the reaction was stirred for 30 min. The solvent 
was evaporated at 35°C to obtain a yellow viscous residue. The residue was purified by flash 
chromatography (C18) using water and acetonitrile as eluents. The appropriate fractions were 
identified, pooled, frozen and lyophilised to give a white powder (Yield: 300mg, 77%). 
 
HRMS: Calculated for C37H62N8O12:811.456 M+H+; Obtained: m/z = 811.456 M+H+, 
833.433 M+Na+ 
 
HPLC: tR= 2.63min, Purity= 99.63% 
 
1H NMR (500 MHz, D2O) δ 1.0 (s, 6H), 1.4 (p, J = 8.1 Hz, 2H), 1.6 – 2.0 (m, 6H), 2.1 – 2.3 
(m, 1H), 2.4 (d, 8H), 2.8 (t,1H), 2.9 – 3.6 (m, 22H), 3.6 – 3.8 (m, 4H), 3.8 – 4.1 (m, 3H). 
 
13C NMR (126 MHz, D2O) δ 17.9, 21.5, 21.5, 27.0, 27.6, 27.6, 29.7, 30.2, 30.2, 33.2, 33.5, 
38.3, 38.6, 38.8, 38.9, 43.0, 43.0, 44.3, 45.8, 49.6, 50.7, 51.6, 53.0, 53.1, 54.0, 56.2, 56.7, 
61.8, 108.2, 169.9, 170.0, 174.9, 174.9, 175.6, 175.7, 200.8. 
 
Elemental Analysis:  
Calculated for C37H62N8O12. 4H2O (%): C: 50.33, H: 7.99, N: 12.69. 
Observed (%): C: 49.96, H: 8.18, N: 12.91. 
 
------------------------------------------------ 
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DOTAGA-Lys-TA-Dde (7) 
 
 
 
 
Chemical Formula: C45H74N8O13S2 
Molecular Weight: 999.25 
 
DOTAGA-Lys-Dde-NH2(350 mg) was weighed in a 50mL round bottom flask and dissolved 
in ACN:Water (3.5mL:1.5mL). DIPEA (0.6 mL, 3.46mmol) was added to the above solution 
and the solution was stirred for 5min. TA-NHS (262mg, 0.86mmol) was weighed a glass tube 
and added to above solution and the reaction was stirred at room temperature for 1h.  The 
product formation was confirmed by LC-MS. The reaction mixture was evaporated to get a 
yellow waxy residue. The above residue was purified by flash chromatography (C18) using 
water and acetonitrile as eluents. Appropriate fractions were identified, pooled, frozen 
and lyophilized to give a yellowish white powder (420mg, 95%). 
 
HRMS: Calculated for C45H74N8O13S2:1021.470 M+Na+; Obtained: m/z = 1021.472 
M+Na+ 
 
HPLC: tR= 3.62min, Purity= 97.62% 
 
1H NMR (500 MHz, Deuterium Oxide) δ 1.0 (s, 6H), 1.4 – 2.0 (m, 13H), 2.1 – 2.6 (m, 12H), 
2.6 – 2.8 (m, 1H), 2.9 (m, 1H), 3.0 – 3.8 (m, 34H), 3.8 – 4.0 (m, 2H), 4.2 (m, 1H). 
 
13C NMR (126 MHz, D2O) δ 12.1, 16.3, 17.7, 18.1, 22.9, 25.0, 25.1, 25.2, 27.2, 27.4, 27.9, 
28.1, 28.3, 29.7, 30.8, 33.4, 33.8, 33.9, 35.3, 35.4, 36.4, 38.2, 38.6, 38.9, 40.3, 42.5, 43.4, 
51.7, 53.6, 53.6, 54.3, 55.2, 56.6, 56.6, 56.7, 63.0, 108.2, 174.3, 174.8, 175.6, 175.6, 176.8, 
176.9, 200.6. 
 
Elemental Analysis:  
Calculated for C45H74N8O13S2 (%): C: 54.09, H: 7.46, N: 11.21, S: 6.42. 
Observed (%): C: 54.87, H: 9.16, N: 10.53, S: 4.87 
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DOTAGA-Lys-TA-NH2 (8) 
 
 
 
 
Chemical Formula: C35H62N8O11S2 
Molecular Weight: 835.05 
 
DOTAGA-Lys-TA-Dde (450mg, 0.42mmol) was weighed in a 50mL round bottom flask and 
was dissolved in 5 mL of DMF. Imidazole (868mg, 12.6mmol) and hydroxylamine 
hydrochloride (877mg, 12.6mmol) was weighed in a glass tube and added to the above 
solution. The reaction mixture was stirred at room temperature for 3h. The reaction was 
completed as confirmed by LC-MS. The DMF was evaporated at 40°C and the residue was 
purified by flash chromatographic (C18) using water and acetonitrile as eluents. The 
appropriate fractions were identified, pooled, evaporated, frozen and lyophilized to get a 
white powder (Yield: 180mg, 48%). 
 
HRMS: Calculated for C52H72N8O14:857.387M+Na+, 858.394 M+H+Na+; Obtained: m/z = 
857.385M+Na+, 858.390 M+H+Na+ 
 
HPLC: tR=2.77 min, Purity= 93.28 % 
 
1H NMR (500 MHz, D2O) δ 1.1 – 1.4 (m, 4H), 1.5 – 1.8 (m, 9H), 1.8 – 2.0 (m, 2H), 2.1 (m, 
1H), 2.2 – 2.4 (m, 3H), 2.4 – 2.5 (m, 1H), 2.7 – 3.5 (m, 26H), 3.6 (m, 4H), 3.9 (m, 2H), 4.1 – 
4.2 (m, 1H). 
 
13C NMR (126 MHz, D2O) δ 22.1, 24.9, 24.9, 26.3, 27.9, 30.6, 30.7, 33.4, 33.7, 34.5, 35.1, 
35.2, 38.1, 38.5, 38.6, 38.9, 39.1, 40.3, 49.2, 50.3, 50.6, 51.7, 53.8, 53.9, 53.9, 55.6, 56.5, 
63.2, 174.2, 174.3, 175.5, 177.0. 
 
Elemental Analysis:  
Calculated for C35H62N8O11S2. 5H2O (%): C: 45.44, H: 7.85, N: 12.11, S: 6.93. 
Observed (%): C: 45.39, H: 8.37, N: 13.33, S: 5.77. 
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DOTAGA(tBu)4-NH2 (9) 
 
 
 
Chemical Formula: C37H70N6O9 
Molecular Weight: 743.00 
 
DOTA-GA(tBu)4 (4.3g, 6.13mmol) was weighed in the round bottom flask 100mL and was 
dissolved in 60mL of ACN under the hood with stirring. DIPEA (6.6mL, 36.8mmol) was 
added first to the above solution followed by coupling agents viz. HBTU (2.44g, 6.43mmol) 
and HOBt (0.87g, 6.43mmol), and the solution was left for stirring at room temperature for 
10min. Ethylenediamine (20.7mL, 306.7mmol) was dissolved in about 60mL of ACN and 
added to the DOTA-GA(tBu)4 solution and was stirred further at room temperature for 30min 
after which the product formation was confirmed through LC-MS The solution was 
evaporated at 35°C to remove ACN to get a viscous residue. The residue was dissolved in 
100mL of DCM and successively extracted with 100mL of citric acid (pH-3), 5%NaHCO3 
and water. The organic phase was dried by passing over MgSO4 and subsequently evaporated 
to get a viscous residue.  The residue was purified by flash chromatography (C18) using 
Water (0.1%TFA) and ACN (0.1%TFA) as eluent to get a white powder as a TFA salt (Yield: 
3.68g, 48%). 
 
HRMS: Calculated for C37H70N6O9:743.527 M+H+; Obtained: m/z = 743.530 M+H+, 
765.509 M+Na+ 
 
HPLC: tR= 3.73min, Purity= 99.62%. 
 
Elemental Analysis:  
Calculated for C48H65N7O12. 4.5TFA (%): C: 43.52, H: 5.88, N: 6.77. 
Observed (%): C: 43.00, H: 6.89, N: 6.96. 
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DOTAGA(tBu)4-Lys-Fmoc-Dde (10) 
 
 
 
 
Chemical Formula: C68H104N8O14 
Molecular Weight: 1257.62 
 
Fmoc-Lysine-Dde-OH (2.5g, 4.7mmol) was weighed into a 500mL round bottom flask and 
dissolved in 20mL of ACN and DIPEA (1.7mL, 9.38mmol) and the solution stirred at room 
temperature for 10 min. TSTU (1.46g, 4.74mmol) was added into lysine solution and reaction 
stirred at room temperature for 30min for the Lysine-NHS ester formation which was verified 
by LC-MS. DOTAGA(tBu)4-NH2 (3.5g) was weighed into 250mLround bottom flask and 
dissolved in 30mL ACN and DIPEA (4.17mL, 23.5mmol) and pipetted slowly into the lysine 
solution. The reaction was stirred for 1h and the peptide coupling was verified by LC-MS. 
The solvent was evaporated off to get a viscous residue that was purified by flash 
chromatography (C18) using water (0.1%TFA) and ACN (0.1%TFA) as eluent to get a white 
powder as a TFA salt (Yield 3.88g, 45%). 
 
HRMS: Calculated for C68H104N8O14:1257.774M+H+; Obtained: m/z = 1257.775 M+H+. 
 
HPLC: tR= 4.94min, Purity= 98.52% 
 
1H NMR (500 MHz, CDCl3-d) δ 1.0 (s, 6H), 1.3 – 1.6 (m, 41H), 1.7 (m, 4H), 1.8 – 2.2 (m, 
3H), 2.3 (s, 4H), 2.5 (s, 6H), 2.7 – 4.6 (m, 33H), 6.8 (d, 1H), 7.3 (dd, J = 7.4, 2.7 Hz, 2H), 7.4 
(td, J = 7.5, 2.5 Hz, 2H), 7.6 (dd, J = 7.5, 2.5 Hz, 2H), 7.7 (d, J = 7.6 Hz, 2H), 8.0 (s, 1H), 8.2 
– 8.3 (m, 1H), 10.5 (s, 2H). 
 
13C NMR (126 MHz, CDCl3) δ 17.2, 17.3, 17.9, 23.0, 27.7, 27.9, 27.9, 28.2, 28.5, 30.1, 32.3, 
37.0, 39.3, 43.3, 47.1, 52.7, 53.8, 55.3, 67.0, 105.0, 107.7, 112.8, 115.1, 117.5, 119.8, 119.9, 
125.4, 125.5, 127.1, 127.7, 141.1, 141.2, 144.0, 144.0, 156.5, 160.4, 160.7, 161.0, 161.3, 
173.1, 173.7, 197.8. 
 
Elemental Analysis:  
Calculated for C68H104N8O14. 5.TFA (%): C: 51.26, H: 6.01, N: 6.13. 
Observed (%): C: 49.50, H: 6.91, N: 7.72. 
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DOTAGA(tBu)4-Lys-Dde-NH2 (11) 
 
 
 
Chemical Formula: C53H94N8O12 
Molecular Weight: 1035.38 
 
DOTAGA(tBu)4-Lys-Fmoc-Dde (3.5 g) was dissolved in 27mL of ACN and 13mL of 
diethylamine and reaction was stirred at room temperature for 1h. The reaction mixture was 
stirred for 0.5h and the product was confirmed through LC-MS. The solvents were evaporated 
at 35°C to get a viscous residue that was purified by flash chromatography (C18) using water 
(0.1%TFA) and ACN (0.1%TFA) as eluents to obtain a white powder as a TFA salt (Yield: 
2.8g, 94%). 
 
HRMS: Calculated for C53H94N8O12:1035.706 M+H+; Obtained: m/z = 1035.709 M+H+, 
1057.685 M+Na+ 
 
HPLC: tR= 4.08min, Purity= 98.86% 
 
1H NMR (500 MHz, CDCl3-d) δ 1.0 (s, 6H), 1.2 – 1.6 (m, 38H), 1.7 (h, J = 7.3 Hz, 2H), 1.9 
(m, 3H), 2.3 (s, 4H), 2.5 (s, 5H), 2.6 – 4.6 (m, 27H), 8.1 (s, 1H), 8.7 (d, 4H). 
 
13C NMR (126 MHz, CDCl3) δ 11.0, 17.8, 22.0, 27.9, 28.2, 28.4, 30.1, 30.7, 30.9, 43.0, 52.7, 
107.7, 113.0, 115.3, 117.6, 120.0, 160.7, 161.0, 161.2, 161.5, 169.4, 173.8, 197.8. 
 
Elemental Analysis:  
Calculated for C53H94N8O12. 4.5TFA (%): C: 48.09, H: 6.41, N: 7.24. 
Observed (%): C: 48.02, H: 6.05, N: 7.72. 
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DOTAGA(tBu)4-Lys-TA-Dde (12) 
 
 
 
 
Chemical Formula: C61H106N8O13S2 
Molecular Weight: 1223.68 
 
DOTAGA(tBu)4-Lys-Dde-NH2 (2.7g) was dissolved in 30mL of ACN in a 500mL round 
bottom flask, to which DIPEA (2.31mL, 13mmol) was added dropwise and stirred for 10min. 
Thioctic acid-NHS (832mg, 2.74mmol) was weighed into a glass tube and added directly into 
the above reaction mixture. The reaction mixture was stirred at room temperature for around 3 
h till the product formation was confirmed using LC-MS. The solvent was evaporated using 
rotavapor at 35°C and the oily residue was purified by flash chromatography (C18) using 
water (0.1%TFA) and ACN (0.1%TFA) as eluent to get a white powder as a TFA salt (Yield: 
2.6g, 95%).  
 
HRMS: Calculated for C61H106N8O13S2:1245.721 M+Na+; Obtained: m/z = 1245.720 
M+Na+ 
 
HPLC: tR= 4.73min, Purity= 93.42% 
 
1H NMR (500 MHz, CDCl3-d) δ 1.0 (s, 6H), 1.5 (q, J = 7.9 Hz, 40H), 1.6 – 1.8 (m, 8H), 1.8 – 
2.1 (m, 4H), 2.1 – 2.3 (m, 3H), 2.4 (s, 4H), 2.4 – 2.7 (m, 7H), 2.7 – 4.5 (m, 32H), 7.5 – 8.4 
(m, 5H). 
 
13C NMR (126 MHz, CDCl3) δ 18.1, 23.4, 24.6, 25.6, 25.8, 28.2, 28.5, 28.7, 29.0, 29.1, 30.3, 
31.0, 32.1, 32.7, 34.6, 34.7, 36.1, 38.6, 39.6, 40.4, 40.5, 43.4, 53.0, 54.0, 56.3, 56.8, 108.0, 
113.1, 115.4, 117.8, 120.1, 160.7, 161.0, 161.3, 161.6, 169.3, 172.9, 173.4, 173.8, 174.1, 
198.0. 
 
Elemental Analysis:  
Calculated for C48H65N7O12. 3.TFA (%): C: 51.40, H: 7.02, N:7.16, S:4.10. 
Observed (%): C: 50.17, H: 7.79, N: 7.24, S: 3.16. 
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DOTAGA(tBu)4-Lys-TA-NH2 (13) 
 
 
 
 
Chemical Formula: C51H94N8O11S2 
Molecular Weight: 1059.48 
 
DOTAGA(tBu)4-Lys-TA-Dde (2.5g) was dissolved in 20mL of ACN in 500mL round bottom 
flask and imidazole (4.22g, 61.3mmol) and hydroxylamine.HCl (4.26g, 61.3mmol) were 
dissolved in 10mL water. The aqueous base solution was added to the DOTAGA(tBu)4-Lys-
TA-Dde solution and the reaction was stirred at room temperature for 30min following which 
the product formation was confirmed by LC-MS. The solvents were evaporated off and 
residue which was purified by flash chromatography (C18) using water (0.1%TFA) and ACN 
(0.1%TFA) as eluent to get a white powder (Yield: 1.8g, 72%). 
 
HRMS: Calculated for C51H94N8O11S2:1081.637 M+Na+; Obtained: m/z = 1061.636 
M+Na+. 
 
HPLC: tR= 4.17min, Purity= 99.72%  
 
1H NMR (500 MHz, CDCl3-d) δ 1.0 – 1.6 (m, 38H), 1.6 – 1.8 (m, 7H), 1.8 – 2.1 (m, 1H), 2.2 
(d, 2H), 2.4 – 4.5 (m, 28H), 7.5 – 8.8 (m, 8H). 
 
13C NMR (126 MHz, CDCl3) δ 22.6, 25.5, 26.9, 28.1, 28.1, 29.0, 34.7, 35.9, 38.6, 39.6, 40.5, 
56.8, 113.1, 115.5, 117.8, 120.1, 160.8, 161.1, 161.4, 161.7, 173.6, 174.3. 
 
Elemental Analysis:  
Calculated for C48H65N7O12. 4.5TFA (%): C: 45.83, H: 6.31, N: 7.13, S: 4.08. 
Observed (%): C: 45.69, H: 7.52, N: 8.05, S: 3.16. 
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DOTAGA(tBu)4-Lys-TA-NODAGA(tBu)3 (14) 
 
 
 
Chemical Formula: C78H141N11O18S2 
Molecular Weight: 1585.17 
 
NODAGA(tBu)3 (400mg, 0.736mmol) was weighed into a 100mL round bottom flask and 
dissolved in 10mL of ACN and DIPEA (0.39mL, 2.2mmol) and the solution was stirred at 
room temperature for 10 min. HBTU (285mg, 0.74mmol) and HOBt (100mg, 0.74mmol) was 
added into the above solution and the reaction stirred at room temperature for 30min 
following which the reaction was verified by LC-MS. DOTAGA(tBu)4-Lys-TA-NH2 (780mg) 
was weighed into a 100mL round bottom flask and dissolved in 10mL of acetonitrile and 
DIPEA (0.65mL, 3.67mmol) and pipetted slowly into the activated NODAGA(tBu)3 solution. 
The reaction was stirred for 1h and the peptide coupling was verified by LC-MS. The solvent 
was evaporated off to get a viscous residue that was purified by flash chromatography (C18) 
using water (0.1%TFA) and acetonitrile (0.1%TFA) as eluent to get a white powder as a TFA 
salt (Yield: 1.1g, 69%). 
 
HRMS: Calculated for C78H141N11O18S2:1606.978 M+Na+; Obtained: m/z = 1606.976 
M+Na+ 
 
HPLC: tR= 4.83min, Purity= 91.12% 
 
1H NMR (500 MHz, CDCl3-d) δ 1.3 – 1.6 (m, 51H), 1.6 – 1.8 (m, 6H), 1.9 (m, 1H), 2.0 (m, 
1H), 2.0 – 2.2 (m, 2H), 2.3 (t, J = 7.5 Hz, 2H), 2.3 – 2.7 (m, 5H), 2.7 – 3.5 (m, 24H), 3.5 – 4.4 
(m, 10H), 7.3 – 8.3 (m, 4H). 
 
13C NMR (126 MHz, CDCl3) δ 22.7, 25.4, 25.5, 28.0, 28.0, 28.3, 28.8, 32.5, 34.5, 35.8, 38.4, 
38.6, 40.2, 50.7, 54.1, 55.9, 56.5, 63.5, 82.7, 115.2, 117.5, 119.8, 160.4, 160.7, 161.0, 161.3, 
171.1, 172.6, 172.7, 173.5, 174.0. 
 
Elemental Analysis:  
Calculated for C78H141N11O18S2. 5.3TFA (%): C: 48.60, H: 6.74, N: 7.04, S:2.93. 
Observed (%): C: 48.53, H: 7.53, N: 8.23, S: 2.06. 
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DOTAGA-Lys-TA-NODAGA (15) 
 
 
 
Chemical Formula: C50H85N11O18S2 
Molecular Weight: 1192.41 
 
DOTAGA(tBu)4-Lys-TA-NODAGA(tBu)3 (1g) was weighed into a 50mL round bottom flask 
and was dissolved in 12.5mL of TFA and 12.5mL of dichlormethane. The solution was stirred 
at room temperature for 24h and the reaction was deemed complete as verified by LC-MS. 
The solvents were evaporated to get a viscous residue which was purified by flash 
chromatography (C18) using water (0.1%TFA) and ACN (0.1%TFA) as eluents to get a white 
powder (Yield: 450mg, 60%). 
 
HRMS: Calculated for C50H85N11O18S2:1192.558 M+H+; Obtained: m/z = 1192.559 
M+H+, 1214.540 M+Na+ 
 
HPLC: tR= 2.93min, Purity= 91.42%. 
 
1H NMR (500 MHz, D2O) δ 1.1 – 1.3 (m, 3H), 1.3 (h, J = 7.6 Hz, 3H), 1.4 – 1.5 (m, 2H), 1.5 
(m, 4H), 1.6 (d, J = 7.1 Hz, 1H), 1.7 (m, 2H), 1.8 – 2.0 (m, 4H), 2.0 – 2.2 (m, 1H), 2.2 – 2.3 
(m, 2H), 2.3 (m, 2H), 2.4 – 2.6 (m, 3H), 2.7 – 3.7 (m, 35H), 3.7 – 4.1 (m, 8H), 4.1 (m, 1H). 
 
13C NMR (126 MHz, D2O) δ 16.3, 22.6, 24.5, 24.9, 25.0, 27.6, 27.7, 27.7, 27.8, 27.8, 27.9, 
30.6, 32.1, 32.7, 33.6, 33.7, 33.7, 35.1, 35.2, 37.1, 38.0, 38.1, 38.5, 38.6, 39.0, 40.2, 40.3, 
40.3, 50.8, 53.9, 55.5, 56.4, 56.6, 63.8, 112.8, 115.1, 117.4, 162.7, 163.0, 174.5, 174.9, 175.2, 
177.0. 
 
Elemental Analysis:  
Calculated for C50H85N11O18S2. 4.TFA (%): C: 42.26, H: 5.44, N:9.35, S:3.89. 
Observed (%): C: 42.49, H: 6.50, N: 9.95, S: 3.95. 
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PSMA(tBu)3-Glutarate (16) 
 
 
 
Chemical Formula: C29H51N3O10 
Molecular Weight: 601.74 
 
PSMA(tBu)3 (600mg, 1.23mmol) was weighed into a 250mL round bottom flask and was 
dissolved in 6mL of anhydrous acetonitrile, to which was added DIPEA (0.43mL, 2.46mmol) 
and the reaction was stirred for 5min. Glutaric anhydride (215mg, 1.85 mmol) was weighed 
into glass tube and added directly into the PSMA solution and the reaction mixture was stirred 
for 1h at room temperature, the product formation was verified by LC-MS. The reaction 
mixture was evaporated at 35°C to get a brownish residue which was purified by flash 
chromatography (C18) using water and acetonitrile as eluents to get a translucent product 
(Yield: 560 mg, 76%).  
 
HRMS: Calculated for C29H51N3O10:602.364 M+H+; Obtained: m/z = 602.364 M+H+, 
624.345 M+Na+ 
 
HPLC: tR= 4.52min, Purity= 90.12% 
 
1H NMR (500 MHz, CDCl3-d) δ 1.1 – 1.6 (m, 31H), 1.6 – 1.8 (m, 1H), 1.9 (hd, J = 6.9, 4.2 
Hz, 2H), 1.9 – 2.0 (m, 1H), 2.1 – 2.5 (m, 5H), 2.9 – 3.1 (m, 1H), 3.3 (m, 1H), 3.6 (hept, J = 
6.7 Hz, 1H), 4.0 – 4.5 (m, 2H), 5.8 (d, J = 8.3 Hz, 1H), 6.0 (d, J = 8.0 Hz, 1H), 6.7 – 7.0 (m, 
1H), 7.9 – 9.0 (m, 1H). 
 
13C NMR (126 MHz, CDCl3) δ 11.8, 18.4, 22.0, 22.2, 28.1, 28.2, 28.7, 31.8, 32.0, 32.4, 34.8, 
35.8, 38.9, 41.4, 52.4, 52.9, 53.3, 80.8, 81.4, 82.0, 158.0, 172.7, 172.8, 173.2, 173.5, 177.7. 
 
Elemental Analysis:  
Calculated for C29H51N3O10 (%): C: 57.89, H: 8.54, N: 6.98. 
Observed (%): C: 56.83, H: 9.28, N: 7.35. 
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DOTAGA(tBu)4-Lys-TA-Glu-PSMA(tBu)3 (17) 
 
 
 
Chemical Formula: C80H143N11O20S2 
Molecular Weight: 1643.20 
 
PSMA(tBu)3-Glutarate (400mg, 0.66mmol) was weighed into a 100mL round bottom flask 
and dissolved in 10mL of ACN and DIPEA (0.12mL, 0.66mmol) and the solution was stirred 
at room temperature for 10 min. TSTU (205mg, 0.66mmol) was added into above solution 
and reaction stirred at room temperature for 30min following which the reaction was verified 
by LC-MS. DOTAGA(tBu)4-Lys-TA-NH2 (705mg) was weighed into a 100mL round bottom 
flask and dissolved in 10mL of acetonitrile and DIPEA (0.59mL, 3.33mmol) and pipetted 
slowly into activated PSMA(tBu)3-Glutarate solution. The reaction was stirred for 1h and the 
peptide coupling was verified by LC-MS. The solvent was evaporated off to get a viscous 
residue that was purified by flash chromatography (C18) using water (0.1%TFA) and 
acetonitrile (0.1%TFA) as eluent to get a white powder as a TFA salt (Yield: 1.05g, 75%). 
 
HRMS: Calculated for C80H143N11O20S2:1643.002 M+H+; Obtained: m/z = 1643.008 
M+H+, 1664.985 M+Na+. 
 
HPLC: tR= 5.08min, Purity= 95.85% 
 
1H NMR (500 MHz, CDCl3-d) δ 1.1 – 1.6 (m, 72H), 1.6 (m, 5H), 1.7 – 1.8 (m, 4H), 1.8 – 1.9 
(m, 2H), 1.9 (m, 3H), 2.1 (m,2H), 2.2 (s, 1H), 2.2 – 2.3 (m, 5H), 2.3 (m, 3H), 2.4 – 2.7 (m, 
5H), 2.7 – 4.5 (m, 39H). 
 
13C NMR (126 MHz, CDCl3) δ 17.8, 22.2, 22.7, 25.6, 28.2, 28.2, 28.3, 28.4, 28.9, 29.1, 31.9, 
34.8, 35.4, 36.0, 38.6, 38.9, 40.5, 53.2, 53.6, 53.9, 56.7, 80.7, 81.5, 82.0, 113.1, 115.4, 117.8, 
120.1, 158.1, 161.1, 161.3, 161.6, 172.6, 172.9, 173.1, 173.7. 
 
Elemental Analysis:  
Calculated for C48H65N7O12. 4.TFA (%): C: 50.35, H: 7.06, N:7.34, S:3.05. 
Observed (%): C: 49.48, H: 7.69, N: 7.92, S: 2.47. 
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DOTAGA-Lys-TA-Glu-PSMA (18) 
 
 
 
 
Chemical Formula: C52H87N11O20S2 
Molecular Weight: 1250.45 
 
DOTAGA(tBu)4-Lys-TA-Glu-PSMA(tBu)3 (1g) was weighed into a 50mL round bottom 
flask and was dissolved in 12.5mL of TFA and 12.5mL of dichloromethane. The solution was 
stirred at room temperature for 24h, following which the reaction was deemed complete as 
verified by LC-MS. The solvents were evaporated to get a viscous residue which was purified 
by flash chromatography (C18) using water (0.1%TFA) and ACN (0.1%TFA) as eluents to 
get a white powder (Yield: 240mg, 34%). 
 
HRMS: Calculated for C52H87N11O20S2:1250.564 M+H+; Obtained: m/z = 1250.568 
M+H+, 1272.542 M+Na+ 
 
HPLC: tR= 3.01min, Purity= 99.01% 
 
1H NMR (500 MHz, D2O) δ 1.2 (t, J = 7.3 Hz, 4H), 1.2 – 1.4 (m, 6H), 1.4 – 1.5 (m, 4H), 1.5 – 
1.6 (m, 4H), 1.6 – 1.7 (m, 3H), 1.7 – 1.8 (m, 3H), 1.8 – 2.0 (m, 4H), 2.0 – 2.1 (m, 1H), 2.2 (t, 
J = 7.5 Hz, 4H), 2.2 (td, J = 7.2, 2.5 Hz, 2H), 2.4 (m, 5H), 2.8 – 4.0 (m, 37H), 4.0 – 4.2 (m, 
3H). 
 
13C NMR (126 MHz, D2O) δ 22.0, 22.3, 22.6, 24.9, 25.0, 26.3, 27.8, 27.9, 27.9, 30.1, 30.6, 
30.7, 33.7, 33.8, 35.0, 35.1, 35.2, 38.1, 38.5, 38.6, 39.0, 40.3, 40.3, 42.2, 52.6, 53.2, 53.9, 
56.6, 115.1, 117.5, 159.2, 174.5, 175.5, 175.5, 176.2, 176.9, 177.1, 177.2. 
 
Elemental Analysis:  
Calculated for C48H65N7O12. 2.TFA (%): C: 45.49, H: 6.07, N:10.42, S: 4.34. 
Observed (%): C: 45.36, H: 7.03, N: 10.87, S: 3.62. 
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NODAGA(tBu)3-NH2 (19) 
 
 
 
Chemical Formula: C29H55N5O7 
Molecular Weight: 585.79 
 
NODAGA(tBu)3 (1g, 1.84 mmol) was weighed into a 100mL round bottom flask and 
dissolved in 10mL of ACN under the hood with stirring. 1.3mL of DIPEA (0.97g, 7.36 mmol) 
was added first to the above solution followed by coupling agents viz. HBTU (0.75g, 1.93 
mmol) and HOBt (0.26g, 1.93mmol), and the solution was left for stirring at room 
temperature for 10-15min. Ethylenediamine was dissolved in about 10mL of ACN and added 
to the NODAGA-GA(tBu)3 solution and stirred further at room temperature for 1h. The 
solution was evaporated at 35°C to remove ACN. The residue was dissolved in 50mL of 
DCM and sequentially extracted with 50mL each of citric acid solution (pH 3), NaHCO3 (5%) 
and finally water using a separating funnel to remove water soluble components. The organic 
phase was dried over MgSO4, filtered and evaporated to get yellowish residue which was 
purified by reverse phase (C18) flash chromatography using water (0.1%TFA) and 
acetonitrile (0.1%TFA) as eluents. The product was recovered as a white solid in form of 
TFA salt (Yield: 1134 mg, 68%).  
 
ESI-MS: Calculated for C29H55N5O7: 585.41; Obtained: m/z = 586.24 M+H+. 
 
HRMS: Calculated for C29H55N5O7: 586.417 M+H+; Obtained: m/z = 586.419 M+H+ 
 
HPLC: tR= 3.84min, Purity= 97.55% 
 
1H NMR (500 MHz, CDCl3-d) δ 1.5 (m, 27H), 1.9 – 2.2 (m, 2H), 2.4 (t, J = 7.3 Hz, 2H), 2.8 – 
3.9 (m, 22H). 
 
13C NMR (126 MHz, CDCl3-d) δ 17.9, 21.5, 27.0, 27.6, 29.7, 30.2, 33.5, 38.3, 38.6, 38.9, 
43.0, 45.8, 49.6, 50.7, 51.6, 53.0, 53.1, 54.0, 56.2, 61.8, 108.2, 169.9, 170.0, 174.9, 175.6, 
175.7. 
 
Elemental Analysis:  
Calculated for C29H55N5O7. 2.8TFA (%): C: 45.92, H: 6.44, N: 7.74. 
Observed (%): C: 45.31, H: 6.30, N: 7.55. 
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NODAGA(tBu)3-Lys-Fmoc-Dde (20) 
 
Chemical Formula: C60H89N7O12 
Molecular Weight: 1099.66 
 
Lysine-Fmoc-Dde-OH (550mg, 1.033 mmol) was dissolved in 10mL of acetonitrile (ACN) in 
a50mL round bottom flask to which DIPEA (0.37 mL, 2.065mmol) was added dropwise 
followed by addition of TSTU (349mg, 1.136mmol). The reaction was left to stir at room 
temperature for 1h. NODAGA(tBu)3-NH2(805 mg) was dissolved in 10mL of acetonitrile and 
DIPEA (1.1 mL, 6.193 mmol), stirred for 5min and added into the activated lysine solution. 
The reaction mixture was left to stir at room temperature for 2h. The reaction mixture was 
evaporated at 35°C to remove acetonitrile to get a white residue, which was dissolved in 
50mL of chloroform. The chloroform solution was mixed with 50mL of water to extract the 
water-soluble components in a separating funnel. The organic layer was recovered and 
evaporated off to get a viscous residue which was purified by reverse phase (C18) flash 
chromatography using water (0.1%TFA) and acetonitrile (0.1%TFA) as eluents. The product 
was recovered as a white solid in form of TFA salt (Yield: 580 mg, 44%).  
 
ESI-MS (m/z): Calculated for C60H89N7O12:1099.66; Obtained: m/z = 551.03 M+H+2. 
 
HRMS: Calculated for C60H89N7O12:1100.664 M+H+; Obtained: m/z = 1100.667 M+H+ 
 
HPLC: tR= 5.24min, Purity= 97.51% 
 
1H NMR (500 MHz, CDCl3-d) δ 13.39 (t, J = 5.3 Hz, 1H), 8.11 (m, 2H), 7.81 – 7.70 (m, 3H), 
7.68 – 7.52 (m, 2H), 7.45 – 7.35 (m, 2H), 7.32 (tt, J = 7.4, 1.3 Hz, 2H), 4.81 – 3.90 (m, 7H), 
3.87 – 3.54 (m, 2H), 3.54 – 3.28 (m, 12H), 3.27 – 2.78 (m, 9H), 2.55 (s, 3H), 2.45 (t, J = 7.2 
Hz, 2H), 2.36 (d, J = 6.1 Hz, 5H), 2.16 (m, 1H), 2.08 – 1.99 (m, 1H), 1.97 – 1.83 (m, 1H), 
1.80 – 1.64 (m, 4H), 1.56 – 1.37 (m, 27H), 1.02 (s, 6H). 
 
13C NMR (126 MHz, CDCl3) δ 18.0, 22.9, 25.1, 28.0, 28.0, 28.2, 28.5, 30.1, 32.6, 39.3, 43.3, 
47.1, 52.6, 54.8, 55.9, 67.1, 76.8, 77.0, 77.3, 83.2, 107.7, 115.1, 117.4, 119.9, 125.3, 127.1, 
127.7, 141.2, 143.9, 160.9, 161.2, 170.4, 170.5, 173.8, 180.4, 198.0. 
 
Elemental Analysis:  
Calculated for C29H55N5O7. 1.5TFA (%): C: 59.51, H: 7.17, N:7.71. 
Observed (%): C: 59.39, H: 7.14, N:7.70. 
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NODAGA(tBu)3-Lys-Dde-NH2 (21) 
 
 
Chemical Formula: C45H79N7O10 
Molecular Weight: 877.59 
 
NODAGA(tBu)3-Lysine-Fmoc-Dde (172mg) was dissolved in 10mL of diethylamine and 
10mL of dichloromethane in 100mL flask and the reaction mixture was stirred for 2h. The 
solvents were evaporated at 35°C to get the light brownish residue which was purified by 
reverse phase (C18) flash chromatography using water (0.1%TFA) and acetonitrile 
(0.1%TFA) as eluents. The product was recovered as a white solid in form of TFA salt 
(Yield: 90 mg, 48%). 
 
ESI-MS (m/z): Calculated for C45H79N7O10:877.59; Obtained: 439.75 M+H+2 and 878.5 
M+H+. 
 
HRMS: Calculated for C45H79N7O10:878.596 M+H+; Obtained: m/z = 878.598 M+H+ 
 
HPLC: tR= 4.13min, Purity= 97.86% 
 
1H NMR (500 MHz, CDCl3-d) δ 0.9 (s, 6H), 1.4 (m, 27H), 1.6 (p, J = 7.1 Hz, 2H), 1.9 (t,  
2H), 2.3 (s, 3H), 2.4 (t, J = 7.2 Hz, 1H), 2.5 (s, 2H), 2.7 – 2.9 (m, 1H), 3.0 (d, 7H), 3.1 – 3.2 
(m, 3H), 3.2 – 3.5 (m, 4H), 3.5 – 3.6 (m, 1H), 3.9 (t, J = 6.9 Hz, 1H), 8.6 (d, J = 6.8 Hz, 1H), 
9.7 (s, 1H). 
 
13C NMR (126 MHz, CDCl3) δ 17.9, 22.2, 24.6, 28.0, 28.1, 28.2, 30.1, 30.6, 32.4, 39.3, 43.0, 
52.8, 53.8, 55.9, 63.5, 77.6, 83.3, 107.8, 115.5, 117.8, 161.7, 161.9, 169.3, 173.0, 173.8, 
189.8, 197.8. 
 
Elemental Analysis:  
Calculated for C29H55N5O7. 2.8TFA (%): C: 50.76, H: 6.89, N:8.19. 
Observed (%): C: 50.79, H: 7.42, N:8.32. 
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NODAGA(tBu)3-Lys-TA-Dde (22) 
 
 
Chemical Formula: C53H91N7O11S2 
Molecular Weight: 1065.62 
 
NODAGA(tBu)3-Lys-Dde-NH2 (90mg) was taken into a 100mL round bottom flask. 3 mL of 
acetonitrile and DIPEA (0.071mL, 0.398 mmol) was added to the above solution which was 
stirred for 5min. Thioctic acid-NHS ester (31mg, 0.1 mmol) was weighed into glass tube and 
added into above solution which was stirred at room temperature for 1h. The reaction mixture 
was evaporated to remove the excess solvents to get the yellowish residue/concentrate. This 
residue was purified by reverse phase (C18) flash chromatography using water (0.1%TFA) 
and acetonitrile (0.1%TFA) as eluents. The product was recovered as a yellowish white solid 
in form of of TFA salt (Yield: 80 mg, 81%). 
 
ESI-MS (m/z): Calculated for C53H91N7O11S2:1065.62; Obtained: 534.04 M+H+2 . 
 
HRMS: Calculated for C53H91N7O11S2:1066.629 M+H+; Obtained: m/z = 1066.629 M+H+ 
 
HPLC: tR= 5.05min, Purity= 93.29% 
 
1H NMR (500 MHz, CDCl3-d) δ 0.9 – 1.0 (s, 6H), 1.1 – 1.2 (m, 2H), 1.3 – 1.5 (m, 32H), 1.5 – 
1.7 (m, 5H), 1.7 – 1.9 (m, 2H), 2.0 – 2.1 (m, 1H), 2.2 – 2.2 (t, J = 7.6 Hz, 2H), 2.3 – 2.3 (s, 
4H), 2.3 – 2.4 (m, 2H), 2.5 – 2.5 (s, 3H), 3.0 – 3.0 (s, 19H), 3.0 – 3.1 (m, 2H), 3.2 – 3.3 (m, 
2H), 3.3 – 3.4 (m, 2H), 3.4 – 3.5 (m, 1H), 3.6 – 3.8 (m, 4H), 7.9 – 8.0 (t, J = 5.3 Hz, 2H). 
 
13C NMR (126 MHz, CDCl3) δ 18.0, 18.4, 23.1, 24.9, 25.4, 28.1, 28.1, 28.3, 28.5, 28.9, 30.1, 
31.9, 32.4, 34.6, 35.9, 38.4, 39.1, 39.4, 40.2, 43.3, 52.7, 55.9, 56.5, 58.5, 63.7, 83.4, 84.4, 
107.7, 170.2, 172.9, 173.8, 197.9, 200.1. 
 
Elemental Analysis:  
Calculated for C29H55N5O7. 2.1TFA (%): C: 52.61, H: 7.19, N:7.51, S:4.91. 
Observed (%): C: 51.21, H:7.36, N:7.89, S:3.92. 
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NODAGA(tBu)3-Lys-TA-NH2 (23) 
 
 
Chemical Formula: C43H79N7O9S2 
Molecular Weight: 901.54 
 
NODAGA(tBu)3-Lys-TA-Dde (400mg) was weighed into 100mL round bottom flask and 
dissolved in 5mL of DMF. Imidazole (774mg, 11.26 mmol) and hydroxylamine 
hydrochloride (782mg, 11.26 mmol) were added into the above solution. The reaction was 
stirred at room temperature for 30min and the solvent was evaporated partially to remove 
DMF at 35°C to a brownish concentrate. This concentrate was purified by reverse phase 
(C18) flash chromatography using water (0.1%TFA) and acetonitrile (0.1%TFA) as eluents. 
The product was recovered as a yellowish white solid (Yield: 200 mg, 52%). 
 
ESI-MS (m/z): Calculated for C43H79N7O9S2:: 901.54; Obtained: 451.75 M+H+2 . 
 
HRMS: Calculated for C43H79N7O9S2:902.545 M+H+; Obtained: m/z = 902.547 M+H+ 
 
HPLC: tR= 4.17min, Purity= 96.76% 
 
1H NMR (500 MHz, CDCl3-d) δ 1.1 – 1.3 (m, 1H), 1.4 (d, J = 5.2 Hz, 32H), 1.5 – 1.8 (m, 
9H), 1.8 (m, 1H), 2.0 (m, 2H), 2.2 (t, J = 7.6 Hz, 2H), 2.2 – 2.5 (m, 4H), 2.7 – 3.8 (m, 34H), 
4.3 (q, J = 7.2 Hz, 1H), 7.4 (m, 1H), 7.8 (d, J = 5.5 Hz, 1H), 8.0 (d, J = 5.8 Hz, 1H). 
 
13C NMR (126 MHz, CDCl3) δ 22.0, 24.6, 25.1, 25.3, 26.5, 28.0, 28.1, 28.8, 31.8, 32.6, 33.5, 
34.5, 34.6, 35.9, 38.4, 38.5, 39.0, 39.2, 39.3, 40.2, 53.3, 56.4, 56.5, 56.5, 63.4, 83.0, 115.4, 
117.8, 161.4, 161.7, 170.9, 172.9, 173.0, 173.8. CDCl3 
 
Elemental Analysis:  
Calculated for C29H55N5O7. 3.2TFA (%): C: 46.83, H: 6.54, N:7.74, S:5.06. 
Observed (%): C: 46.83, H:7.31, N:7.89, S:4.82. 
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NODAGA-Lys-TA-Cy5 (24) 
 
 
 
Chemical Formula: C43H79N7O9S2 
Molecular Weight: 901.54 
 
Cy5 (18.06mg, 33 mol) was weighed into a 50mL round bottom flask and dissolved in 1mL 
of acetonitrile containing DIPEA (12L, 67mol). The solution was stirred for 5min followed 
by addition of TSTU (10.2 mg, 33 mol). The reaction was left stirring at room temperature 
for 30min. NODAGA(tBu)3-Lys-TA-NH2(43mg) was weighed in a glass tube and was 
dissolved in 1mL of ACN and of DIPEA (24L, 133mol). This solution was added into the 
dye solution and the reaction was stirred at room temperature for 4h. The solution was 
evaporated to remove the solvents at room temperature. The residue was dissolved in 1mL of 
DCM and 1mL of TFA and the reaction was stirred at room temperature for 6h to effect 
deprotection of NODAGA moiety. The solvents were evaporated and the residue was purified 
by semi-prep HPLC using water (0.1%TFA) and ACN (0.1%TFA) as eluents. The product 
was recovered as a dark blue powder (10 mg, 20%). 
 
ESI-MS (m/z): Calculated for C64H94N9O10S2: 1212.66 ; Obtained: 606.89 M+H+2 . 
 
HRMS: Calculated for C64H94N9O10S2:1212.655 M+H+; Obtained: m/z = 1212.658 M+H+ 
 
HPLC: tR= 4.67min, Purity= 94.63% 
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NODAGA-Lys-Fmoc-Dde (25) 
 
 
 
 
Chemical Formula: C48H65N7O12 
Molecular Weight: 932.09 
 
Lysine-Fmoc-Dde (2.68g, 5.03mmol) was weighed into a 100mL round bottom flask and 
solubilized in 16mL of DMF, this was followed by addition of DIPEA (0.9mL, 5.03mmol) 
and stirring for 5min. TSTU (1.55g, 5.03mmol) was added to the above reaction mixture and 
reaction stirred for 30min. the NHS ester formation was confirmed by LC-MS. NODAGA-
NH2 (2g, 4.8mmol) was weighed into glass tube and dissolved into DMF: Water - 12mL:4mL 
and DIPEA (3.4mL, 19.2mmol). The above solution was pipetted into the activated lysine 
solution and the reaction was left stirred at room temperature for 1h. The solvents were 
evaporated at 40°C for 30min to get a pale yellow viscous solution that was purified by flash 
chromatography (C18) using water (0.1%TFA) and acetonitrile (0.1%TFA) as eluents to get a 
white powder (Yield:3.6 g, 68%). 
 
HRMS: Calculated for C48H65N7O12:932.476 M+H+; Obtained: m/z = 932.475 M+H+ 
 
HPLC: tR= 4.12min, Purity= 99.45% 
 
1H NMR (300 MHz, MeOD-d4) δ 1.0 (s, 6H), 1.3 – 2.2 (m, 8H), 2.3 (d, 6H), 2.5 (s, 3H), 2.7 – 
3.3 (m, 12H), 3.4 – 4.1 (m, 8H), 4.2 (d, J = 6.7 Hz, 1H), 4.3 (dd, J = 10.5, 6.7 Hz, 1H), 4.5 
(m, 1H), 7.2 – 7.5 (m, 4H), 7.7 (dd, J = 7.4, 3.9 Hz, 2H), 7.8 (d, J = 7.4 Hz, 2H). 
 
13C NMR (75 MHz, MeOD-d4) δ 18.5, 24.2, 26.4, 28.4, 29.4, 31.0, 32.6, 33.7, 44.3, 53.3, 
56.4, 64.5, 67.9, 108.6, 116.1, 119.9, 121.0, 126.3, 128.2, 128.9, 142.6, 145.2, 145.3, 158.6, 
162.4, 162.8, 175.1, 175.2, 175.5, 175.5, 199.9. 
 
Elemental Analysis:  
Calculated for C48H65N7O12. 1.5TFA (%): C, 55.53; H, 6.08; N, 8.89. 
Observed (%): C: 55.48, H: 6.85, N: 8.89. 
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NODAGA-Lys-Dde-NH2 (26) 
 
 
 
Chemical Formula: C33H55N7O10 
Molecular Weight: 709.84 
 
500mg of NODAGA-Lys-Fmoc-Dde was weighed into a 100mL round bottom flask and 
dissolved in 5mL of methanol. Diethylamine (5mL) was added into the above solution and the 
solution was stirred at room temperature for 5-10min, the reaction was deemed complete as 
verified by LC-MS. The solution was evaporated at 30°C to remove methanol/DEA to get a 
viscous brownish residue. This residue was purified by flash chromatography (C18) using 
water (0.1%TFA) and acetonitrile (0.1%TFA) as eluents to get a white powder as a TFA salt 
(Yield: 480 mg, 95%). 
 
HRMS: Calculated for C33H55N7O10:710.408 M+H+; Obtained: m/z = 710.409 M+H+ 
 
HPLC: tR= 2.76min, Purity= 98.72% 
 
1H NMR (500 MHz, MeOD) δ 1.0 (s, 6H), 1.5 (dq, J = 9.7, 7.7, 7.2 Hz, 2H), 1.7 (p, J = 7.0 
Hz, 2H), 1.7 – 1.9 (m, 2H), 1.9 – 2.0 (m, 1H), 2.0 – 2.1 (m, 1H), 2.3 (s, 4H), 2.3 – 2.4 (m, 
2H), 2.5 (s, 3H), 2.7 – 3.3 (m, 12H), 3.3 – 3.4 (m, 3H), 3.5 (t, J = 6.9 Hz, 2H), 3.6 (t, J = 7.2 
Hz, 1H), 3.6 – 4.1 (m, 5H). 
 
13C NMR (126 MHz, MeOD) δ 18.4, 23.3, 26.5, 28.4, 29.5, 31.1, 32.1, 33.7, 39.9, 40.3, 44.0, 
53.4, 54.4, 64.5, 108.7, 116.4, 118.7, 161.7, 162.0, 170.3, 175.1, 175.5, 175.6, 199.9. 
 
Elemental Analysis:  
Calculated for C29H55N5O7. 3.5TFA (%): C: 43.32; H: 5.32, N: 8.84. 
Observed (%): C: 43.34, H: 6.27, N: 9.45.  
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NODAGA-Lys-TA-Dde (27) 
 
 
 
Chemical Formula: C41H67N7O11S2 
Molecular Weight: 898.15 
 
NODAGA-Lys-Dde-NH2 (1.2g) was taken into a 100mL round bottom flask, to which was 
added 10 mL of MeOH and DIPEA (1.2mL, 6.8mmol) followed by stirring for 5min. Thioctic 
acid-NHS (514mg, 1.7mmol) was weighed into glass tube, dissolved in 5mLof ACN and 
added into above solution which was stirred at room temperature for 3h. The reaction mixture 
was evaporated to remove the excess of solvents to get the yellowish residue. This residue 
was further purified by flash chromatography (C18) using water (0.1%TFA) and acetonitrile 
(0.1%TFA) as eluents to get a white powder after lyophilization (Yield: 980 mg, 80%). 
 
HRMS: Calculated for C41H67N7O11S2:898.441 M+H+; Obtained: m/z = 898.442 M+H+ 
 
HPLC: tR= 3.76min, Purity= 99.32% 
 
1H NMR (500 MHz, MeOD-d4) δ 1.2 – 1.5 (m, 4H), 1.5 – 1.7 (m, 7H), 1.7 – 1.8 (m, 2H), 1.9 
– 2.0 (m, 1H), 2.0 – 2.1 (m, 2H), 2.2 (td, J = 7.3, 1.6 Hz, 2H), 2.3 – 2.4 (m, 3H), 2.6 – 3.2 (m, 
16H), 3.4 – 3.6 (m, 2H), 3.6 – 4.0 (m, 4H), 4.2 (m, 1H). 
 
13C NMR (126 MHz, MeOD-d4) δ 23.9, 24.2, 26.4, 26.5, 26.5, 28.1, 29.8, 29.9, 30.6, 32.3, 
33.7, 35.7, 35.7, 36.5, 36.6, 39.3, 39.9, 40.2, 40.4, 41.3, 41.3, 54.8, 57.6, 64.4, 116.7, 119.0, 
120.4, 162.2, 162.5, 162.8, 174.6, 175.1, 175.5, 176.3, 176.3. 
 
Elemental Analysis:  
Calculated for C41H67N7O11S2. 2TFA (%): C: 47.99, H: 6.18, N: 8.71, S: 5.69. 
Observed (%): C: 47.52, H: 6.64, N: 8.63, S: 5.0. 
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NODAGA-Lys-TA-NH2 (28) 
 
 
Chemical Formula: C31H55N7O9S2 
Molecular Weight: 733.94 
 
NODAGA-Lys-TA-Dde (800mg) was weighed into a 100mL round bottom flask and 
dissolved in 10mL of methanol. Imidazole (1.22g, 17.8mmol) and hydroxylamine 
hydrochloride (1.22g, 17.8mmol) was added into the above solution and few drops of water 
were added to dissolve them in methanolic solution. The solution was stirred at room 
temperature for 30min and reaction was deemed complete as verified by LC-MS. The solution 
was evaporated at 30°C to remove methanol to obtain a viscous whitish residue. This residue 
was purified by flash chromatography (C18) using water (0.1%TFA) and acetonitrile 
(0.1%TFA) as eluents to get a white powder after lyophilization (550mg, 72%). 
 
HRMS: Calculated for C31H55N7O9S2:734.357 M+H+; Obtained: m/z = 734.358 M+H+ 
 
HPLC: tR= 2.91min, Purity= 93.62% 
 
1H NMR (500 MHz, MeOD-d4) δ 1.2 – 1.5 (m, 4H), 1.5 – 1.7 (m, 7H), 1.7 – 1.8 (m, 2H), 1.9 
– 2.0 (m, 1H), 2.0 – 2.1 (m, 2H), 2.2 (td, J = 7.3, 1.6 Hz, 2H), 2.3 – 2.4 (m, 3H), 2.6 – 3.2 (m, 
16H), 3.4 – 3.6 (m, 2H), 3.6 – 4.0 (m, 4H), 4.2 (m, 1H). 
 
13C NMR (126 MHz, MeOD-d4) δ 23.9, 24.2, 26.4, 26.5, 26.5, 28.1, 29.8, 29.9, 30.6, 32.3, 
33.7, 35.7, 35.7, 36.5, 36.6, 39.3, 39.9, 40.2, 40.4, 41.3, 41.3, 54.8, 57.6, 64.4, 116.7, 119.0, 
120.4, 162.2, 162.5, 162.8, 174.6, 175.1, 175.5, 176.3, 176.3. 
 
Elemental Analysis:  
Calculated for C29H55N5O7. 3TFA (%): C, 41.30; H, 5.43; N, 9.11; S: 5.96 
Observed (%): C: 40.81, H: 6.34, N: 9.21, S: 5.19. 
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NODAGA-Lys-Fmoc-NH2 (29) 
 
 
Chemical Formula: C38H53N7O10 
Molecular Weight: 767.88 
 
500mg of NODAGA-Lys-Fmoc-dde was weighed into a 100mL round bottom flask and 
dissolved in 10mL of methanol. Imidazole (1.1g, 16.1mmol) and hydroxylamine.HCl (1.1g, 
16.1mmol) was added into the above solution and few drops of water were added to dissolve 
them in methanolic solution. The solution was stirred at room temperature for 15min and the 
reaction was deemed complete as verified by LC-MS. The solution was evaporated at 30°C to 
remove methanol to get a viscous whitish residue. This residue was purified by flash 
chromatography (C18) using Water (0.1%TFA) and acetonitrile (0.1%TFA) as eluents to get 
a white powder as a TFA salt (Yield: 465mg, 94%). 
 
HRMS: Calculated for C38H53N7O3:768.392 M+H+; Obtained: m/z = 768.392 M+H+ 
 
HPLC: tR= 3.32min, Purity= 100% 
 
1H NMR (500 MHz, MeOD -d4) δ 1.1 – 1.4 (m, 2H), 1.6 (m, 3H), 1.7 (m, 1H), 1.9 (m, 1H), 
2.0 (m, 1H), 2.3 (m, 2H), 2.6 – 3.2 (m, 15H), 3.4 (t, J = 7.2 Hz, 1H), 3.5 – 4.0 (m, 5H), 4.1 (t, 
J = 6.6 Hz, 1H), 4.2 – 4.4 (m, 2H), 7.2 (t, J = 7.4 Hz, 2H), 7.3 (t, J = 7.4 Hz, 2H), 7.6 (t, J = 
7.1 Hz, 2H), 7.7 (d, J = 7.5 Hz, 2H). 
 
13C NMR (126 MHz, MeOD) δ 23.8, 26.4, 28.1, 32.4, 33.7, 39.9, 40.1, 40.5, 56.5, 64.4, 67.9, 
114.3, 116.7, 119.0, 121.0, 121.3, 126.2, 128.2, 128.9, 142.6, 142.6, 145.1, 145.3, 158.6, 
161.8, 162.1, 162.4, 175.1, 175.5. 
 
Elemental Analysis:  
Calculated for C38H53N7O3. 3TFA (%): C: 47.61, H: 5.09, N: 8.83 
Observed (%): C: 47.63, H: 5.82, N: 9.19. 
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PSMA(tBu)3-Suberate (30) 
 
 
 
Chemical Formula: C32H57N3O10 
Molecular Weight: 643.82 
 
Suberic acid (103mg, 0.69mmol) was weighed into a 50mL round bottom flask to which was 
added 1mL of ACN, the suberic acid remained undissolved. DIPEA (0.102mL, 0.57mmol) 
was added into the above solution, which effected the dissolution of suberic acid in ACN. 
TSTU (176mg, 0.57mmol) was weighed into a glass tube and added directly into the suberic 
acid solution which was stirred for 30min. The monoester formation was confirmed by LC-
MS. PSMA(tBu)3 (280mg, 0.57mmol) was weighed into a glass tube and was dissolved into 
1mL of ACN followed by addition of DIPEA (0.2mL, 1.148mmol). The PSMA solution was 
pipetted into the activated suberic acid solution. The reaction was stirred for 1h at room 
temperature and the reaction completion was verified by LC-MS. The solvent was evaporated 
to obtain a viscous translucent residue that was further purified by flash chromatography 
(C18) using water and acetonitrile as eluents to get a translucent product (Yield: 200mg, 
53%).   
 
HRMS: Calculated for C32H57N3O10:644.411 M+H+; Obtained: m/z = 644.414 M+H+, 
666.393 M+Na+. 
 
HPLC: tR= 4.77min, Purity= 90.80% 
 
13C NMR (126 MHz, CDCl3) δ 18.4, 22.5, 25.2, 25.6, 28.0, 28.1, 28.5, 28.6, 28.8, 31.7, 32.4, 
35.4, 36.3, 38.9, 40.9, 52.3, 53.1, 53.3, 53.4, 80.5, 80.6, 81.5, 81.5, 81.9, 157.6, 172.4, 172.4, 
172.7, 172.7, 173.8, 178.2. 
 
1H NMR (500 MHz, CDCl3) δ 1.1 – 1.5 (m, 27H), 1.5 – 1.7 (m, 4H), 1.7 – 1.9 (m, 1H), 2.1 
(m, 1H), 2.1 – 2.4 (m, 4H), 3.1 (m, 1H), 3.3 (m, 1H), 4.3 (td, J = 8.2, 4.6 Hz, 1H), 5.9 (m, 
1H), 6.5 (dq, J = 11.3, 5.5 Hz, 1H). 
 
Elemental Analysis:  
Calculated for C32H57N3O10 (%): C: 59.70, H: 8.92, N: 6.53. 
Observed (%): C: 59.07, H: 9.35, N: 8.12. 
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NODAGA-Lys-Fmoc-Sub-PSMA(tBu)3 (31) 
 
Chemical Formula: C70H108N10O19 
Molecular Weight: 1393.69 
 
PSMA(tBu)3-Suberate (80mg) was weighed into a glass tube and dissolved in 2mL of ACN 
and this solution was added into a 50mL round bottom flask. To the above solution was added 
DIPEA (0.022mL, 0.124mmol) by pipette followed by direct addition of TSTU (38mg, 
0.124mmol) weighed previously into a glass tube. The reaction was stirred at room 
temperature for 30min and the NHS ester formation was verified by LC-MS. NODAGA-Lys-
Fmoc-NH2 (96mg) was weighed into a glass tube and dissolved in 2mL each of acetonitrile 
and MeOH followed by base treatment with DIPEA (0.044mL, 0.249mmol). This solution 
was added into activated PSMA(tBu)3-Suberate solution and the reaction was stirred at room 
temperature for 2.5h after which the reaction was deemed complete as verified by LC-MS. 
The residue obtained upon solvent evaporation was purified by flash chromatography (C18) 
using water (0.1%TFA) and acetonitrile (0.1%TFA) as eluents to get a white product after 
lyophilization (Yield: 162mg, 87%).   
 
HRMS: Calculated for C70H108N10O19:1393.786 M+H+; Obtained: m/z = 1393.786 M+H+ 
 
HPLC: tR= 4.77min, Purity= 99.55% 
 
1H NMR (500 MHz, MeOD-d4) δ 1.3 – 1.3 (m, 2H), 1.3 – 1.5 (m, 27H), 1.5 – 1.6 (m, 2H), 1.6 
– 1.7 (m, 3H), 1.7 – 1.9 (m, 2H), 2.0 – 2.1 (m, 1H), 2.2 (s, 8H), 2.3 – 2.4 (m, 2H), 2.8 – 2.9 
(m, 1H), 2.9 – 3.1 (m, 2H), 3.1 – 3.3 (m, 8H), 3.4 (m, 1H), 3.5 – 3.7 (m, 2H), 3.7 – 3.8 (m, 
2H), 4.0 – 4.3 (m, 2H), 4.4 (m, 1H), 7.2 – 7.9 (m, 4H). 
 
13C NMR (126 MHz, MeOD-d4) δ 13.1, 23.9, 24.4, 26.9, 27.2, 28.3, 28.3, 28.3, 29.0, 29.9, 
29.9, 30.0, 30.7, 32.5, 33.1, 37.0, 40.0, 40.1, 40.2, 43.6, 48.5, 48.6, 48.8, 49.0, 49.1, 49.3, 
49.5, 54.1, 54.8, 55.7, 56.6, 67.8, 68.1, 81.7, 82.5, 82.7, 120.9, 126.3, 128.2, 128.8, 142.5, 
158.4, 159.9, 173.4, 173.7, 173.9, 175.2, 175.9, 176.1, 176.1. 
 
Elemental Analysis:  
Calculated for C72H109N10O21. 0.7TFA (%): C: 58.20, H: 7.44, N, 9.51 
Observed (%): C: 58.02, H: 8.44, N: 9.52. 
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NODAGA-Lys-Sub-PSMA(tBu)3-NH2(32) 
 
 
 
Chemical Formula: C55H98N10O17 
Molecular Weight: 1171.44 
 
NODAGA-Lys-Fmoc-Sub-PSMA(tBu)3 (140mg) was weighed into a glass tube and dissolved 
in 5mL methanol and added into a 25mL round bottom flask. To the above solution was 
added 5 mL of diethylamine followed by stirring at room temperature for 30min. The Fmoc 
deprotection was deemed complete as verified by LC-MS. The residue obtained upon solvent 
evaporation was purified by flash chromatography (C18) using water (0.1%TFA) and 
acetonitrile (0.1%TFA) as eluents to get a white product recovered after lyophilization (Yield: 
102mg, 67%).   
 
HRMS: Calculated for C55H98N10O17:1193.700 M+H+; Obtained: m/z = 1193.701 M+H+ 
 
HPLC: tR= 4.05min, Purity= 98.31% 
 
1H NMR (500 MHz, MeODl-d4) δ 1.3 – 1.4 (m, 5H), 1.4 – 1.5 (m, 30H), 1.5 – 1.6 (m, 4H), 
1.6 – 1.7 (m, 5H), 1.7 – 2.0 (m, 4H), 2.0 – 2.1 (m, 2H), 2.1 – 2.2 (m, 1H), 2.2 (td, J = 7.5, 3.4 
Hz, 4H), 2.3 – 2.4 (m, 2H), 2.4 – 2.5 (m, 2H), 2.8 – 3.3 (m, 16H), 3.3 – 3.5 (m, 3H), 3.6 (t, J = 
7.3 Hz, 1H), 3.8 (t, J = 6.6 Hz, 1H), 4.1 (dd, J = 8.2, 5.2 Hz, 1H), 4.2 (dd, J = 8.7, 5.1 Hz, 
1H). 
 
13C NMR (126 MHz, MeODl-d4) δ 23.5, 24.2, 26.8, 27.1, 28.5, 28.6, 29.3, 30.2, 30.4, 32.4, 
32.7, 33.4, 34.0, 37.3, 40.0, 40.1, 40.3, 40.5, 49.9, 54.4, 54.7, 55.1, 64.8, 82.0, 82.8, 83.1, 
116.9, 119.2, 160.2, 162.3, 162.6, 170.7, 173.7, 174.0, 174.2, 175.4, 175.8, 176.4, 176.6. 
 
Elemental Analysis:  
Calculated for C55H98N10O17. 3.8TFA (%): C: 46.85; H: 6.39; N: 8.73. 
Observed (%): C: 46.89, H: 6.33, N: 8.98. 
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NODAGA-Lys-Sub-PSMA(tBu)3-PEG2-NH2(33) 
 
 
 
Chemical Formula: C61H109N11O20 
Molecular Weight: 1316.60 
 
The Fmoc-PEG2-COOH (18mg, 0.047mmol) was weighed into a 25mL round bottom flask 
and was dissolved in 1mL of ACN. DIPEA (0.009mL, 0051mmol) was added into the above 
solution and the solution was stirred for 5min followed by addition of TSTU (15mg, 0.049). 
The reaction was further stirred for 30min and ester formation was verified by LC-MS. 
NODAGA-Lys-Sub-PSMA(tBu)3-NH2 (55mg) was dissolved in 2mL of MeOH and DIPEA 
(0.033mL, 0.187mmol) and was pipetted into PEG solution. The reaction was stirred for 
30min and amide coupling was verified by LC-MS. 1mL of diethyamine was added into 
above reaction mixture and the reaction was stirred at room temperature for 30min. The 
deprotection was verified by LC-MS. The solvents were evaporated off and the residue was 
purified by flash chromatography (C18) using water (0.1%TFA) and acetonitrile (0.1%TFA) 
as eluents to get a white product after lyophilization (Yield: 48mg, 56%) 
 
HRMS: Calculated for C61H109N11O20:1316.792 M+H+; Obtained: m/z = 1316.793 M+H+, 
1338.773 M+Na+. 
 
HPLC: tR= 4.03min, Purity= 92.11% 
 
Elemental Analysis:  
Calculated for C61H109N11O20. 3.5 TFA(%): C: 47.6; H: 6.61; N: 8.98. 
Observed (%): C: 47.26, H: 6.62, N: 8.72. 
 
--------------------------------------- 
 
 
 
 
 
 
 
  
Experimental Section 
 
Multifunctional platforms for cancer theranosis   211
NODAGA-Lys-Sub-PSMA-PEG2-NH2 (34)  
 
 
 
 
Chemical Formula: C49H85N11O20 
Molecular Weight: 1148.28 
 
NODAGA-Lys-Sub-PSMA(tBu)3-PEG2-NH2 (30mg) was taken in a 25mL round bottom 
flask to which was added 1mL each of DCM and TFA. The reaction was stirred for 60min at 
room temperature after which deprotection was confirmed by LC-MS. The solvents were 
evaporated off at 35°C and 2 times flushed-evaporated with DCM to get a translucent residue 
which was purified by semi preparative HPLC (C18) using water (0.1%TFA) and acetonitrile 
(0.1%TFA) as eluents to get a white product. Yield: 20mg, 60%. 
 
HRMS: Calculated for C49H85N11O20:1148.604 M+H+; Obtained: m/z = 1148.605 M+H+. 
 
HPLC: tR= 2.60min, Purity= 96.17% 
 
Elemental Analysis:  
Calculated for C49H85N11O20. 3.5TFA. 6H2O (%): C: 40.63; H: 6.12; N: 9.31. 
Observed (%): C: 40.12, H: 6.11, N: 9.51. 
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IR-783-Propionic Acid (35) 
 
 
 
Chemical Formula: C41H53N2O8S3 
Molecular Weight: 797.05 
 
IR-783 (56mg, 0.067mmol) was weighed into a 25mL round bottom flask to which was added 
3mL of MeOH. Triethylamine (0.038mL, 0.267mmol) and 3-Mercaptopropionic acid 
(0.012mL, 0.133mmol) was pipetted into the dye solution and the reaction was stirred 
overnight (15h) protected from light in dark. The solvents were evaporated to get a dark green 
residue which was purified by semi-prep HPLC (C18) using water (0.1%TFA) and 
acetonitrile (0.1%TFA) as eluents to get a green powder (Yield: 45 mg, 66%). 
 
HRMS: Calculated for C41H53N2O8S3:797.295 M+; Obtained: m/z = 797.295 M+, 819.277 
M-H+Na+. 
 
HPLC: tR= 3.86min, Purity= 99.15% 
 
Elemental Analysis:  
Calculated for C41H53N2O8S3. 1TFA (%): C: 56.63, H: 5.97, N, 3.07, S:10.55. 
Observed (%): C: 56.35, H: 6.30, N: 2.95, S: 9.32.  
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PSMA-Suberate-NODAGA-Lys-PEG2-PA-IR783 (36) 
 
 
Chemical Formula: C90H136N13O27S3 
Molecular Weight: 1928.32 
 
IR783-Propionic acid (8mg) was weighed into eppendorf tube and dissolved in anhydrous 
0.4mL of DMF, followed by addition of Triethylamine (0.004mL, 0.028mmol) and TSTU 
(3mg, 0.01mmol). The reaction mixture was stirred for 15min and the NHS ester was verified 
by LC-MS. NODAGA-Lys-Sub-PSMA-PEG2-NH2 was weighed into eppendorf tube (12mg) 
and was dissolved in 0.4mL of 0.5M Borate buffer (pH was measured and adjusted to 
between 7-8, if needed with 2M NaOH). The aqueous solution was added into DMF solution 
and the reaction mixture was stirred for 15min after which the product formation was verified 
by LC-MS. The solution was directly purified by Semiprep HPLC (C18) using water 
(0.1%TFA) and acetonitrile (0.1%TFA) as eluents to get a green powder after lyophilization 
(6mg, 32%). 
 
HRMS: Calculated for C90H136N13O27S3:1970.846 M-2H+2Na+; Obtained: m/z = 1970.853 
M-2H+2Na+. 
 
HPLC: tR= 3.93min, Purity= 97.93% 
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6-Maleimidohexanoic-Lysine-Boc (37) 
 
 
 
Chemical Formula: C21H33N3O7 
Molecular Weight: 439.51 
 
6-Mercaptohexanoic acid (204mg, 0.947 mmol) was weighed into a 50mL round bottom flask 
and dissolved in 4mL of ACN, to which was added DIPEA (0.18mL, 0.99mmol) followed by 
TSTU (305mg, 0.99mmol). The reaction was stirred for 30min and the NHS ester formation 
was verifed by LC-MS. Boc-Lys-OH (236mg, 0.95mmol) was dissolved in 4mL of MeOH 
and DIPEA (0.34mL, 1.9mmol) and was pipetted into the maleimide solution. The reaction 
was stirrred at room temperature for 1h and the product formation was verified by LC-MS. 
The solvents were evaporated to get a residue that was purified by flash chromatography 
(C18) using water (0.1%TFA) and acetonitrile (0.1%TFA) as eluents to get a cream colored 
powder after lyophilisation (Yield: 451 mg, 96%). 
 
HRMS: Calculated for C21H33N3O7:462.221 M+Na+; Obtained: m/z = 462.222 M+Na+. 
 
HPLC: tR= 3.55min, Purity= 96.80% 
 
1H NMR (500 MHz, CDCl3-d) δ 1.2 – 1.3 (m, 2H), 1.4 (d, J = 3.0 Hz, 10H), 1.5 – 1.7 (m, 
4H), 1.8 (m, 1H), 2.1 (m, 2H), 3.1 – 3.2 (m, 2H), 3.5 (t, J = 7.2 Hz, 2H), 6.6 – 6.9 (m, 1H). 
 
13C NMR (126 MHz, CDCl3-d) δ 26.6, 29.1, 30.1, 32.0, 32.6, 35.8, 39.9, 41.5, 42.9, 57.1, 
83.8, 138.0, 160.1, 175.1, 178.1, 178.7. 
 
Elemental Analysis:  
Calculated for C21H33N3O7. 2.5H2O (%): C: 52.06, H: 7.91, N: 8.67. 
Observed (%): C: 51.83, H: 7.49, N: 9.74. 
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6-Maleimidohexanoic-Lysine-Boc-NODAGA(tBu)3 (38) 
 
 
Chemical Formula: C50H86N8O13 
Molecular Weight: 1007.28 
 
6-Maleimidohexanoic-Lysine-Boc (180mg) was dissolved in 5mL of acetonitrile (ACN) in 
50mL round bottom flask to which DIPEA (0.073 mL, 0.41mmol) was added dropwise 
followed by addition of TSTU (126mg, 0.410mmol). The reaction was left to stir at room 
temperature for 1h. NODAGA(tBu)3-NH2(240 mg) was dissolved in 10mL of acetonitrile and 
DIPEA (0.29 mL, 1.64 mmol), stirred for 5min and added into the activated lysine solution. 
The reaction mixture was left to stir at room temperature for 2h. The reaction mixture was 
evaporated at 35°C to remove acetonitrile to get a translucent residue, which was purified by 
reverse phase (C18) flash chromatography using water (0.1%TFA) and acetonitrile 
(0.1%TFA) as eluents. The product was recovered as a white solid after lyophilization. 
(Yield: 280 mg, 55%).  
 
HRMS: Calculated for C50H86N8O13:1007.638 M+H+; Obtained: m/z = 1007.639 M+H+. 
 
1H NMR (500 MHz, CDCl3-d) δ 1.2 – 1.4 (m, 4H), 1.4 (s, 38H), 1.6 (m, 5H), 1.7 – 1.8 (m, 
2H), 2.0 – 2.1 (m, 1H), 2.1 (dq, 1H), 2.2 (q, 2H), 2.4 (t, J = 7.2 Hz, 2H), 2.5 – 3.6 (m, 21H), 
3.6 – 3.9 (m, 5H), 4.0 – 4.2 (m, 1H), 4.3 – 4.6 (m, 1H), 6.7 (s, 2H). 
 
13C NMR (126 MHz, CDCl3-d) δ 17.5, 22.6, 25.2, 26.2, 28.0, 28.0, 28.2, 28.3, 28.5, 32.2, 
32.5, 36.1, 37.2, 37.6, 38.9, 39.1, 39.5, 50.4, 53.9, 54.7, 55.9, 63.5, 79.8, 83.1, 114.8, 117.1, 
134.1, 160.6, 160.9, 170.7, 170.9, 173.1, 173.6, 174.2. 
 
HPLC: tR= 4.68min, Purity= 98.02% 
 
Elemental Analysis:  
Calculated for C21H33N3O7. 2TFA. 4H2O (%): C: 49.61, H: 7.40, N: 8.57. 
Observed (%): C: 49.61, H: 7.56, N: 9.38. 
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6-Maleimidohexanoic-Lysine-NODAGA-NH2 (39) 
 
 
 
Chemical Formula: C33H54N8O11 
Molecular Weight: 738.84 
 
6-Maleimidohexanoic-Lysine-Boc-NODAGA(tBu)3(180mg) was weighed into a 50mL round 
bottom flask and was dissolved in 3mL of TFA. The solution was stirred at room temperature 
for 3h, after which the reaction was deemed complete as verified by LC-MS. The TFA was 
evaporated to get a viscous residue which was dissolved in 5mL of DCM and re-evaporated to 
remove residual TFA. The residue was purified by flash chromatography (C18) using water 
(0.1%TFA) and acetonitrile (0.1%TFA). The product was obtained as a cream white powder 
after lyophilization of the appropriately identified and collected fractions (Yield: 110mg, 
76%). 
 
HRMS: Calculated for C33H54N8O11:739.398 M+H+; Obtained: m/z = 739.400 M+H+. 
 
HPLC: tR= 2.6min, Purity= 90.20% 
 
1H NMR (500 MHz, D2O) δ 1.3 (m, 3H), 1.4 – 1.6 (m, 7H), 1.7 – 1.8 (m, 2H), 1.9 (m,1H), 2.0 
– 2.1 (m, 1H), 2.1 (t, J = 7.4 Hz, 2H), 2.3 – 2.4 (m, 2H), 3.0 (m, 9H), 3.1 – 3.3 (m, 15H), 3.3 – 
3.5 (m, 4H), 3.5 (dd, J = 7.8, 6.5 Hz, 1H), 3.8 (s, 4H), 3.9 (t, J = 6.7 Hz, 1H), 6.8 (s, 2H). 
 
13C NMR (126 MHz, D2O) δ 21.5, 24.3, 24.9, 25.4, 27.3, 28.0, 30.4, 32.6, 35.6, 37.4, 38.5, 
38.7, 38.7, 42.2, 50.8, 53.2, 55.8, 64.1, 115.1, 117.5, 134.3, 162.8, 163.0, 169.9, 173.3, 175.4, 
175.4, 176.7. 
 
Elemental Analysis:  
Calculated for C21H33N3O7. 2TFA. 2H2O (%): C: 44.31, H: 6.03, N: 11.17. 
Observed (%): C: 43.85, H: 6.47, N: 11.29. 
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IR-783-Hexanoic Acid (40) 
 
 
 
Chemical Formula: C44H59N2O8S3 
Molecular Weight: 840.14 
 
IR-783 (56mg, 0.07mmol) was weighed into a 25mL round bottom flask to which was added 
3mL of MeOH (dye was soluble with clear green solution). Triethylamine (0.036mL, 
0.267mmol) and 6-mercaptohexanoic acid (22mg, 0.133mmol) was pipetted into the dye 
solution and reaction was stirred overnight (15h) protected from light in dark. The solvents 
were evaporated to get a dark green residue which was purified by semi-prep HPLC (C18) 
using water (0.1%TFA) and acetonitrile (0.1%TFA). The fractions were identified, 
evaporated and lyophilized to get a green powder (Yield: 45 mg, 68%). 
 
HRMS: Calculated for C44H57N2O8S3:837.328 M-2H; Obtained: m/z = 837.331 M-2H 
 
HPLC: tR= 4.29min, Purity= 97.96% 
 
Elemental Analysis:  
Calculated for C44H59N2O8S3. 3H2O (%): C: 59.10, H: 7.33, N: 3.13, S: 10.08. 
Observed (%): C: 58.89, H: 7.07, N: 2.72, S: 10.53. 
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6-Maleimidohexanoic-Lysine-NODAGA-HA-IR783 (41) 
 
 
 
Chemical Formula: C77H111N10O18S3 
Molecular Weight: 1560.97 
 
IR-783-Hexanoic Acid (24mg) was weighed into an eppendorf tube and dissolved in 
anhydrous 0.5mL of DMF, followed by addition of triethylamine (0.015mL, 0.108mmol) and 
TSTU (8.5mg, 0.027mmol). The reaction mixture was stirred for 15min and the NHS ester 
was verified by LC-MS. 6-Maleimidohexanoic-Lysine-NODAGA-NH2 was weighed into an 
eppendorf tube (20mg) and was dissolved in 0.5mL of 0.5M Borate buffer (pH was measured 
and adjusted to between 7-8, if needed with 2M NaOH). The aqueous solution was added into 
the DMF solution and the reaction mixture was stirred for 15min. The solution was directly 
purified by semi-prep HPLC to get a green powder after lyophilization (Yield: 15mg, 32%). 
 
HRMS: Calculated for C77H111N10O18S3:1559.723 M+; Obtained: m/z = 1559.727 M+ 
 
HPLC: tR= 4.17min, Purity= 99.11% 
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Abstract: 
The objective of this thesis was to develop multifunctional tools for cancer theranosis, 
particularly based on nanotechnology. The work is based on the premise of monomolecular 
multimodal platform that aims to create the building blocks that can be used for the synthesis 
of functionalized nanoparticles, bioconjugates or targeted small molecular imaging probes.  
The initial work focused on the synthesis of the chelator based silane precursors. These novel 
precursors were employed for the functionalization of AGuIX nanoparticles and have also 
been implicated in a one pot AGuIX synthesis. Radiolabelling of these nanoparticles was 
performed with the aim to evaluate the stability of these nanoparticles under physiological 
conditions. Furthermore, these nanoparticles were investigated in TSA tumor model in order 
to evaluate their pharmacokinetics, biodistribution behaviour and value in PET-MRI imaging.  
In the second part of the work, building blocks/ligands have been developed and successfully 
deployed for the functionalization of gold nanoparticles. Multimodal ligands containing 
different combinations of chelators, targeting moieties, functional groups and dyes were 
synthesized. Gold nanoparticles for PET-MRI and PSMA targeting SPECT imaging were 
further radiolabelled (64Cu/111In) and showed excellent stability. PSMA targeting ligand 
exhibited good affinity towards PSMA, whereas the in vivo studies of the gold nanoparticles 
for PET-MRI in TSA tumor model demonstrated good pharmacokinetics properties, 
underscoring their potential in cancer imaging and radiotherapy.  
The latter half of the thesis work focusses on the development of PET-Optical probes for 
PSMA positive cancer targeting imaging using small molecular probes, and for 
bioconjugation to antibody fragments and nanoparticles. A PSMA targeting probe based on 
NODAGA and IR-783 dye has been developed and characterized for its affinity, 
photophysical and radiolabelling properties. Likewise, a similar probe bearing a maleimide 
handle has been successfully used for the site-specific labelling of trastuzumab Fab’ 
fragments and functionalization of AGuIX nanoparticles. These bioconjugates and the 
nanoparticles have been thoroughly characterized and evaluated in relevant biological models 
to highlight their value in cancer theranosis.  
 
Keywords: Nanoparticles, functionalization, AGuIX, NODAGA, DOTAGA, 
bioconjugation, multimodality, theranosis, PET-MRI, PET-Optical, PSMA.  
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Résumé: 
L'objectif de cette thèse était de développer des outils multifonctionnels pour l’élaboration 
d’agents théranostiques en oncologie, notamment à base de nanotechnologies. Le projet est 
basé sur l’utilisation de plateformes multimodales monomoléculaires comme précurseurs pour 
la synthèse de nanoparticules, de bioconjugués ou encore de sondes imageantes à base de 
petites molécules.  
Les premiers travaux ont concerné la synthèse de précurseurs silanes comportant un agent 
chélatant. Ces nouveaux précurseurs ont été mis en oeuvre pour la fonctionnalisation de 
nanoparticules AGuIX et ont également été utilisés dans un nouveau procédé de synthèse « 
one-pot »  d’AGuIX. Le radiomarquage de ces nanoparticules a été réalisé dans le but 
d'évaluer la stabilité de ces nanoparticules dans des conditions physiologiques. Par ailleurs, 
ces nanoparticules ont été étudiées dans un modèle de tumeur TSA afin de déterminer leur 
comportement pharmacocinétique, leur biodistribution et leur potentiel en imagerie bimodale 
TEP-IRM.  
Dans une deuxième partie, des blocs de construction / ligands ont été développés et utilisés 
avec succès pour la fonctionnalisation de nanoparticules d'or. Des ligands multimodaux 
contenant différentes combinaisons de chélateurs, de fonctions de ciblage, de groupes 
fonctionnels et de chromophores, ont été synthétisés. Les nanoparticules d'or pour l'imagerie 
TEP-IRM et SPECT (ciblant le PSMA) ont été ensuite radiomarquées (64Cu/111In) et ont 
montré une excellente stabilité. Le ligand à base de PSMA présente une bonne affinité vis-à-
vis du PSMA, tandis que les études in vivo dans un modèle tumoral TSA des nanoparticules 
d'or pour l'IRM-TEP ont démontré les bonnes propriétés pharmacocinétiques de ces 
nanoparticules fonctionnalisées, et donc leur potentiel en imagerie et en radiothérapie.  
La dernière partie du travail de thèse concerne le développement de sondes TEP-Optique pour 
l'imagerie ciblée de tumeurs surexprimant le PSMA en utilisant de petites sondes 
moléculaires, ainsi que pour leur bioconjugaison sur des fragments d'anticorps et des 
nanoparticules. Une sonde ciblant le PSMA, à base de NODAGA et du fluorophore IR-783, a 
été développée et caractérisée afin de déterminer ses propriétés photophysiques, son affinité 
pour le PSMA, et les conditions de radiomarquage. Enfin, un analogue comportant une 
fonction maléimide a été utilisée avec succès pour le marquage site spécifique de fragments 
Fab' du trastuzumab, ainsi que pour la fonctionnalisation de nanoparticules AGuIX. Ces 
bioconjugués et ces nanoparticules ont été soigneusement caractérisés et évalués dans des 
modèles biologiques pertinents afin de mettre en évidence leur intérêt comme agents 
théranostiques.  
 
Mots clés: Nanoparticules, fonctionnalisation, AGuIX, NODAGA, DOTAGA, 
bioconjugaison, multimodalité, théranostique, TEP-IRM, TEP-Optique, PSMA.  
 
